"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,TW,A,TW 201524801 A,156-676-629-483-132,2015-07-01,2015,TW 102149411 A,2013-12-31,TW 102149411 A,2013-12-31,Electric vehicle energy-saving system,"An electric vehicle energy-saving system for controlling the operation of a vehicle performance is disclosed. The electric vehicle energy-saving system comprises a power supply unit for providing an input voltage, a DC-DC conversion unit connected to the power supply unit for converting the input voltage into a driving voltage to drive the motor, a rotational speed detection unit for detecting a rotational speed of the motor to generate a rotational speed signal, a acceleration detection unit for detecting a throttle signal, an electric capacity detection unit for detecting power voltage and storage of capacity signal; and a control unit which is connected with the rotation speed detection unit, the acceleration detection unit, the electric capacity detection unit and the DC/DC conversion unit. In order to maintain the optimal operation and energy-saving mode for the motor at different demand, state and condition, the control unit is able to generate a control signal, which is calculated and compared with input from the rotation speed detection unit, the acceleration detection unit and the electric capacity detection unit, to adjust the voltage of DC/DC conversion unit.",ASIA PACIFIC FUEL CELL TECH,YANG JEFFERSON YS;;CHEN CHIH-HSUEH,,https://lens.org/156-676-629-483-132,Patent of Addition,no,0,0,1,1,0,Y02T10/72,B60L11/18;;B60L3/00,,0,0,,,,PENDING
2,US,B2,US 7467292 B2,106-382-934-321-327,2008-12-16,2008,US 13277805 A,2005-05-19,US 13277805 A,2005-05-19,Method and system for migrating information between information handling systems,"A system for migrating information includes a first information handling system (IHS). The first IHS is for, in response to a first boot event, booting from a computer readable medium, bypassing the first IHS user authentication requirement, and establishing a connection between the first IHS and a second IHS. The system for migrating information also includes the second IHS, coupled to the first IHS. The second IHS is for, in response to a second boot event, booting from a storage device of the second IHS, establishing the connection between the first IHS and the second IHS, and migrating information from the first IHS to the second IHS.",DELL PRODUCTS LP,RALEY JEFFERSON;;CHEN SHAOFEI;;JARVIS MARC;;RONES CRAIG,DELL PRODUCTS L.P (2005-05-16),https://lens.org/106-382-934-321-327,Granted Patent,yes,13,8,6,6,0,G06F8/60;;G06F8/60,G06F9/00,713/1;;713/100;;710/62;;709/203;;709/231;;709/232,0,0,,,,ACTIVE
3,US,A1,US 2009/0013169 A1,050-745-937-814-266,2009-01-08,2009,US 21137408 A,2008-09-16,US 21137408 A;;US 13277805 A,2005-05-19,Method And System For Migrating Information Between Information Handling Systems,"A system for migrating information includes a first information handling system (IHS). The first IHS is for, in response to a first boot event, booting from a computer readable medium, bypassing the first IHS user authentication requirement, and establishing a connection between the first IHS and a second IHS. The system for migrating information also includes the second IHS, coupled to the first IHS. The second IHS is for, in response to a second boot event, booting from a storage device of the second IHS, establishing the connection between the first IHS and the second IHS, and migrating information from the first IHS to the second IHS.",DELL PRODUCTS LP,RALEY JEFFERSON;;CHEN SHAOFEI;;JARVIS MARC;;RONES CRAIG,,https://lens.org/050-745-937-814-266,Patent Application,yes,20,5,6,6,0,G06F8/60;;G06F8/60,G06F15/177,713/2,0,0,,,,ACTIVE
4,US,A1,US 2006/0075400 A1,061-272-087-390-779,2006-04-06,2006,US 95207304 A,2004-09-28,US 95207304 A,2004-09-28,System and method for data migration integration with information handling system manufacture,"Data migration from existing to replacement information handling systems is integrated with manufacture of the replacement information handling system by including a data migration application and rules in the image copied to the replacement information handling system during manufacture. The rules define the data migration, such as the types of files allowed and disallowed for data migration, the physical interface for the data migration, the initial power up and display interface to support the data migration application and the deletion of the data migration application after completion of the data migration operation. The replacement information handling system ships to the end user and initiates the data migration application on power-up to present instruction to perform the data migration.",JARVIS MARC;;CHEN SHAOFEI;;HANES KEVIN;;RALEY JEFFERSON,JARVIS MARC;;CHEN SHAOFEI;;HANES KEVIN;;RALEY JEFFERSON,DELL PRODUCTS L.P (2004-09-22),https://lens.org/061-272-087-390-779,Patent Application,yes,9,5,2,2,0,G06F8/63;;G06F8/63,H04N7/18;;G06F9/445,717/174;;725/80,0,0,,,,ACTIVE
5,US,A1,US 2008/0216068 A1,112-718-711-657-935,2008-09-04,2008,US 5308008 A,2008-03-21,US 5308008 A;;US 13277805 A,2005-05-19,Method And System For Migrating Information Between Information Handling Systems,"A system for migrating information includes a first information handling system (“IHS”). The first IHS is for, in response to a first boot event, booting from a computer readable medium, bypassing the first IHS' user authentication requirement, and establishing a connection between the first IHS and a second IHS. The system for migrating information also includes the second IHS, coupled to the first IHS. The second IHS is for, in response to a second boot event, booting from a storage device of the second IHS, establishing the connection between the first IHS and the second IHS, and migrating information from the first IHS to the second IHS.",DELL PRODUCTS LP,RALEY JEFFERSON;;CHEN SHAOFEI;;JARVIS MARC;;RONES CRAIG,,https://lens.org/112-718-711-657-935,Patent Application,yes,18,0,6,6,0,G06F8/60;;G06F8/60,G06F9/44;;G06F15/177,717/174;;713/2,0,0,,,,ACTIVE
6,US,B2,US 7953964 B2,181-885-872-374-064,2011-05-31,2011,US 5308008 A,2008-03-21,US 5308008 A;;US 13277805 A,2005-05-19,Method and system for migrating information between information handling systems,"A system for migrating information includes a first information handling system (“IHS”). The first IHS is for, in response to a first boot event, booting from a computer readable medium, bypassing the first IHS' user authentication requirement, and establishing a connection between the first IHS and a second IHS. The system for migrating information also includes the second IHS, coupled to the first IHS. The second IHS is for, in response to a second boot event, booting from a storage device of the second IHS, establishing the connection between the first IHS and the second IHS, and migrating information from the first IHS to the second IHS.",DELL PRODUCTS LP,RALEY JEFFERSON;;CHEN SHAOFEI;;JARVIS MARC;;RONES CRAIG,,https://lens.org/181-885-872-374-064,Granted Patent,yes,18,0,6,6,0,G06F8/60;;G06F8/60,G06F9/00,713/1;;713/2;;713/100;;710/62;;709/203;;709/231;;709/232,0,0,,,,ACTIVE
7,US,B2,US 8458692 B2,033-599-311-908-579,2013-06-04,2013,US 95207304 A,2004-09-28,US 95207304 A,2004-09-28,System and method for data migration integration with information handling system manufacture,"Data migration from existing to replacement information handling systems is integrated with manufacture of the replacement information handling system by including a data migration application and rules in the image copied to the replacement information handling system during manufacture. The rules define the data migration, such as the types of files allowed and disallowed for data migration, the physical interface for the data migration, the initial power up and display interface to support the data migration application and the deletion of the data migration application after completion of the data migration operation. The replacement information handling system ships to the end user and initiates the data migration application on power-up to present instruction to perform the data migration.",JARVIS MARC;;CHEN SHAOFEI;;HANES KEVIN;;RALEY JEFFERSON;;DELL PRODUCTS LP,JARVIS MARC;;CHEN SHAOFEI;;HANES KEVIN;;RALEY JEFFERSON,DELL PRODUCTS L.P (2004-09-22),https://lens.org/033-599-311-908-579,Granted Patent,yes,9,1,2,2,0,G06F8/63;;G06F8/63,G06F9/445;;G06F3/00;;G06F9/44;;G06F13/00;;G06F15/177,717/176;;717/175;;717/121;;710/33;;709/220,0,0,,,,ACTIVE
8,CN,A,CN 116261399 A,150-977-000-576-404,2023-06-13,2023,CN 202180059333 A,2021-11-12,EP 20216229 A;;CN 2020129016 W;;EP 2021081553 W,2020-11-16,Citrus oil extract,"The present invention relates to a citrus oil extract comprising a reduced amount of oxidation by-product compounds, wherein the amount of oxidation by-product compounds is less than 2500 ppm. Preferably, the oxidation by-product compounds are selected from the group consisting of p-cymene, t-p-menth-2-en-1-ol, t-p-menth-2, 8-dienol, t-limonene oxide, camphor, p-cymene-8-ol, t-limonene 8, 9-epoxide, c-limonene 8, 9-epoxide, and t-carveol. The invention also relates to a process for preparing a citrus oil extract, as well as a flavored or perfumed consumer product comprising a citrus oil extract of the invention.",FIRMENICH & CIE,BERTIS ERIC;;ARRUDA JEFFERSON;;CHEN LONG;;ZHANG HUIJUAN,,https://lens.org/150-977-000-576-404,Patent Application,no,0,0,5,5,0,C11B9/022;;C11B9/0007;;C11B9/0034;;C11B9/0049;;A23G1/48;;A23L2/56;;A21D2/10;;A23G3/48;;C12G3/06;;A23L27/13;;C11B9/0034;;C11B9/0049;;C11B9/0061;;C11B9/0076;;C11B9/022,A23G1/48,,0,0,,,,PENDING
9,US,A1,US 2006/0265701 A1,105-028-856-340-750,2006-11-23,2006,US 13277805 A,2005-05-19,US 13277805 A,2005-05-19,Method and system for migrating information between information handling systems,"A system for migrating information includes a first information handling system (“IHS”). The first IHS is for, in response to a first boot event, booting from a computer readable medium, bypassing the first IHS′ user authentication requirement, and establishing a connection between the first IHS and a second IHS. The system for migrating information also includes the second IHS, coupled to the first IHS. The second IHS is for, in response to a second boot event, booting from a storage device of the second IHS, establishing the connection between the first IHS and the second IHS, and migrating information from the first IHS to the second IHS.",DELL PRODUCTS LP,RALEY JEFFERSON;;CHEN SHAOFEI;;JARVIS MARC;;RONES CRAIG,DELL PRODUCTS L.P (2005-05-16),https://lens.org/105-028-856-340-750,Patent Application,yes,13,7,6,6,0,G06F8/60;;G06F8/60,G06F9/44,717/168,0,0,,,,ACTIVE
10,US,A1,US 2006/0129769 A1,053-563-824-514-111,2006-06-15,2006,US 870304 A,2004-12-09,US 870304 A,2004-12-09,System and method for migration to manufactured information handling systems,Data migration directly from legacy to replacement information handling systems is managed over a set of one or more switches. The legacy information handling system boots with a manufacturing operating system provided from a data migration information handling system server and runs a data migration application also provided from the server. Running the data migration application over the manufacturing operating system avoids password protection of the legacy information handling system. A pair of target storage device keys interface with a legacy and associated replacement system to aid in location of the replacement system on the network for direct system-to-system data transfer.,CHEN SHAOFEI;;JARVIS MARC;;KAMALANATHAN CHANDAR;;RALEY JEFFERSON,CHEN SHAOFEI;;JARVIS MARC;;KAMALANATHAN CHANDAR;;RALEY JEFFERSON,DELL PRODUCTS L.P (2004-12-02),https://lens.org/053-563-824-514-111,Patent Application,yes,20,21,1,1,0,G06F3/0647;;G06F3/0647;;G06F3/0607;;G06F3/0607;;G06F3/067;;G06F3/067;;G06F9/4416;;G06F9/4416,G06F12/16,711/162,0,0,,,,DISCONTINUED
11,US,B2,US 8127123 B2,167-322-660-797-763,2012-02-28,2012,US 21137408 A,2008-09-16,US 21137408 A;;US 13277805 A,2005-05-19,Method and system for migrating information between information handling systems,"A system for migrating information includes a first information handling system (IHS). The first IHS is for, in response to a first boot event, booting from a computer readable medium, bypassing the first IHS user authentication requirement, and establishing a connection between the first IHS and a second IHS. The system for migrating information also includes the second IHS, coupled to the first IHS. The second IHS is for, in response to a second boot event, booting from a storage device of the second IHS, establishing the connection between the first IHS and the second IHS, and migrating information from the first IHS to the second IHS.",RALEY JEFFERSON;;CHEN SHAOFEI;;JARVIS MARC;;RONES CRAIG;;DELL PRODUCTS LP,RALEY JEFFERSON;;CHEN SHAOFEI;;JARVIS MARC;;RONES CRAIG,,https://lens.org/167-322-660-797-763,Granted Patent,yes,20,3,6,6,0,G06F8/60;;G06F8/60,G06G17/30,713/1;;713/2;;713/100;;717/148;;715/243;;709/203;;709/206,0,0,,,,ACTIVE
12,EP,A2,EP 1171452 A2,109-963-140-607-467,2002-01-16,2002,EP 00929365 A,2000-04-17,EP 0003459 W;;US 13021599 P,1999-04-20,PYRROLIDINCARBOLYLAMINO CYCLIC DISULFIDES AS VCAM-VLA4 ANTAGONISTS,,HOFFMANN LA ROCHE,CHEN LI;;FOTOUHI NADER;;JACKSON DAVID YOUNG;;TILLEY JEFFERSON WRIGHT,,https://lens.org/109-963-140-607-467,Patent Application,yes,0,0,21,21,0,A61K38/00;;C07C323/60;;C07K5/0202;;C07K5/0205;;C07K5/0207;;C07C2601/08;;C07C2603/18;;A61P11/06;;A61P29/00;;C07K5/02;;C07C323/60;;A61K38/00;;C07K5/0207;;C07K5/0205;;C07K5/0202;;C07C2601/08;;C07C2603/18,A61K38/00;;A61P11/06;;A61P29/00;;C07C323/60;;C07K5/02,,0,0,,,,EXPIRED
13,ZA,B,ZA 200108018 B,093-201-234-667-84X,2003-03-26,2003,ZA 200108018 A,2001-09-28,US 13021599 P,1999-04-20,Pyrrolidincarbonylamino cyclic disulfides.,,HOFFMANN LA ROCHE,CHEN LI;;FOTOUHI NADER;;JACKSON DAVID YOUNG;;TILLEY JEFFERSON WRIGHT,,https://lens.org/093-201-234-667-84X,Granted Patent,no,0,0,21,21,0,A61K38/00;;C07C323/60;;C07K5/0202;;C07K5/0205;;C07K5/0207;;C07C2601/08;;C07C2603/18;;A61P11/06;;A61P29/00;;C07K5/02;;C07C323/60;;A61K38/00;;C07K5/0207;;C07K5/0205;;C07K5/0202;;C07C2601/08;;C07C2603/18,A61P11/06;;A61P29/00;;C07C323/60;;A61K38/00;;C07K5/02,,0,0,,,,EXPIRED
14,AT,T1,AT E337331 T1,076-035-735-030-727,2006-09-15,2006,AT 00929365 T,2000-04-17,US 13021599 P,1999-04-20,PYRROLIDINCARBONYLAMIN-ENTHALTENDE CYCLISCHE PEPTID-DISULFIDE ALS ANTAGONISTS VON VCAM-VLA4,,HOFFMANN LA ROCHE,CHEN LI;;FOTOUHI NADER;;JACKSON DAVID YOUNG;;TILLEY JEFFERSON WRIGHT,,https://lens.org/076-035-735-030-727,Granted Patent,no,0,0,21,21,0,A61K38/00;;C07C323/60;;C07K5/0202;;C07K5/0205;;C07K5/0207;;C07C2601/08;;C07C2603/18;;A61P11/06;;A61P29/00;;C07K5/02;;C07C323/60;;A61K38/00;;C07K5/0207;;C07K5/0205;;C07K5/0202;;C07C2601/08;;C07C2603/18,A61K38/00;;A61P11/06;;A61P29/00;;C07C323/60;;C07K5/02,,0,0,,,,EXPIRED
15,BR,A,BR 0009838 A,153-593-937-068-616,2002-01-08,2002,BR 0009838 A,2000-04-17,EP 0003459 W;;US 13021599 P,1999-04-20,Dissulfetos cìclicos de pirrolidincarbonilamino,"Patente de Invenção: ""DISSULFETOS CìCLICOS DE PIRROLIDINCAR-BONILAMINO"". Compostos da fórmula (1) são descritos que têm atividade como agentes antiinflamatórios. Compostos de dissulfeto cíclicos são providos que inibem ligação de células a endotélio. Tais compostos são úteis para o tratamento de doenças inflamatórias, tais como asma, cujos sintomas e/ou danos estão relacionados com a ligação de moléculas de adesão celular a células de expressão de integrina.",HOFFMANN LA ROCHE,CHEN LI;;FOTOUHI NADER;;JACKSON DAVID YOUNG;;TILLEY JEFFERSON WRIGHT,,https://lens.org/153-593-937-068-616,Patent Application,no,0,0,21,21,0,A61K38/00;;C07C323/60;;C07K5/0202;;C07K5/0205;;C07K5/0207;;C07C2601/08;;C07C2603/18;;A61P11/06;;A61P29/00;;C07K5/02;;C07C323/60;;A61K38/00;;C07K5/0207;;C07K5/0205;;C07K5/0202;;C07C2601/08;;C07C2603/18,A61K38/00;;A61P11/06;;A61P29/00;;C07C323/60;;C07K5/02,,0,0,,,,DISCONTINUED
16,AU,B2,AU 769294 B2,125-578-988-838-739,2004-01-22,2004,AU 2000/047482 A,2000-04-17,EP 0003459 W;;US 13021599 P,1999-04-20,Pyrrolidincarbonylamino cyclic disulfides,,HOFFMANN LA ROCHE,CHEN LI;;FOTOUHI NADER;;JACKSON DAVID YOUNG;;TILLEY JEFFERSON WRIGHT,,https://lens.org/125-578-988-838-739,Granted Patent,no,0,0,21,21,0,A61K38/00;;C07C323/60;;C07K5/0202;;C07K5/0205;;C07K5/0207;;C07C2601/08;;C07C2603/18;;A61P11/06;;A61P29/00;;C07K5/02;;C07C323/60;;A61K38/00;;C07K5/0207;;C07K5/0205;;C07K5/0202;;C07C2601/08;;C07C2603/18,A61K38/00;;A61P11/06;;A61P29/00;;C07C323/60;;C07K5/02,,0,0,,,,EXPIRED
17,ES,T3,ES 2269141 T3,139-538-737-869-831,2007-04-01,2007,ES 00929365 T,2000-04-17,US 13021599 P,1999-04-20,DISULFUROS CICLICOS DE PIRROLIDINCARBONILAMINO COMO ANTAGONISTAS DE VCAM-VLA4.,"Los compuestos de la fórmula general 1: donde R2 y R3 son, cada una de manera independiente, alquilo inferior o junto con el átomo de carbono que tienen unido forman un anillo carbocíclico alifático con entre 4 y 6 átomos de carbono, R5 es hidrógeno, alquilo C1-7, R-SO2, R6- (CH2)m-CO- o R8-X-(CH2)y-CO-; R es alquilo C1-7; R6 y R8 son hidrógeno o alquilo C1-7, X es ¿O- o ¿NH-; m es un entero que va de 1 a 7, y es un entero que va de 0 a 7, y n es un entero que va de 1 a 3; donde a, b, c y d denotan átomos de carbono asimétricos; y sus ésteres o éteres hidrolizables o sus sales farmacéuticamente aceptables.",HOFFMANN LA ROCHE,CHEN LI;;FOTOUHI NADER;;JACKSON DAVID YOUNG;;TILLEY JEFFERSON WRIGHT,,https://lens.org/139-538-737-869-831,Granted Patent,no,0,0,21,21,0,A61K38/00;;C07C323/60;;C07K5/0202;;C07K5/0205;;C07K5/0207;;C07C2601/08;;C07C2603/18;;A61P11/06;;A61P29/00;;C07K5/02;;C07C323/60;;A61K38/00;;C07K5/0207;;C07K5/0205;;C07K5/0202;;C07C2601/08;;C07C2603/18,A61K38/00;;C07K5/02;;A61K38/04;;A61P11/06;;A61P29/00;;C07C323/60,,0,0,,,,EXPIRED
18,CA,A1,CA 2370259 A1,044-669-242-665-365,2000-10-26,2000,CA 2370259 A,2000-04-17,EP 0003459 W;;US 13021599 P,1999-04-20,PYRROLIDINCARBONYLAMINO CYCLIC DISULFIDES,"Compounds of formula (I) are described which have activity as anti- inflammatory agents. Cyclic disulfide compounds are provided which inhibit o f binding of cells to endothelium. Such compounds are useful for treating inflammatory diseases, such as asthma, whose symptoms and/or damage are related to the binding of cell adhesion molecules to integrin expressing cel ls.",HOFFMANN LA ROCHE,CHEN LI;;FOTOUHI NADER;;JACKSON DAVID YOUNG;;TILLEY JEFFERSON WRIGHT,,https://lens.org/044-669-242-665-365,Patent Application,no,0,0,21,21,0,A61K38/00;;C07C323/60;;C07K5/0202;;C07K5/0205;;C07K5/0207;;C07C2601/08;;C07C2603/18;;A61P11/06;;A61P29/00;;C07K5/02;;C07C323/60;;A61K38/00;;C07K5/0207;;C07K5/0205;;C07K5/0202;;C07C2601/08;;C07C2603/18,A61K38/00;;A61P11/06;;A61P29/00;;C07C323/60;;C07K5/02,,0,0,,,,DISCONTINUED
19,AU,A,AU 2000/047482 A,097-880-812-516-545,2000-11-02,2000,AU 2000/047482 A,2000-04-17,EP 0003459 W;;US 13021599 P,1999-04-20,Pyrrolidincarbonylamino cyclic disulfides,,HOFFMANN LA ROCHE,CHEN LI;;FOTOUHI NADER;;JACKSON DAVID YOUNG;;TILLEY JEFFERSON WRIGHT,,https://lens.org/097-880-812-516-545,Patent Application,no,0,0,21,21,0,A61K38/00;;C07C323/60;;C07K5/0202;;C07K5/0205;;C07K5/0207;;C07C2601/08;;C07C2603/18;;A61P11/06;;A61P29/00;;C07K5/02;;C07C323/60;;A61K38/00;;C07K5/0207;;C07K5/0205;;C07K5/0202;;C07C2601/08;;C07C2603/18,A61K38/00;;A61P11/06;;A61P29/00;;C07C323/60;;C07K5/02,,0,0,,,,EXPIRED
20,EP,B1,EP 1171452 B1,124-047-121-450-345,2006-08-23,2006,EP 00929365 A,2000-04-17,EP 0003459 W;;US 13021599 P,1999-04-20,PYRROLIDINCARBOLYLAMINO CYCLIC DISULFIDES AS VCAM-VLA4 ANTAGONISTS,,HOFFMANN LA ROCHE,CHEN LI;;FOTOUHI NADER;;JACKSON DAVID YOUNG;;TILLEY JEFFERSON WRIGHT,,https://lens.org/124-047-121-450-345,Granted Patent,yes,0,0,21,21,0,A61K38/00;;C07C323/60;;C07K5/0202;;C07K5/0205;;C07K5/0207;;C07C2601/08;;C07C2603/18;;A61P11/06;;A61P29/00;;C07K5/02;;C07C323/60;;A61K38/00;;C07K5/0207;;C07K5/0205;;C07K5/0202;;C07C2601/08;;C07C2603/18,A61K38/00;;C07K5/02;;A61K38/04;;A61P11/06;;A61P29/00;;C07C323/60,,2,0,,,"D Y JACKSON ET AL.: ""Potent alpha4beta1 peptide antagonists as potential anti-inflammatory agents"" JOURNAL OF MEDICINAL CHEMISTRY., vol. 40, no. 21, 1997, pages 3359-3368, XP002148351 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0022-2623;;DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FOTOUHI, NADER ET AL: ""The design and synthesis of potent cyclic peptide VCAM-VLA-4 antagonists incorporating an achiral Asp-Pro mimetic"" retrieved from STN Database accession no. 133:171743 CA XP002148355 & BIOORG. MED. CHEM. LETT. (2000), 10(11), 1171-1173 , 2000,",EXPIRED
21,TR,T2,TR 200103004 T2,042-934-248-382-560,2002-01-21,2002,TR 200103004 T,2000-04-17,US 13021599 P,1999-04-20,Pirolidinkarbonilamino siklik disülfitler.,"Antiiltihabik maddeler olarak aktif formül (I)'e ait bilesikler tarif edilmektedir. Hücrelerin endotelyuma baglanmasini önleyen siklik disülfit bilesikleri saglanmistir. Bu gibi bilesikler, semptomlari ve/veya zarari, hücre yapistirma moleküllerinin integrini tanimlayan hücrelere baglanmasiyla ilgili astim gibi iltihabik hastaliklarin tedavisinde faydalidir.",HOFFMANN LA ROCHE,CHEN LI;;FOTOUHI NADER;;JACKSON DAVID YOUNG;;TILLEY JEFFERSON WRIGHT,,https://lens.org/042-934-248-382-560,Patent Application,no,0,0,21,21,0,A61K38/00;;C07C323/60;;C07K5/0202;;C07K5/0205;;C07K5/0207;;C07C2601/08;;C07C2603/18;;A61P11/06;;A61P29/00;;C07K5/02;;C07C323/60;;A61K38/00;;C07K5/0207;;C07K5/0205;;C07K5/0202;;C07C2601/08;;C07C2603/18,A61P11/06;;A61K38/00;;A61P29/00;;C07C323/60;;C07K5/02,,0,0,,,,PENDING
22,US,B1,US 6265572 B1,031-763-204-993-754,2001-07-24,2001,US 54899200 A,2000-04-14,US 54899200 A;;US 13021599 P,1999-04-20,Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents,"Compounds of the formula: ##STR1## are described which have activity as anti-inflammatory agents. Cyclic disulfide compounds are provided which inhibit of binding of cells to endothelium. Such compounds are useful for treating inflammatory diseases, such as asthma, whose symptoms and/or damage are related to the binding of cell adhesion molecules to integrin expressing cells.",HOFFMANN LA ROCHE,CHEN LI;;FOTOUHI NADER;;JACKSON DAVID YOUNG;;TILLEY JEFFERSON WRIGHT,,https://lens.org/031-763-204-993-754,Granted Patent,yes,1,10,21,21,0,A61K38/00;;C07C323/60;;C07K5/0202;;C07K5/0205;;C07K5/0207;;C07C2601/08;;C07C2603/18;;A61P11/06;;A61P29/00;;C07K5/02;;C07C323/60;;A61K38/00;;C07K5/0207;;C07K5/0205;;C07K5/0202;;C07C2601/08;;C07C2603/18,A61P11/06;;A61P29/00;;A61K38/00;;C07C323/60;;C07K5/02,540/453;;540/454,3,2,075-658-894-818-399;;102-386-394-876-884,10.1021/jm970175s;;9341911;;10.1016/s0021-9258(20)80735-2;;7690755,"Jackson, et al. J. Med. Chem. vol. 40, No. 21, pp. 3359-3368 (1997).;;Nowlin, et al. J. Biol. Chem. vol. 268, pp. 20352-20359 (1993).;;CA 133:171743 (2000).",EXPIRED
23,WO,A3,WO 2000/063234 A3,102-157-794-687-725,2001-01-18,2001,EP 0003459 W,2000-04-17,US 13021599 P,1999-04-20,PYRROLIDINCARBONYLAMINO CYCLIC DISULFIDES AS VCAM-VLA4 ANTAGONISTS,"Compounds of formula (I) are described which have activity as anti-inflammatory agents. Cyclic disulfide compounds are provided which inhibit of binding of cells to endothelium. Such compounds are useful for treating inflammatory diseases, such as asthma, whose symptoms and/or damage are related to the binding of cell adhesion molecules to integrin expressing cells.",HOFFMANN LA ROCHE,CHEN LI;;FOTOUHI NADER;;JACKSON DAVID YOUNG;;TILLEY JEFFERSON WRIGHT,,https://lens.org/102-157-794-687-725,Search Report,yes,0,0,21,21,0,A61K38/00;;C07C323/60;;C07K5/0202;;C07K5/0205;;C07K5/0207;;C07C2601/08;;C07C2603/18;;A61P11/06;;A61P29/00;;C07K5/02;;C07C323/60;;A61K38/00;;C07K5/0207;;C07K5/0205;;C07K5/0202;;C07C2601/08;;C07C2603/18,A61P11/06;;A61P29/00;;C07C323/60;;A61K38/00;;C07K5/02,,2,2,075-658-894-818-399;;073-154-320-416-399,10.1021/jm970175s;;9341911;;10.1016/s0960-894x(00)00174-8;;10866374,"D Y JACKSON ET AL.: ""Potent alpha4beta1 peptide antagonists as potential anti-inflammatory agents"", JOURNAL OF MEDICINAL CHEMISTRY., vol. 40, no. 21, 1997, AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 3359 - 3368, XP002148351, ISSN: 0022-2623;;DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FOTOUHI, NADER ET AL: ""The design and synthesis of potent cyclic peptide VCAM-VLA-4 antagonists incorporating an achiral Asp-Pro mimetic"", XP002148355, retrieved from STN Database accession no. 133:171743 CA",PATENTED
24,WO,A2,WO 2000/063234 A2,033-188-626-679-313,2000-10-26,2000,EP 0003459 W,2000-04-17,US 13021599 P,1999-04-20,PYRROLIDINCARBONYLAMINO CYCLIC DISULFIDES,"Compounds of formula (I) are described which have activity as anti-inflammatory agents. Cyclic disulfide compounds are provided which inhibit of binding of cells to endothelium. Such compounds are useful for treating inflammatory diseases, such as asthma, whose symptoms and/or damage are related to the binding of cell adhesion molecules to integrin expressing cells.",HOFFMANN LA ROCHE,CHEN LI;;FOTOUHI NADER;;JACKSON DAVID YOUNG;;TILLEY JEFFERSON WRIGHT,,https://lens.org/033-188-626-679-313,Patent Application,yes,0,5,21,21,0,A61K38/00;;C07C323/60;;C07K5/0202;;C07K5/0205;;C07K5/0207;;C07C2601/08;;C07C2603/18;;A61P11/06;;A61P29/00;;C07K5/02;;C07C323/60;;A61K38/00;;C07K5/0207;;C07K5/0205;;C07K5/0202;;C07C2601/08;;C07C2603/18,A61P11/06;;A61P29/00;;C07C323/60;;A61K38/00;;C07K5/02,,0,0,,,,PATENTED
25,US,B1,US 10785064 B1,177-298-594-094-116,2020-09-22,2020,US 201916659998 A,2019-10-22,US 201916659998 A;;US 201962884749 P,2019-08-09,Semiconductor device and method therefor,"In one embodiment, a transmitter circuit may be configured to transmit a signal to a receiver. The transmitter circuit may also be configured to detect receiving energy from a transient event, for example detect a transient current, and to direct at least a portion of the energy away from the transmitted signal while the transmitter circuit is transmitting the signal.",SEMICONDUCTOR COMPONENTS IND LLC,CHEN TAI-HUA;;HALL JEFFERSON W;;VLADOIANU FLORIN CORNEL;;GRAY RANDALL,SEMICONDUCTOR COMPONENTS INDUSTRIES LLC (2019-08-08),https://lens.org/177-298-594-094-116,Granted Patent,yes,5,4,2,2,0,H03K19/017545;;H04L25/0266;;H04L25/0272;;H03K19/018557;;H04B1/0475;;H04B1/0475;;H04B15/00;;H04L25/0266;;H04L25/0282,H04L25/02;;H04B1/04;;H04B15/00,,2,1,018-215-281-759-576,10.1109/vlsic.2016.7573497,"ON Semiconductor, “NCD5700—Isolated High Current IGBT Gate Driver,” Publication Order No. NCD57000/D, Feb. 2019, Rev. 2, 13 pages.;;Ruida Yun et al., “Transformer-based Digital Isolator With 20kVPK Surge Capability and > 200kV/uS Common Mode Transient Immunity,” 2016 Symposium on VLSI Circuits Digest of Technical Papers, IEEE 978-1-5090-0635, 2 pages.",ACTIVE
26,CN,A,CN 112350708 A,191-198-624-937-305,2021-02-09,2021,CN 202010788685 A,2020-08-07,US 201962884749 P;;US 201916659998 A,2019-08-09,Semiconductor device and method therefor,"The invention relates to a semiconductor device and a method thereof. In one embodiment, a transmitter circuit may be configured to transmit a signal to a receiver. The transmitter circuit may also beconfigured to detect received energy from a transient event, such as a transient current, and direct at least a portion of the energy away from the transmitted signal while the transmitter circuit transmits the signal.",SEMICONDUCTOR COMPONENTS IND LLC,CHEN TAI-HUA;;HALL JEFFERSON W;;VLADOIANU FLORIN CORNEL;;GRAY RANDALL,,https://lens.org/191-198-624-937-305,Patent Application,no,0,0,2,2,0,H03K19/017545;;H04L25/0266;;H04L25/0272;;H03K19/018557;;H04B1/0475;;H04B1/0475;;H04B15/00;;H04L25/0266;;H04L25/0282,H03K19/0175;;H03K19/0185,,0,0,,,,PENDING
27,EP,A3,EP 2339221 A3,178-099-190-858-161,2015-10-14,2015,EP 10015897 A,2010-12-21,TW 98145000 A,2009-12-25,Method for measuring remaining hydrogen capacity of hydrogen storage canister incorporating RFID device,"A method and system of gas refilling management for gas storage canister utilizing identification accessing control includes an identification information transmission device, a control device, and a gas refilling equipment, which are applicable for management of refilling of at least one storage canister. The storage canister is provided with an information identification label, which contains at least one record of canister information. By using the identification information transmission device to first read the information contained in the label of a storage canister, the control device may then set a refilling condition based on which the gas refilling equipment carries out a refilling operation to the storage canister, so as to suit for management of refilling various types of gas storage canisters to provide the best performance in a practical application.
",ASIA PACIFIC FUEL CELL TECH,YANG JEFFERSON YS;;HSIAO FENG-HSIANG;;CHANG HONG-SHI;;CHEN CHIH-HSUEH,,https://lens.org/178-099-190-858-161,Search Report,yes,7,1,7,7,0,F17C2201/0109;;F17C2205/0338;;F17C2205/054;;F17C2205/058;;F17C2221/011;;F17C2221/013;;F17C2227/04;;F17C2250/0421;;F17C2250/043;;F17C2250/0439;;F17C2250/0443;;F17C2250/0626;;F17C2250/0631;;F17C2250/0636;;F17C2250/075;;F17C2260/038;;F17C2270/0184;;F17C2270/0763;;F17C13/003;;Y02E60/32;;F17C2227/04;;F17C2270/0763;;F17C2250/0439;;F17C2205/058;;F17C2250/0421;;F17C2201/0109;;F17C2250/043;;F17C2250/0443;;F17C2205/0338;;F17C2205/054;;F17C2221/011;;F17C2250/075;;F17C2270/0184;;F17C2221/013;;F17C2250/0636;;F17C2260/038;;F17C2250/0631;;F17C2250/0626;;Y02E60/32;;F17C13/003,F17C13/00;;C01B3/00;;F17C5/06;;F17C13/02,,0,0,,,,DISCONTINUED
28,US,A1,US 2011/0227742 A1,136-454-013-985-397,2011-09-22,2011,US 97594210 A,2010-12-22,TW 98144996 A,2009-12-25,METHOD FOR MEASURING REMAINING HYDROGEN CAPACITY OF HYDROGEN STORAGE CANISTER INCORPORATING RFID DEVICE,"A method is provided for measuring remaining hydrogen capacity of hydrogen storage canister incorporating tag information. An information identification tag is attached to a hydrogen storage canister. The information identification tag contains therein at least one record of tag information indicating the hydrogen storage quantity of the hydrogen storage canister. Once the hydrogen storage quantity is read from the tag information of the information identification tag and hydrogen consumption quantity supplied from the hydrogen storage canister is detected, the hydrogen storage quantity is operated by subtracting the hydrogen consumption quantity therefrom to calculate a hydrogen residue, which is then used to update the tag information of the information identification tag or is stored for subsequent use.",ASIA PACIFIC FUEL CELL TECH,YANG JEFFERSON YS;;HSIAO FENG-HSIANG;;CHANG HONG-SHI;;CHEN CHIH-HSUEH,ASIA PACIFIC FUEL CELL TECHNOLOGIES LTD (2010-12-21),https://lens.org/136-454-013-985-397,Patent Application,yes,5,4,7,7,0,G01F9/001;;G01F9/001;;G01F13/006;;G01F13/006;;G01F23/18;;G01F23/18;;G01F23/185;;G01F23/185;;H01M8/04216;;H01M8/04216;;H01M8/04776;;H01M8/04776;;H01M2250/20;;H01M2250/20;;Y02E60/32;;Y02E60/32;;Y02E60/50;;Y02E60/50;;Y02T90/40;;Y02T90/40,G08B21/00;;H04Q5/22,340/614;;340/10.4,0,0,,,,ACTIVE
29,TW,B,TW I533155 B,040-308-653-278-934,2016-05-11,2016,TW 98144996 A,2009-12-25,TW 98144996 A,2009-12-25,TW I533155 B,,ASIA PACIFIC FUEL CELL TECH,YANG JEFFERSON YS;;XIAO FENG-XIANG;;ZHANG HONG-XI;;CHEN ZHI-XUE,,https://lens.org/040-308-653-278-934,Granted Patent,no,0,1,7,7,0,G01F9/001;;G01F9/001;;G01F13/006;;G01F13/006;;G01F23/18;;G01F23/18;;G01F23/185;;G01F23/185;;H01M8/04216;;H01M8/04216;;H01M8/04776;;H01M8/04776;;H01M2250/20;;H01M2250/20;;Y02E60/32;;Y02E60/32;;Y02E60/50;;Y02E60/50;;Y02T90/40;;Y02T90/40,,,0,0,,,,ACTIVE
30,EP,A1,EP 2339304 A1,127-300-854-540-845,2011-06-29,2011,EP 10015896 A,2010-12-21,TW 98144996 A,2009-12-25,Method for measuring remaining hydrogen capacity of hydrogen storage canister incorporating RFID device,"A method is provided for measuring remaining hydrogen capacity of hydrogen storage canister (3) incorporating tag information. An information identification tag (5) is attached to a hydrogen storage canister (3). The information identification tag contains therein at least one record of tag information indicating the hydrogen storage quantity of the hydrogen storage canister. Once the hydrogen storage quantity is read from the tag information of the information identification tag and hydrogen consumption quantity supplied from the hydrogen storage canister is detected, the hydrogen storage quantity is operated by subtracting the hydrogen consumption quantity therefrom to calculate a hydrogen residue, which is then used to update the tag information of the information identification tag or is stored for subsequent use.",ASIA PACIFIC FUEL CELL TECH,YS YANG JEFFERSON;;HSIAO FENG-HSIANG;;CHANG HONG-SHI;;CHEN CHIH-HSUEH,,https://lens.org/127-300-854-540-845,Patent Application,yes,5,5,7,7,0,G01F9/001;;G01F9/001;;G01F13/006;;G01F13/006;;G01F23/18;;G01F23/18;;G01F23/185;;G01F23/185;;H01M8/04216;;H01M8/04216;;H01M8/04776;;H01M8/04776;;H01M2250/20;;H01M2250/20;;Y02E60/32;;Y02E60/32;;Y02E60/50;;Y02E60/50;;Y02T90/40;;Y02T90/40,G01F9/00;;F17C1/00;;F17C13/02;;G01F13/00;;G01F23/18;;G01F25/00;;G01M3/00;;H01M8/04,,1,1,064-170-072-651-042,10.1016/j.jpowsour.2007.05.092,"MUELLER ET AL: ""Novel solid oxide fuel cell system controller for rapid load following"", JOURNAL OF POWER SOURCES, ELSEVIER SA, CH, vol. 172, no. 1, 20 September 2007 (2007-09-20), pages 308 - 323, XP022260076, ISSN: 0378-7753, DOI: 10.1016/J.JPOWSOUR.2007.05.092",ACTIVE
31,EP,A2,EP 2339221 A2,167-470-095-768-47X,2011-06-29,2011,EP 10015897 A,2010-12-21,TW 98145000 A,2009-12-25,Method for measuring remaining hydrogen capacity of hydrogen storage canister incorporating RFID device,"A method and system of gas refilling management for gas storage canister utilizing identification accessing control includes an identification information transmission device, a control device, and a gas refilling equipment, which are applicable for management of refilling of at least one storage canister. The storage canister is provided with an information identification label, which contains at least one record of canister information. By using the identification information transmission device to first read the information contained in the label of a storage canister, the control device may then set a refilling condition based on which the gas refilling equipment carries out a refilling operation to the storage canister, so as to suit for management of refilling various types of gas storage canisters to provide the best performance in a practical application.
",ASIA PACIFIC FUEL CELL TECH,YANG JEFFERSON YS;;HSIAO FENG-HSIANG;;CHANG HONG-SHI;;CHEN CHIH-HSUEH,,https://lens.org/167-470-095-768-47X,Patent Application,yes,0,7,7,7,0,F17C2201/0109;;F17C2205/0338;;F17C2205/054;;F17C2205/058;;F17C2221/011;;F17C2221/013;;F17C2227/04;;F17C2250/0421;;F17C2250/043;;F17C2250/0439;;F17C2250/0443;;F17C2250/0626;;F17C2250/0631;;F17C2250/0636;;F17C2250/075;;F17C2260/038;;F17C2270/0184;;F17C2270/0763;;F17C13/003;;Y02E60/32;;F17C2227/04;;F17C2270/0763;;F17C2250/0439;;F17C2205/058;;F17C2250/0421;;F17C2201/0109;;F17C2250/043;;F17C2250/0443;;F17C2205/0338;;F17C2205/054;;F17C2221/011;;F17C2250/075;;F17C2270/0184;;F17C2221/013;;F17C2250/0636;;F17C2260/038;;F17C2250/0631;;F17C2250/0626;;Y02E60/32;;F17C13/003,C01B3/00;;F17C13/00;;F17C5/06;;F17C13/02,,0,0,,,,DISCONTINUED
32,TW,A,TW 201123039 A,182-831-966-751-636,2011-07-01,2011,TW 98145000 A,2009-12-25,TW 98145000 A,2009-12-25,Gas-charging management system for storage tank combined with information identification and method thereof.,"A gas-charging management system for storage tanks combined with information identification includes an identification information transmission device, a control device and a gas filling apparatus. The gas-charging control system is used to perform gas-charging management for at least one storage tank. The storage tank has an information identification label that is used to store at least one piece of storage tank information. After the identification information transmission device reads label information on storage tank, the control device sets the gas-charging condition according to the label information. Furthermore, the gas filling apparatus charges the storage tank with the gas-charging condition to response to each type of storage tank for performing a proper gas-charging management, so as to bring a best effect in practical applications.",ASIA PACIFIC FUEL CELL TECH,YANG JEFFERSON YS;;XIAO FENG-XIANG;;ZHANG HONG-XI;;CHEN ZHI-XUE,,https://lens.org/182-831-966-751-636,Patent of Addition,no,0,0,7,7,0,F17C2201/0109;;F17C2205/0338;;F17C2205/054;;F17C2205/058;;F17C2221/011;;F17C2221/013;;F17C2227/04;;F17C2250/0421;;F17C2250/043;;F17C2250/0439;;F17C2250/0443;;F17C2250/0626;;F17C2250/0631;;F17C2250/0636;;F17C2250/075;;F17C2260/038;;F17C2270/0184;;F17C2270/0763;;F17C13/003;;Y02E60/32;;F17C2227/04;;F17C2270/0763;;F17C2250/0439;;F17C2205/058;;F17C2250/0421;;F17C2201/0109;;F17C2250/043;;F17C2250/0443;;F17C2205/0338;;F17C2205/054;;F17C2221/011;;F17C2250/075;;F17C2270/0184;;F17C2221/013;;F17C2250/0636;;F17C2260/038;;F17C2250/0631;;F17C2250/0626;;Y02E60/32;;F17C13/003,C01B3/00;;F17C5/06;;F17C13/02;;G06K19/067,,0,0,,,,ACTIVE
33,US,B2,US 8944119 B2,009-802-014-283-833,2015-02-03,2015,US 97596710 A,2010-12-22,TW 98145000 A,2009-12-25,Method and system of gas refilling management for gas storage canister utilizing identification accessing control,"A method and system of gas refilling management for gas storage canister utilizing identification accessing control includes an identification information transmission device, a control device, and a gas refilling equipment, which are applicable for management of refilling of at least one storage canister. The storage canister is provided with an information identification label, which contains at least one record of canister information. By using the identification information transmission device to first read the information contained in the label of a storage canister, the control device may then set a refilling condition based on which the gas refilling equipment carries out a refilling operation to the storage canister, so as to suit for management of refilling various types of gas storage canisters to provide the best performance in a practical application.",YANG JEFFERSON YS;;HSIAO FENG-HSIANG;;CHANG HONG-SHI;;CHEN CHIH-HSUEH;;ASIA PACIFIC FUEL CELL TECH,YANG JEFFERSON YS;;HSIAO FENG-HSIANG;;CHANG HONG-SHI;;CHEN CHIH-HSUEH,ASIA PACIFIC FUEL CELL TECHNOLOGIES LTD (2010-12-21),https://lens.org/009-802-014-283-833,Granted Patent,yes,34,4,7,7,0,F17C2201/0109;;F17C2205/0338;;F17C2205/054;;F17C2205/058;;F17C2221/011;;F17C2221/013;;F17C2227/04;;F17C2250/0421;;F17C2250/043;;F17C2250/0439;;F17C2250/0443;;F17C2250/0626;;F17C2250/0631;;F17C2250/0636;;F17C2250/075;;F17C2260/038;;F17C2270/0184;;F17C2270/0763;;F17C13/003;;Y02E60/32;;F17C2227/04;;F17C2270/0763;;F17C2250/0439;;F17C2205/058;;F17C2250/0421;;F17C2201/0109;;F17C2250/043;;F17C2250/0443;;F17C2205/0338;;F17C2205/054;;F17C2221/011;;F17C2250/075;;F17C2270/0184;;F17C2221/013;;F17C2250/0636;;F17C2260/038;;F17C2250/0631;;F17C2250/0626;;Y02E60/32;;F17C13/003,B65B1/04;;C01B3/00;;F17C5/06;;F17C13/00;;F17C13/02,141/3;;141/83;;141/94;;141/95;;340/572.1;;340/614,1,0,,,"Xiao, Shijie Title: Design and Implementation of Gas Cylinder Management System Based on RFID Master's Thesis Publication of Xiamen University, CN Publication Date: Jun. 26, 2007.",ACTIVE
34,EP,B1,EP 2339304 B1,159-853-802-112-778,2018-10-17,2018,EP 10015896 A,2010-12-21,TW 98144996 A,2009-12-25,Method for measuring remaining hydrogen capacity of hydrogen storage canister incorporating RFID device,,ASIA PACIFIC FUEL CELL TECH LTD,YS YANG JEFFERSON;;HSIAO FENG-HSIANG;;CHANG HONG-SHI;;CHEN CHIH-HSUEH,,https://lens.org/159-853-802-112-778,Granted Patent,yes,5,0,7,7,0,G01F13/006;;G01F23/18;;G01F23/185;;H01M8/04216;;H01M8/04776;;H01M2250/20;;G01F9/001;;Y02E60/32;;Y02T90/40;;Y02E60/50;;G01F13/006;;G01F23/18;;G01F23/185;;H01M8/04216;;H01M8/04776;;H01M2250/20;;Y02E60/32;;Y02T90/40;;G01F9/001;;Y02E60/50,G01F9/00;;G01F13/00;;G01F23/18;;H01M8/04082;;H01M8/04746,,1,0,,,"MUELLER ET AL: ""Novel solid oxide fuel cell system controller for rapid load following"", JOURNAL OF POWER SOURCES, ELSEVIER SA, CH, vol. 172, no. 1, 20 September 2007 (2007-09-20), pages 308-323, XP022260076, ISSN: 0378-7753, DOI: DOI:10.1016/J.JPOWSOUR.2007.05.092",ACTIVE
35,US,B2,US 9046393 B2,066-343-342-383-101,2015-06-02,2015,US 97594210 A,2010-12-22,TW 98144996 A,2009-12-25,Method for measuring remaining hydrogen capacity of hydrogen storage canister incorporating RFID device,"A method is provided for measuring remaining hydrogen capacity of hydrogen storage canister incorporating tag information. An information identification tag is attached to a hydrogen storage canister. The information identification tag contains therein at least one record of tag information indicating the hydrogen storage quantity of the hydrogen storage canister. Once the hydrogen storage quantity is read from the tag information of the information identification tag and hydrogen consumption quantity supplied from the hydrogen storage canister is detected, the hydrogen storage quantity is operated by subtracting the hydrogen consumption quantity therefrom to calculate a hydrogen residue, which is then used to update the tag information of the information identification tag or is stored for subsequent use.",YANG JEFFERSON YS;;HSIAO FENG-HSIANG;;CHANG HONG-SHI;;CHEN CHIH-HSUEH;;ASIA PACIFIC FUEL CELL TECH,YANG JEFFERSON YS;;HSIAO FENG-HSIANG;;CHANG HONG-SHI;;CHEN CHIH-HSUEH,ASIA PACIFIC FUEL CELL TECHNOLOGIES LTD (2010-12-21),https://lens.org/066-343-342-383-101,Granted Patent,yes,11,0,7,7,0,G01F9/001;;G01F9/001;;G01F13/006;;G01F13/006;;G01F23/18;;G01F23/18;;G01F23/185;;G01F23/185;;H01M8/04216;;H01M8/04216;;H01M8/04776;;H01M8/04776;;H01M2250/20;;H01M2250/20;;Y02E60/32;;Y02E60/32;;Y02E60/50;;Y02E60/50;;Y02T90/40;;Y02T90/40,G08B21/00;;G01F9/00;;G01F13/00;;G01F23/18;;H01M8/04,,0,0,,,,ACTIVE
36,TW,A,TW 201122888 A,075-712-217-030-320,2011-07-01,2011,TW 98144996 A,2009-12-25,TW 98144996 A,2009-12-25,Method of detecting hydrogen remaining amount in hydrogen storage tank by applying tag information.,"A method of detecting a hydrogen remaining amount in a hydrogen storage tank by applying tag information is disclosed. The hydrogen storage tank is provided with an information identification tag. The information identification tag is stored with at least one tag information representing hydrogen storage capacity of the hydrogen storage tank. After reading the tag information from the information identification tag, the present invention detects hydrogen consumption supplied by the hydrogen storage tank, subtracts the hydrogen consumption from the hydrogen storage capacity to obtain a hydrogen remaining amount, and updates the tag information of the information identification tag with the obtained hydrogen remaining volume, or stores the hydrogen remaining amount.",ASIA PACIFIC FUEL CELL TECH,YANG JEFFERSON YS;;XIAO FENG-XIANG;;ZHANG HONG-XI;;CHEN ZHI-XUE,,https://lens.org/075-712-217-030-320,Patent of Addition,no,0,0,7,7,0,G01F9/001;;G01F9/001;;G01F13/006;;G01F13/006;;G01F23/18;;G01F23/18;;G01F23/185;;G01F23/185;;H01M8/04216;;H01M8/04216;;H01M8/04776;;H01M8/04776;;H01M2250/20;;H01M2250/20;;Y02E60/32;;Y02E60/32;;Y02E60/50;;Y02E60/50;;Y02T90/40;;Y02T90/40,G06F19/00;;G06K19/067,,0,0,,,,ACTIVE
37,US,A1,US 2011/0226382 A1,142-070-057-776-356,2011-09-22,2011,US 97596710 A,2010-12-22,TW 98145000 A,2009-12-25,METHOD AND SYSTEM OF GAS REFILLING MANAGEMENT FOR GAS STORAGE CANISTER UTILIZING IDENTIFICATION ACCESSING CONTROL,"A method and system of gas refilling management for gas storage canister utilizing identification accessing control includes an identification information transmission device, a control device, and a gas refilling equipment, which are applicable for management of refilling of at least one storage canister. The storage canister is provided with an information identification label, which contains at least one record of canister information. By using the identification information transmission device to first read the information contained in the label of a storage canister, the control device may then set a refilling condition based on which the gas refilling equipment carries out a refilling operation to the storage canister, so as to suit for management of refilling various types of gas storage canisters to provide the best performance in a practical application.",ASIA PACIFIC FUEL CELL TECH,YANG JEFFERSON YS;;HSIAO FENG-HSIANG;;CHANG HONG-SHI;;CHEN CHIH-HSUEH,ASIA PACIFIC FUEL CELL TECHNOLOGIES LTD (2010-12-21),https://lens.org/142-070-057-776-356,Patent Application,yes,21,4,7,7,0,F17C2201/0109;;F17C2205/0338;;F17C2205/054;;F17C2205/058;;F17C2221/011;;F17C2221/013;;F17C2227/04;;F17C2250/0421;;F17C2250/043;;F17C2250/0439;;F17C2250/0443;;F17C2250/0626;;F17C2250/0631;;F17C2250/0636;;F17C2250/075;;F17C2260/038;;F17C2270/0184;;F17C2270/0763;;F17C13/003;;Y02E60/32;;F17C2227/04;;F17C2270/0763;;F17C2250/0439;;F17C2205/058;;F17C2250/0421;;F17C2201/0109;;F17C2250/043;;F17C2250/0443;;F17C2205/0338;;F17C2205/054;;F17C2221/011;;F17C2250/075;;F17C2270/0184;;F17C2221/013;;F17C2250/0636;;F17C2260/038;;F17C2250/0631;;F17C2250/0626;;Y02E60/32;;F17C13/003,C01B3/00;;B65B65/00;;F17C5/06;;F17C13/02,141/4;;141/94,0,0,,,,ACTIVE
38,TW,B,TW 490458 B,189-664-702-946-295,2002-06-11,2002,TW 87113768 A,1998-08-21,US 5671897 P,1997-08-22,"N-alkanoylphenylalanine derivatives, the preparation processes and uses thereof","Compounds of the formula, are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/189-664-702-946-295,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
39,WO,A2,WO 2001/035072 A2,036-056-961-194-633,2001-05-17,2001,US 0030896 W,2000-11-09,US 16435399 P;;US 17650400 P,1999-11-09,A SYSTEM FOR CELL-BASED SCREENING,"The present invention provides methods, computer readable storage medium, and kits for cell state identification in cells, where the method includes providing arrays of cells that possess luminescently labelled cell identification and cell state reporter molecules that have distinguishable luminescent emission spectra; imaging the cells to obtain luminescent signals from the cell identification and the cell state reporter molecules; converting the luminescent signals into digital data to create a mask of the cell identification reporter molecule and the cell state reporter molecules; and determining the intensity of the cell state reporter molecule mask that co-localizes with the cell identification reporter molecule mask to identify the cell as being in a particular physiological state.",CELLOMICS INC;;GHOSH RICHIK N;;DEBIASIO RICHARD;;CHEN YIH TAI;;BELLUTTA PAOLO;;GIULIANO KENNETH;;PASLEY JEFFERSON W,GHOSH RICHIK N;;DEBIASIO RICHARD;;CHEN YIH-TAI;;BELLUTTA PAOLO;;GIULIANO KENNETH;;PASLEY JEFFERSON W,,https://lens.org/036-056-961-194-633,Patent Application,yes,0,33,3,3,15,G01N33/5091;;G01N33/56966;;G01N15/1433,G01N15/14;;G01N33/50;;G01N33/569,,0,0,,,,PENDING
40,WO,A3,WO 2001/035072 A3,158-234-073-969-43X,2001-11-22,2001,US 0030896 W,2000-11-09,US 16435399 P;;US 17650400 P,1999-11-09,A SYSTEM FOR CELL-BASED SCREENING,"The present invention provides methods, computer readable storage medium, and kits for cell state identification in cells, where the method includes providing arrays of cells that possess luminescently labelled cell identification and cell state reporter molecules that have distinguishable luminescent emission spectra; imaging the cells to obtain luminescent signals from the cell identification and the cell state reporter molecules; converting the luminescent signals into digital data to create a mask of the cell identification reporter molecule and the cell state reporter molecules; and determining the intensity of the cell state reporter molecule mask that co-localizes with the cell identification reporter molecule mask to identify the cell as being in a particular physiological state.",CELLOMICS INC;;GHOSH RICHIK N;;DEBIASIO RICHARD;;CHEN YIH TAI;;BELLUTTA PAOLO;;GIULIANO KENNETH;;PASLEY JEFFERSON W,GHOSH RICHIK N;;DEBIASIO RICHARD;;CHEN YIH-TAI;;BELLUTTA PAOLO;;GIULIANO KENNETH;;PASLEY JEFFERSON W,,https://lens.org/158-234-073-969-43X,Search Report,yes,7,0,3,3,0,G01N33/5091;;G01N33/56966;;G01N15/1433,G01N15/14;;G01N33/50;;G01N33/569,,2,2,009-773-692-292-245;;160-318-959-113-702,1710962;;10.1002/cyto.990120214;;8085946;;10.1007/s002040050078,"POOT M ET AL: ""FLOW CYTOMETRIC ANALYSIS OF CELL CYCLE-DEPENDENT CHANGES IN CELL THIOL LEVEL BY COMBINING A NEW LASER DYE WITH HOECHST 33342"", CYTOMETRY, vol. 12, no. 2, 1991, pages 184 - 187, XP001006094, ISSN: 0196-4763;;SCHAPER MICHELLE M ET AL: ""Computer programs for calculation of median effective dose (LD-50 or ED-50) using the method of moving average interpolation."", ARCHIVES OF TOXICOLOGY, vol. 68, no. 5, 1994, pages 332 - 337, XP001006095, ISSN: 0340-5761",PENDING
41,WO,A1,WO 2020/214683 A1,088-762-436-412-350,2020-10-22,2020,US 2020/0028288 W,2020-04-15,US 201916386006 A,2019-04-16,COMPUTER-IMPLEMENTED NATURAL LANGUAGE UNDERSTANDING OF MEDICAL REPORTS,"A natural language understanding method begins with a radiological report text containing clinical findings. Errors in the text are corrected by analyzing character- level optical transformation costs weighted by a frequency analysis over a corpus corresponding to the report text. For each word within the report text, a word embedding is obtained, character-level embeddings are determined, and the word and character-level embeddings are concatenated to a neural network which generates a plurality of NER tagged spans for the report text. A set of linked relationships are calculated for the NER tagged spans by generating masked text sequences based on the report text and determined pairs of potentially linked NER spans. A dense adjacency matrix is calculated based on attention weights obtained from providing the one or more masked text sequences to a Transformer deep learning network, and graph convolutions are then performed over the calculated dense adjacency matrix.",COVERA HEALTH,VIANU RON;;BROWN NATHANIEL W;;DUBBIN GREGORY;;ELGORT DANIEL;;ODRY BENJAMIN;;SUUTARI BENJAMIN;;CHEN JEFFERSON,,https://lens.org/088-762-436-412-350,Patent Application,yes,0,0,11,15,0,G16H15/00;;G16H50/70;;G16H30/40;;G16H40/20;;G06N3/084;;G06N7/01;;G06N3/044;;G06N3/045;;G16H50/70;;G16H10/60;;G06N7/01,G16H15/00,,2,2,008-651-598-364-087;;098-405-398-975-810,10.1016/j.jbi.2017.11.007;;29146561;;10.1016/j.ipm.2018.06.001,"JAUREGI UNANUE IÑIGO ET AL: ""Recurrent neural networks with specialized word embeddings for health-domain named-entity recognition"", JOURNAL OF BIOMEDICAL INFORMATICS, vol. 76, 1 December 2017 (2017-12-01), pages 102 - 109, XP085290206, ISSN: 1532-0464, DOI: 10.1016/J.JBI.2017.11.007;;JIE MEI ET AL: ""Statistical learning for OCR error correction"", INFORMATION PROCESSING & MANAGEMENT., vol. 54, no. 6, 1 November 2018 (2018-11-01), GB, pages 874 - 887, XP055701792, ISSN: 0306-4573, DOI: 10.1016/j.ipm.2018.06.001",PENDING
42,AU,A,AU 2001/016564 A,143-917-385-217-892,2001-06-06,2001,AU 2001/016564 A,2000-11-09,US 16435399 P;;US 17650400 P;;US 0030896 W,1999-11-09,A system for cell-based screening,,CELLOMICS INC,GHOSH RICHIK N;;DEBIASIO RICHARD;;CHEN YIH-TAI;;BELLUTTA PAOLO;;GIULIANO KENNETH;;PASLEY JEFFERSON W,,https://lens.org/143-917-385-217-892,Patent Application,no,0,0,3,3,0,G01N33/5091;;G01N33/56966;;G01N15/1433,G01N15/14;;G01N33/50;;G01N33/569,,0,0,,,,DISCONTINUED
43,NO,L,NO 20000841 L,039-248-380-260-423,2000-02-21,2000,NO 20000841 A,2000-02-21,EP 9805135 W;;US 5671897 P,1997-08-22,N-Aroylfenylalanin-derivater,"Forbindelser med formelen:. så vel som deres salter og estere er beskrevet, hvor X, X', Z og Y er som beskrevet i beskrivelsen og som har aktivitet som inhibitorer av binding mellom VCAM-1 og celler som uttrykker VLA-4. Slike forbindelser er nyttige for behandling av sykdommer hvis symptomer og/eller skade er relatert til bindingen av VCAM-1 til celler som uttrykker VLA-4.",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/039-248-380-260-423,Abstract,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,DISCONTINUED
44,NO,D0,NO 20000841 D0,086-293-943-393-236,2000-02-21,2000,NO 20000841 A,2000-02-21,EP 9805135 W;;US 5671897 P,1997-08-22,N-Aroylfenylalanin-derivater,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/086-293-943-393-236,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,DISCONTINUED
45,AU,B2,AU 739511 B2,117-518-894-976-853,2001-10-11,2001,AU 1998/092620 A,1998-08-13,EP 9805135 W;;US 5671897 P,1997-08-22,N-aroylphenylalanine derivatives,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/117-518-894-976-853,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
46,TR,T2,TR 200000482 T2,121-502-827-014-310,2000-06-21,2000,TR 200000482 T,1998-08-13,US 5671897 P,1997-08-22,N-Aroilfenilalanin türevleri.,"Burada tarif edildigi gibi, formül (I) olan X, X', Z ve Y'nin sartnamede tarif edildigi gibi oldugu ve VCAM-1 hücreleri ile VLA-4 çikaran hücreler arasinda meydana gelen baglanmayi inhibe edici aktivite gösterdikleri bilesikler. Bu bilesikler. Bu bilesikler, semptomlari ve/veya harabiyeti VCAM-1'in VLA-4 çikaran hücrelere baglanmasi ile ilgili olan hastaliklarin tedavisinde yararlidir. Formül (I).",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/121-502-827-014-310,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,PENDING
47,WO,A1,WO 1999/010313 A1,148-203-290-946-07X,1999-03-04,1999,EP 9805144 W,1998-08-13,US 5692997 P,1997-08-22,N-AROYLPHENYLALANINE DERIVATIVES,Compounds of formula (I) are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and /or damage are related to the binding of VCAM-1 to cells expressing VLA-4.,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/148-203-290-946-07X,Patent Application,yes,2,137,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,2,1,035-230-547-171-641,10.1021/cr950066q;;11848856,"PATANI G A ET AL: ""BIOISOSTERISM: A RATIONAL APPROACH IN DRUG DESIGN"", CHEMICAL REVIEWS, vol. 96, no. 8, 1996, pages 3147 - 3176, XP000652176;;PATENT ABSTRACTS OF JAPAN vol. 013, no. 029 (C - 562) 23 January 1989 (1989-01-23)",PATENTED
48,SA,B1,SA 98190557 B1,082-688-386-566-966,2006-08-20,2006,SA 98190557 A,1998-09-16,US 5671897 P,1997-08-22,مشتقات N- آرويل فنيل ألانينN-aroylphenylalanine derivatives,الملخص: يتعلق الإختراع بمركبات compounds جديدة لها الصيغة:الأمراض، وبالأخص أمراض الإلتهاب التي فيها يؤدي هذا الإتحاد إلى إحداث المرض.49وأملاحها وأستراتها المقبولة صيدليا pharmaceutically acceptable حيث X، Z ،‘X و Y تكون كما يعرف فيما بعد والتي تقوم بتثبيط inhibit ارتباط4-VLA، طرق لتحضير تلك المركبات،الأدوية، طريقة لإنتاج تلك الأدوية والإستخدام للمركبات compounds الجديدة في علاج,HOFFMANN LA ROCHE,TILLEY JEFFERSON WRIGHT;;HULL KENNETH G;;GUTHRIE ROBERT WILLIAM;;HUANG TAI NANG;;CHEN LI;;SIDDURI ACHYTHARAO,,https://lens.org/082-688-386-566-966,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
49,UY,A1,UY 25150 A1,114-239-024-153-043,2001-01-31,2001,UY 25150 A,1998-08-21,US 5692997 P,1997-08-22,DERIVADOS DE LA N-AROILFENILALANINA,"Se describen compuestos de fórmula I los cuales tienen actividad como inhibidores de la unión entre la VCAM - 1 y las células que expresan la VLA - 4. Dichos compuestos son de utilidad para el tratamiento de enfermedades cuyos síntomas y/o lesiones están relacionados con la unión de la VCAM - 1 a las células que expresan la VLA - 4. Se trata de compuestos de fórmula l (como por ejemplo: 4-[[(2,6-diclorofenil)carbonil]amino]-N-[[1-[(4-metoxifenil)metil]ciclopentil]carbonil]-L-fenilalanina), en donde uno de X y X' son H, halogeno o alquilo inferior y el otro es un grupo de fórmula ll; Y es un grupo de fórmula lll; Z se selecciona entre H o alquilo inferior; y las sales farmacéuticamente aceptables de los mismos. Compuestos de fórmula l para emplear como medicamento en el tratamiento de artritis reumatoide, esclerosis múltiple, enfermedad inflamatoria del intestino o asma.",HOFFMANN LA ROCHE,TILLEY JEFFERSON WRIGHT;;SIDDURI ACHYTHARAO;;HULL KENNETH G;;HUANG TAI-NANG;;GUTHRIE ROBERT WILLIAM;;CHEN LI,,https://lens.org/114-239-024-153-043,Patent Application,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,EXPIRED
50,DE,D1,DE 69534204 D1,029-600-431-106-213,2005-06-16,2005,DE 69534204 T,1995-11-17,US 34205394 A;;US 9515110 W,1994-11-17,ENTNEHMER EINER FLÜSSIGKEITSPROBE,"An optical scheme for in situ identification of particulates in fluid such as engine oil, in which a portion of the fluid flow is tapped, fed via a conduit to a pair of optically transparent opposed plates, imaged through the plates, and the fluid returned to the main flow. Imaging is preferably done with a laser and photodetector array, and the output fed to a computer for image processing. Separation between the plates ensures that all the oil therebetween will be in the imaging system's near field. Preferably, the computer counts the number of particles in the oil, and classifies their shape, by scanning the image until it hits an object (i.e. hits an opaque pixel), using known chain code to trace the object's outline, determining the object's aspect ratio, and repeating for each object in the image. One embodiment uses a planar rotary member which is scalloped about its periphery. The scallops act to push oil continuously against an outer casing. The casing has a light source for directing coherent light at the rotary member, which is made reflective. As the rotary member moves in the casing, it carries fluid with it, and packs the fluid against the casing. The gap between the light source and the rotary member then constitutes the passageway which is imaged.",US GOV SEC NAVY,REINTJES F;;DUNCAN D;;MAHON RITA;;TANKERSLEY L;;HOWARD L;;SCHULTZ ABRAHAM;;CHEN VICTOR;;WILLEY JEFFERSON,,https://lens.org/029-600-431-106-213,Granted Patent,no,0,0,13,15,0,G01N15/0227;;G01N2015/0294;;G01N15/0227;;G01N2015/0294,G01N15/02,,0,0,,,,EXPIRED
51,EP,A1,EP 1005445 A1,045-191-527-123-937,2000-06-07,2000,EP 98945235 A,1998-08-13,EP 9805135 W;;US 5671897 P,1997-08-22,N-ALKANOYLPHENYLALANINE DERIVATIVES,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/045-191-527-123-937,Patent Application,yes,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
52,CO,A1,CO 4990955 A1,132-560-386-218-880,2000-12-26,2000,CO 98047880 A,1998-08-21,US 5671897 P,1997-08-22,DERIVADOS DE N-ALCANOILOFENILALANINA,"Un compuesto de la fórmula en donde: uno de X y X´ es hidrógeno, halógeno, o alquilo inferior, el otro es un grupo de la fórmula: en donde R1 es hidrógeno o alquilo inferior, R15 es halógeno, nitro, alquil sulfonilo inferior, ciano, alquilo inferior, OH, alcoxilo inferior, alcoxicarbonilo inferior, carboxilo, alquil aminosulfonilo inferior, perfluoro alquilo inferior, alquiltio inferior, hidroxi alquilo inferior, alcoxi alquilo inferior, halo alquilo inferior, alquiltio alquilo inferior, alquilsulfinil alquilo inferior, alquilsulfonil alquilo inferior, alquilsulfinilo inferior, alcanoilo inferior, aroilo, ariloxilo un grupo de la fórmula R17 CºC-, R16 es hidrógeno, halógeno, nitro, ciano, alquilo inferior, OH, perfluoro alquilo inferior o alquiltio inferior, R17 es hidrógeno, arilo, heteroarilo o alquilo inferior que está insustituido o sustituido por OH, arilo o heteroarilo, y a es 0 o 1; o uno de X y X´ es un grupo de la fórmula: ...",HOFFMANN LA ROCHE,LI CHEN;;GUTHRIE ROBERT WILLIAM;;TAI-NANG HUANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/132-560-386-218-880,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/13;;A61K31/135;;A61K31/165;;A61K31/195;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,PENDING
53,DE,T2,DE 69416753 T2,025-004-547-492-025,1999-10-07,1999,DE 69416753 T,1994-06-24,US 9370393 A,1993-07-26,Herstellung von 3-Pentensäure und Katalysator dafür,,DU PONT,BUNEL EMILIO ENRIQUE;;D AMORE MICHAEL BRIAN;;CHIANG CHEN-CHOU;;SCHAUMANN ERIK JEFFERSON;;SCOTT LEON SINGREY,,https://lens.org/025-004-547-492-025,Granted Patent,no,0,0,6,6,0,C07C51/04;;C07C51/58;;C07C51/04;;C07C51/58,B01J31/22;;C07B61/00;;C07C51/04;;C07C51/377;;C07C51/58;;C07C57/03;;C07C57/66;;C07F15/00,,0,0,,,,EXPIRED
54,DK,T3,DK 1005446 T3,030-271-003-896-053,2004-06-07,2004,DK 98946326 T,1998-08-13,EP 9805144 W;;US 5692997 P,1997-08-22,N-aroylphenylalaninderivater,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH G,,https://lens.org/030-271-003-896-053,Granted Patent,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,EXPIRED
55,EP,A1,EP 0640580 A1,156-445-422-061-92X,1995-03-01,1995,EP 94109784 A,1994-06-24,US 9370393 A,1993-07-26,Preparation of 3-pentenoic acid and a catalyst therefore.,"Preparation of 3-pentenoic acid by the reaction of 3-pentenoylchloride, water and butadiene. 3-chloro-1-butene and 1-chloro-2-butene are also formed. Preferably the 3-pentenoylchloride is formed by the reaction of chlorobutene with carbon monoxide using a palladium catalyst.",DU PONT,BUNEL EMILIO ENRIQUE;;D AMORE MICHAEL BRIAN;;CHIANG CHEN-CHOU;;SCHAUMANN ERIK JEFFERSON;;SCOTT LEON SINGREY,,https://lens.org/156-445-422-061-92X,Patent Application,yes,3,1,6,6,0,C07C51/04;;C07C51/58;;C07C51/04;;C07C51/58,C07B61/00;;C07C51/04;;C07C51/377;;C07C51/58;;C07C57/03;;B01J31/22;;C07C57/66;;C07F15/00,,0,0,,,,EXPIRED
56,CA,A1,CA 2300121 A1,185-425-771-673-477,1999-03-04,1999,CA 2300121 A,1998-08-13,EP 9805144 W;;US 5692997 P,1997-08-22,N-ALKANOYLPHENYLALANINE DERIVATIVES,Compounds of formula (I) are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and /or damage are related to the binding of VCAM-1 to cells expressing VLA-4.,HOFFMANN LA ROCHE,SIDDURI ACHYTHARAO;;HULL KENNETH G;;TILLEY JEFFERSON WRIGHT;;CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG,,https://lens.org/185-425-771-673-477,Patent Application,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,DISCONTINUED
57,US,B1,US 6229011 B1,188-023-376-046-737,2001-05-08,2001,US 13779898 A,1998-08-21,US 13779898 A;;US 9459298 P;;US 5671897 P,1997-08-22,N-aroylphenylalanine derivative VCAM-1 inhibitors,Compounds of the formula: ##STR1## are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;SIDDURI ACHYUTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH GREGORY,,https://lens.org/188-023-376-046-737,Granted Patent,yes,12,82,1,85,0,C07D213/82;;C07D213/82;;C07C233/87;;C07C233/87;;C07C235/52;;C07C235/52;;C07C237/36;;C07C237/36;;C07C311/17;;C07C311/17;;C07C311/21;;C07C311/21;;C07C317/44;;C07C317/44;;C07C323/62;;C07C323/62;;C07D211/64;;C07D211/64;;C07D215/30;;C07D215/30;;C07D215/50;;C07D215/50;;C07D233/32;;C07D233/32;;C07D233/36;;C07D233/36;;C07D239/28;;C07D239/28;;C07D249/06;;C07D249/06;;C07D261/18;;C07D261/18;;C07D277/56;;C07D277/56;;C07D295/15;;C07D295/15;;C07D401/12;;C07D401/12;;C07D413/12;;C07D413/12;;C07D471/04;;C07D471/04;;C07D487/04;;C07D487/04,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/88;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,544/171;;548/324.5;;548/323.5;;548/200;;548/215;;548/254;;548/261;;548/512;;562/443;;562/446;;562/447;;562/448;;562/449;;562/455;;562/457;;562/430;;560/34;;560/41;;544/171;;544/263;;544/325;;544/400;;546/116;;546/121;;546/175;;546/199;;546/215;;546/316,5,1,035-230-547-171-641,10.1021/cr950066q;;11848856,"Patani, et al. Chem. Reviews vol. 96, No. 8, 1996 pp. 3147-3176.;;Abstract corresponding to DE19654483.;;Abstract corresponding to DE 19548709 (B1) 1997.;;Patent Abstracts of Japan vol. 013, No. 029 (C-562), Jan. 23, 1989-JP 63233963 A, Showa Denko.;;Abstract corresponding to JP63233963 (1998).",EXPIRED
58,EP,A1,EP 1005446 A1,032-754-720-928-125,2000-06-07,2000,EP 98946326 A,1998-08-13,EP 9805144 W;;US 5692997 P,1997-08-22,N-AROYLPHENYLALANINE DERIVATIVES,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/032-754-720-928-125,Patent Application,yes,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,EXPIRED
59,HU,A2,HU P0003642 A2,038-384-275-915-408,2001-02-28,2001,HU P0003642 A,1998-08-13,US 5671897 P;;EP 9805135 W,1997-08-22,N-ALKANOYLPHENYLALANINE DERIVATIVES,"Az (I) általános képletű vegyületek[mely képletben X és X' közül az egyik hidrogénatomot, halogénatomot vagyalkilcsoportot és a másik (X-6) általános képletű csoport képvisel;ahol R1 jelentése hidrogénatom vagy alkilcsoport; R15 jelentése halogénatom, nitro-, alkilszulfonil-, ciano-, alkil-,hidroxil-, alkoxi-, alkoxi-karbonil-, karboxil-, alkil-amino-szulfonil-, perfluor-alkil-, alkil-tio-, hidroxi-alkil-, alkoxi-alkil-, halogén-alkil-, alkil-tio-alkil-, alkilszulfinil-alkil-,alkilszulfonil-alkil-, alkilszulfinil-, alkanoil-, aroil-, aril-oxi-csoport vagy R17-CC- csoport; R16 jelentése hidrogénatom, halogénatom, nitro-, ciano-, alkil-,hidroxil-, perfluor-alkil- vagy alkil-tio-csoport; R17 jelentése hidrogénatom, aril-, heteroaril- vagy alkilcsoport,amely helyettesítetlen vagy hidroxil-, aril- vagy heteroarilcsoporttalhelyettesítve lehet; a értéke 0 vagy 1; vagy X és X' közül az egyik(X-7) általános képletű csoportot képvisel, ahol Het jelentéseheteroaromás gyűrű; a, R1, R15 és R16 jelentése a fenti; R30 jelentése hidrogénatom, alkilcsoport vagy nincs jelen; vagy X ésX' közül az egyik (X-10) általános képletű csoport, ahol R18 jelentése alkil-, aril-, heteroaril-, aralkil- vagyheteroaralkilcsoport; R19 jelentése adott esetben helyettesített alkilcsoport, vagy R19jelentése aril- vagy heteroarilcsoport; R20 jelentése alkil- vagy alkanoilcsoport; vagy R19 és R20 együtt tetrametiléncsoport; és Y jelentése (Y-1) általános képletű csoport, ahol R22 és R23 jelentése hidrogénatom, alkil-, alkoxi-, alkoxi-alkil-,alkil-amino-, aril-, aralkil-, nitro-, ciano-, alkil-tio-,alkilszulfinil-, alkilszulfonil-, alkanoilcsoport, halogénatom és/vagyperfluor-alkil-csoport; és R24 jelentése hidrogénatom, hidroxil-, alkil-, alkoxi-,alkilszulfonil-, amino-, aril-, nitro-, cianocsoport, halogénatom vagy(1), (2) vagy (3) általános képletű csoport, ahol R25 jelentése hidrogénatom, alkil-, aril-, aril-alkil- vagy alkoxi-alkil-csoport; és R26 jelentése hidrogénatom vagy alkilcsoport; vagy R22 és R24 együtt kondenzált benzolgyűrű; vagy Y jelentése adott esetben helyettesített heteroaromás csoport; Z jelentése hidrogénatom vagy alkilcsoport], valamint sóik ésésztereik a VCAM-1-et és a VLA-4-et kifejező sejtek közötti kötődéstgátolják. Ó",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/038-384-275-915-408,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
60,PT,E,PT 1005445 E,078-160-535-831-269,2004-09-30,2004,PT 98945235 T,1998-08-13,US 5671897 P,1997-08-22,DERIVADOS DE N-ALCANOILFENILALANINA,,HOFFMANN LA ROCHE,TILLEY JEFFERSON WRIGHT;;CHEN LI;;HUANG TAI-NANG;;SIDDURI ACHYTHARAO;;GUTHRIE ROBERT WILLIAM;;HULL KENNETH G,,https://lens.org/078-160-535-831-269,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
61,AU,B2,AU 742928 B2,137-285-245-110-524,2002-01-17,2002,AU 1998/093419 A,1998-08-13,EP 9805144 W;;US 5692997 P,1997-08-22,N-alkanoylphenylalanine derivatives,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/137-285-245-110-524,Granted Patent,no,1,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,EXPIRED
62,AT,T1,AT E372768 T1,040-999-292-734-118,2007-09-15,2007,AT 02731094 T,2002-03-15,US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARYLETHYL) BENZYLAMINE ALS 5-HT6 REZEPTOR- ANTAGONISTE,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL;;FISHER MATTHEW;;GIETHLEN BRUNO;;GILLIG JAMES;;MCCOWAN JEFFERSON;;MILLER SHAWN;;SCHAUS JOHN,,https://lens.org/040-999-292-734-118,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,C07D233/64;;A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
63,CO,A1,CO 4990936 A1,108-701-132-660-19X,2000-12-26,2000,CO 98047882 A,1998-08-21,US 5692997 P,1997-08-22,DERIVADOS DE N-AROILFENILALANINA,"Un compuesto de fórmulaen donde uno de X y X´ es H, halógeno o alquilo inferior y el otro es un grupo de fórmulaen donde:R1 es hidrógeno o alquilo inferior, R15 es hidrógeno, halógeno, nitro, alquilsulfonilo inferior, ciano, alquilo inferior, alcoxicarbonilo inferior, carboxilo, alquilaminosulfonilo inferior, perfluoroalquilo inferior, alquiltio inferior, hidroxialquilo inferior, alcoxialquilo inferior, alquiltio alquilo inferior, alquilsulfinilalquilo inferior, alquilsulfonilalquilo inferior, alquilsulfinilo inferior, alcanoilo inferior, ariloxilo, aroilo, arilo o un grupo de fórmula R17 -CºC-, R16 es H, halógeno, nitro, ciano, alquilo inferior, OH, perfluoroalquilo inferior o alquiltio inferior, y R17 es H, arilo, heteroarilo, o alquilo inferior el cual está sin substituir o substituido con OH, arilo o heteroarilo, y a es 0 o 1; ...",HOFFMANN LA ROCHE,LI CHEN;;GUTHRIE ROBERT WILLIAM;;TAI-NANG HUANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/108-701-132-660-19X,Patent Application,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/165;;A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/40;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,PENDING
64,TR,T2,TR 200000481 T2,122-922-640-241-035,2000-06-21,2000,TR 200000481 T,1998-08-13,US 5692997 P,1997-08-22,N-Alkonoilfenilalenin türevleri.,"Formül (I)'in bilesimleri, açiklanmaktadir, bunlar VCAM-1 ve VLA-4'ü ifade eden hücreler arasinda baglama önleyicileri olarak aktiviteye sahiptirler. Bu tür bilesimler, semptom ve/veya hasarlari VCAM-1 ve VLA-4'ü ifade eden hücrelere baglanmasi ile ilgili oldugu hastaliklarin tedavisi için yararlidir.",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/122-922-640-241-035,Patent Application,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,PENDING
65,YU,A,YU 9600 A,150-871-722-199-959,2002-03-18,2002,YU 9600 A,1998-08-13,US 5671897 P,1997-08-22,N-ALKANOYLPHENYLALANINE DERIVATIVES,"Compounds of formula (1) as well as their salts and esters are disclosed wherein X, X', Z and Y are as described in the specification and which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.",HOFFMANN LA ROCHE,LI CHEN;;WILLIAM GUTHRIE ROBERT;;TAI-NANG HUANG;;HULL KENNETH G;;ACHYTHARAO SIDDURI;;WRIGHT TILLEY JEFFERSON,,https://lens.org/150-871-722-199-959,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,PENDING
66,EP,B1,EP 1005445 B1,186-669-271-856-16X,2004-05-26,2004,EP 98945235 A,1998-08-13,EP 9805135 W;;US 5671897 P,1997-08-22,N-ALKANOYLPHENYLALANINE DERIVATIVES,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/186-669-271-856-16X,Granted Patent,yes,4,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,1,0,,,"PATANI G A ET AL: ""BIOISOSTERISM: A RATIONAL APPROACH IN DRUG DESIGN"" CHEMICAL REVIEWS, vol. 96, no. 8, 1996, pages 3147-3176, XP000652176",EXPIRED
67,DK,T3,DK 1005445 T3,036-689-175-897-585,2004-10-04,2004,DK 98945235 T,1998-08-13,US 5671897 P,1997-08-22,N-alkanoylphenylaninderivater,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/036-689-175-897-585,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
68,WO,A1,WO 1999/010312 A1,025-871-104-947-364,1999-03-04,1999,EP 9805135 W,1998-08-13,US 5671897 P,1997-08-22,N-ALKANOYLPHENYLALANINE DERIVATIVES,"Compounds of formula (1) as well as their salts and esters are disclosed wherein X, X', Z and Y are as described in the specification and which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/025-871-104-947-364,Patent Application,yes,4,197,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,1,1,035-230-547-171-641,10.1021/cr950066q;;11848856,"PATANI G A ET AL: ""BIOISOSTERISM: A RATIONAL APPROACH IN DRUG DESIGN"", CHEMICAL REVIEWS, vol. 96, no. 8, 1996, pages 3147 - 3176, XP000652176",PATENTED
69,MA,A1,MA 26534 A1,082-863-596-793-556,2004-12-20,2004,MA 25222 A,1998-08-21,US 5692997 P,1997-08-22,INHIBITEURS DE FIXATION DE MOLECULES DE VCAM-1 A DES CELLULES EXPRIMANT VLA-4 ET LEUR PROCEDE DE FABRICATION.,,HOFFMANN LA ROCHE,LI CHEN;;ROBERT WILLIAM GUTHRIE;;TAI-NANG HUANG;;ACHYTHARAO SIDDURI;;JEFFERSON WRIGHT TILLEY;;KENNETH G HULL,,https://lens.org/082-863-596-793-556,Granted Patent,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,EXPIRED
70,MY,A,MY 129295 A,093-657-273-689-617,2007-03-30,2007,MY PI9803840 A,1998-08-21,US 5692997 P,1997-08-22,N-ALKANOYLPHENYLALANINE DERIVATIVES,"COMPOUDS OF THE FORMULA :(FORMULA 1) AS WELL AS THEIR SALTS AND ESTERS ARE DISCLOSED WHEREIN X, X', Z, AND Y ARE AS DESCRIBED IN THE SPECIFICATION AND WHICH HAVE ACTIVITY AS INHIBITORS OF BINDING BETWEEN VCAM-1 AND CELLS EXPRESSING VLA-4. SUCH COMPOUNDS ARE USEFUL FOR TREATING DISEASES WHOSE SYMPTOMS AND/OR DAMAGE ARE RELATED TO THE BINDING OF VCAM-1 TO CELLS EXPRESSING VLA-4.",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/093-657-273-689-617,Granted Patent,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,C07C233/87;;A61K31/165;;A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C235/40;;C07C235/52;;C07C235/64;;C07C235/82;;C07C237/24;;C07C237/36;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,EXPIRED
71,ES,T3,ES 2214728 T3,105-806-306-886-634,2004-09-16,2004,ES 98946326 T,1998-08-13,US 5692997 P,1997-08-22,DERIVADOS DE N-AROILFENILALANINA.,"Un compuesto de **fórmula** en donde: R1 es hidrógeno o alquilo C1-6, R15 es hidrógeno, halógeno, nitro, alquilsulfonilo C1-6, ciano, alquilo C1-6, alcoxilo C1-6, alcoxicarbonilo C1-6, carboxilo, alquilaminosulfonilo C1-6, perfluoroalquilo C1-6, alquiltio inferior, hidroxialquilo C1-6, alcoxialquilo C1-6, alquiltio-alquilo C1-6, alquilsulfinilalquilo C1-6, alquilsul- fonilalquilo C1-6, alquilsulfinilo C1-6, alcanoilo C1-6, ariloxilo, aroilo, arilo o un grupo de fórmula R17-CºC-, R16 es H, halógeno, nitro, ciano, alquilo C1-6, OH, perfluoroalquilo C1-6 o alquiltio C1-6, R17 es H, arilo, heteroarilo, o alquilo C1-6 el cual está sin substituir o substituido con OH, arilo o heteroarilo, y a es 0 ó 1.",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/105-806-306-886-634,Granted Patent,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,EXPIRED
72,US,B2,US 6806365 B2,109-004-355-522-862,2004-10-19,2004,US 11761602 A,2002-04-05,US 11761602 A;;US 13835398 A;;US 5692997 P;;US 9459198 P,1997-08-22,N-alkanoylphenylalanine derivatives,"
    Compounds of the formula: 

    are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4. 
",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH GREGORY,,https://lens.org/109-004-355-522-862,Granted Patent,yes,8,17,4,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;C07D213/81;;C07C275/18;;C07D261/18;;C07D213/89;;C07D295/088;;C07C275/60;;C07D487/04;;C07C235/64;;C07C235/82;;C07C317/44;;C07D317/30;;C07C335/08;;C07D317/68;;C07C271/22;;C07C233/87;;C07D211/64;;C07D249/06;;C07D233/32;;C07D217/26;;C07C323/60;;C07D257/04;;C07C255/57;;C07C275/30;;C07D231/14;;C07C255/41;;C07C275/24;;C07D277/14;;C07D401/06;;C07C235/40;;C07C237/24;;C07C2601/08;;C07C2601/14,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,544/169;;546/323;;548/214;;548/253;;548/374.1;;548/536;;549/436;;552/10;;558/406;;558/415;;560/30;;562/426;;562/429;;562/430;;562/435;;562/441;;562/448;;562/449,3,1,035-230-547-171-641,10.1021/cr950066q;;11848856,"Patani, et al. Chem. Reviews vol. 96, No. 8, 1996 pp. 3147-3176.;;Abstract corresponding to DE19654483, 1998.;;Abstract corresponding to DE 19548709 (B1), 1997.",EXPIRED
73,AU,A,AU 1998/092620 A,131-673-868-556-166,1999-03-16,1999,AU 1998/092620 A,1998-08-13,EP 9805135 W;;US 5671897 P,1997-08-22,N-alkanoylphenylalanine derivatives,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/131-673-868-556-166,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
74,AT,T1,AT E260243 T1,142-710-093-125-860,2004-03-15,2004,AT 98946326 T,1998-08-13,EP 9805144 W;;US 5692997 P,1997-08-22,N-AROYLPHENYLALANINDERIVATE,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/142-710-093-125-860,Granted Patent,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,DISCONTINUED
75,EP,B1,EP 0640580 B1,016-323-398-169-823,1999-03-03,1999,EP 94109784 A,1994-06-24,US 9370393 A,1993-07-26,Preparation of 3-pentenoic acid and a catalyst therefor,,DU PONT,BUNEL EMILIO ENRIQUE;;D AMORE MICHAEL BRIAN;;CHIANG CHEN-CHOU;;SCHAUMANN ERIK JEFFERSON;;SCOTT LEON SINGREY,,https://lens.org/016-323-398-169-823,Granted Patent,yes,3,0,6,6,0,C07C51/04;;C07C51/58;;C07C51/04;;C07C51/58,C07B61/00;;C07C51/04;;C07C51/377;;C07C51/58;;C07C57/03;;B01J31/22;;C07C57/66;;C07F15/00,,0,0,,,,EXPIRED
76,PL,B1,PL 193283 B1,086-493-429-939-714,2007-01-31,2007,PL 33885798 A,1998-08-13,EP 9805135 W;;US 5671897 P,1997-08-22,Derivatives of N-arylphenylalanine,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/086-493-429-939-714,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,C07C233/87;;A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/81;;C07D213/82;;C07D215/30;;C07D215/48;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/04;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
77,US,B1,US 6455550 B1,065-189-389-157-890,2002-09-24,2002,US 13835398 A,1998-08-21,US 13835398 A;;US 9459198 P;;US 5692997 P,1997-08-22,N-alkanoylphenylalanine derivatives,"
    Compounds of the formula: 

    are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4. 
",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH GREGORY,,https://lens.org/065-189-389-157-890,Granted Patent,yes,7,60,4,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;C07D213/81;;C07C275/18;;C07D261/18;;C07D213/89;;C07D295/088;;C07C275/60;;C07D487/04;;C07C235/64;;C07C235/82;;C07C317/44;;C07D317/30;;C07C335/08;;C07D317/68;;C07C271/22;;C07C233/87;;C07D211/64;;C07D249/06;;C07D233/32;;C07D217/26;;C07C323/60;;C07D257/04;;C07C255/57;;C07C275/30;;C07D231/14;;C07C255/41;;C07C275/24;;C07D277/14;;C07D401/06;;C07C235/40;;C07C237/24;;C07C2601/08;;C07C2601/14,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,514/341;;514/386;;546/274.4;;548/322.5;;548/325.5,5,1,035-230-547-171-641,10.1021/cr950066q;;11848856,"Patani, et al. Chem. Reviews vol. 96, No. 8, 1996 pp. 3147-3176.;;Abstract corresponding to DE19654483 (1998).;;Abstract corresponding to DE 19548709 (B1) (1997).;;Patent Abstracts of Japan vol. 013, No. 029 (C-562), Jan. 23, 1989-JP 63233963 A, Showa Denko.;;Abstract corresponding to JP63233963 (1989).",EXPIRED
78,DE,T2,DE 69534204 T2,135-898-236-737-56X,2006-02-23,2006,DE 69534204 T,1995-11-17,US 34205394 A;;US 9515110 W,1994-11-17,ENTNEHMER EINER FLÜSSIGKEITSPROBE,"An optical scheme for in situ identification of particulates in fluid such as engine oil, in which a portion of the fluid flow is tapped, fed via a conduit to a pair of optically transparent opposed plates, imaged through the plates, and the fluid returned to the main flow. Imaging is preferably done with a laser and photodetector array, and the output fed to a computer for image processing. Separation between the plates ensures that all the oil therebetween will be in the imaging system's near field. Preferably, the computer counts the number of particles in the oil, and classifies their shape, by scanning the image until it hits an object (i.e. hits an opaque pixel), using known chain code to trace the object's outline, determining the object's aspect ratio, and repeating for each object in the image. One embodiment uses a planar rotary member which is scalloped about its periphery. The scallops act to push oil continuously against an outer casing. The casing has a light source for directing coherent light at the rotary member, which is made reflective. As the rotary member moves in the casing, it carries fluid with it, and packs the fluid against the casing. The gap between the light source and the rotary member then constitutes the passageway which is imaged.",US GOV SEC NAVY,REINTJES F;;DUNCAN D;;MAHON RITA;;TANKERSLEY L;;HOWARD L;;SCHULTZ ABRAHAM;;CHEN VICTOR;;WILLEY JEFFERSON,,https://lens.org/135-898-236-737-56X,Granted Patent,no,0,2,13,15,0,G01N15/0227;;G01N2015/0294;;G01N15/0227;;G01N2015/0294,G01N15/02,,0,0,,,,EXPIRED
79,MY,A,MY 138140 A,128-991-492-518-799,2009-04-30,2009,MY PI9803841 A,1998-08-21,US 5671897 P,1997-08-22,N-AROYLPHENYLALANINE DERIVATIVES,COMPOUNDS OF THE FORMULA: ARE DISCLOSED WHICH HAVE ACTIVITY AS INHIBITORS OF BINDING BETWEEN VCAM-L AND CELLS EXPRESSING VLA-4. SUCH COMPOUNDS ARE USEFUL FOR TREATING DISEASES WHOSE SYMPTOMS AND/OR DAMAGE ARE RELATED TO THE BINDING OF VCAM-L TO CELLS EXPRESSING VLA-4.,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/128-991-492-518-799,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
80,SA,A,SA 98190557 A,138-275-132-138-43X,2005-12-03,2005,SA 98190557 A,1998-09-16,US 5671897 P,1997-08-22,N-aroylphenylalanine derivatives.,يتعلق الإختراع بمركبات compounds جديدة لها الصيغة:وأملاحها وأستراتها المقبولة صيدليا pharmaceutically acceptable حيث Z ،X' ،X و Y تكون كما يعرف فيما بعد والتي تقوم بتثبيط inhibit ارتباط 1-VCAM مع 4-VLA، طرق لتحضير تلك المركبات، الأدوية، طريقة لإنتاج تلك الأدوية والإستخدام للمركبات compounds الجديدة في علاج الأمراض، وبالأخص أمراض الإلتهاب التي فيها يؤدي هذا الإتحاد إلى إحداث المرض.,F HOFFMANN LAROCHE AG,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH G,,https://lens.org/138-275-132-138-43X,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,C07C233/87;;A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
81,WO,B1,WO 1999/010312 B1,146-650-029-432-851,1999-06-03,1999,EP 9805135 W,1998-08-13,US 5671897 P,1997-08-22,N-ALKANOYLPHENYLALANINE DERIVATIVES,"Compounds of formula (1) as well as their salts and esters are disclosed wherein X, X', Z and Y are as described in the specification and which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/146-650-029-432-851,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,PATENTED
82,ES,T3,ES 2221197 T3,088-650-612-328-734,2004-12-16,2004,ES 98945235 T,1998-08-13,US 5671897 P,1997-08-22,DERIVADOS DE N-ALCANOILFENILALANINA.,"Un compuesto de la **fórmula** en donde uno de X y X'' es hidrógeno, halógeno, o alquilo C1-6, el otro es un grupo es R1 es hidrógeno o alquilo C1-6, R15 es halógeno, nitro, alquil sulfonilo C1-6, ciano, alquilo C1-6, OH, alcoxilo C1-6, alcoxicarbonilo C1-6, carboxilo, alquil aminosulfonilo C1-6, perfluoro alquilo C1-6, alquiltio C1-6, hidroxi alquilo C1-6, alcoxi alquilo C1-6, halo alquilo C1-6, alquiltio alquilo C1-6, alquilsulfinil alquilo C1-6, alquilsulfonil alquilo C1-6, alquilsulfinilo C1-6, alcanoilo C1-6, aroilo, ariloxilo o un grupo de la fórmula R17 CC-, R16 es hidrógeno, halógeno, nitro, ciano, alquilo C1-6, OH, perfluoro alquilo C1-6 o alquiltio C1-6, R17 es hidrógeno, arilo, heteroarilo o alquilo C1-6 que está insustituido o sustituido por OH, arilo o heteroarilo, y a es 0 o 1.",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/088-650-612-328-734,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
83,BR,A,BR 9811730 A,157-630-215-237-938,2000-09-05,2000,BR 9811730 A,1998-08-13,EP 9805135 W;;US 5671897 P,1997-08-22,Derivados de n-aroilfenilalanina,"Patente de Invenção: <B>""DERIVADOS DE N-AROILFENILALANINA""<D>. São divulgados compostos da fórmula (I) bem como seus sais e ésteres, em que X, X', Z e Y são como descritos na especificação e que possuem atividade como inibidores de ligação entre VCAM-1 e células expressantes de VLA-4. Tais compostos são úteis para tratar doenças cujos sintomas e/ou danos são relacionados à ligação de VCAM-1 a células expressantes de VLA-4.",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/157-630-215-237-938,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
84,CZ,A3,CZ 2000597 A3,004-821-424-358-748,2000-07-12,2000,CZ 2000597 A,1998-08-13,CZ 2000597 A,1998-08-13,N-aroylphenyl alanine derivatives,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/004-821-424-358-748,Patent Application,no,0,0,1,1,0,,A61K31/165;;A61K31/33;;A61P11/06;;A61P19/02;;A61P29/00;;C07C233/87;;C07C235/52;;C07C237/36;;C07C317/50;;C07C323/39;;C07D215/50;;C07D231/00;;C07D233/32;;C07D239/00;;C07D295/088;;C07D487/04,,0,0,,,,PENDING
85,DZ,A1,DZ 3493 A1,038-391-589-168-754,2002-10-10,2002,DZ 023493 A,2002-03-15,US 32944901 P;;US 27992801 P;;US 0205115 W,2001-03-29,N-(2-ARYLETHYL)BENZYLAMINES COMME ANTAGONISTES DU RECEPTEUR 5-HT6,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL;;FISHER MATTHEW;;GIETHLEN BRUNO;;GILLIG JAMES;;MCCOWAN JEFFERSON;;MILLER SHAWN;;SCHAUS JOHN,,https://lens.org/038-391-589-168-754,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,C07D233/64;;A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
86,BR,B1,BR 9811730 B1,099-257-507-737-200,2014-04-08,2014,BR 9811730 A,1998-08-13,EP 9805135 W;;US 5671897 P,1997-08-22,"DERIVADOS DE N-AROILFENILALANINA, USO DOS MESMOS, MEDICAMENTOS CONTENDO OS MESMOS.",,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;WRIGHT TILLEY JEFFERSON,,https://lens.org/099-257-507-737-200,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,C07C233/87;;A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
87,EP,A1,EP 1403247 A1,003-824-693-129-57X,2004-03-31,2004,EP 03027533 A,1998-08-13,EP 98945235 A;;US 5671897 P,1997-08-22,N-Alkanoylphenylalanine derivatives,"Compounds of the formula:
   as well as their salts and esters are disclosed wherein X, X', Z, and Y are as described in the specification and which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.",HOFFMANN LA ROCHE,GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;TILLEY WRIGHT JEFFERSON;;CHEN LI;;HULL KENNETH GREGORY;;SIDDURI ACHYTHARAO,,https://lens.org/003-824-693-129-57X,Patent Application,yes,4,2,2,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D215/50;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,A61K31/00;;C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D215/50;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,1,1,035-230-547-171-641,10.1021/cr950066q;;11848856,"PATANI G A ET AL: ""BIOISOSTERISM: A RATIONAL APPROACH IN DRUG DESIGN"", CHEMICAL REVIEWS, vol. 96, no. 8, 1996, pages 3147 - 3176, XP000652176",DISCONTINUED
88,BR,A,BR 9811988 A,030-686-870-060-398,2000-09-05,2000,BR 9811988 A,1998-08-13,EP 9805144 W;;US 5692997 P,1997-08-22,Derivados de n-alcanoilfenilalanina,"Patente de Invenção: <B>""DERIVADOS DE N-ALCANOILFENILALANINA""<D>. São descritos compostos da fórmula (I) que têm atividades como inibidores da ligação entre <B>VCAM-1<D> e células expressando <B>VLA-4<D>. Estes compostos são utilizáveis para tratar doenças cujos sintomas e/ou dano estão relacionados com a ligação de <B>VCAM-1<D> às células expressando <B>VLA-4<D>.",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/030-686-870-060-398,Patent Application,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,DISCONTINUED
89,CA,C,CA 2301377 C,011-350-011-023-232,2009-10-06,2009,CA 2301377 A,1998-08-13,EP 9805135 W;;US 5671897 P,1997-08-22,N-AROYLPHENYLALANINE DERIVATIVES,"Compounds of formula (1) as well as their salts and esters are disclosed wherein X, X', Z and Y are as described in the specification and which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 t o cells expressing VLA-4.",HOFFMANN LA ROCHE,CHEN LI;;SIDDURI ACHYUTHARAO;;TILLEY JEFFERSON WRIGHT;;GUTHRIE ROBERT WILLIAM;;HULL KENNETH G;;HUANG TAI-NANG,,https://lens.org/011-350-011-023-232,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,C07C233/87;;A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/395;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
90,ZA,B,ZA 987604 B,016-097-239-460-290,1999-07-28,1999,ZA 987604 A,1998-08-21,US 5671897 P,1997-08-22,N-aroylphenylalanine derivatives,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYUTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/016-097-239-460-290,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
91,EC,A,EC SP982636 A,090-778-877-766-224,2001-07-27,2001,EC SP982636 A,1998-08-21,EC SP982636 A,1998-08-21,DERIVADOS DE N-ALCANOILOFENILALANINA,"Un compuesto de la fórmula en donde: uno de X y X¿ es hidrógeno, halógeno, o alquilo inferior, el otro es un grupo de la fórmula: en donde R1 es hidrógeno o alquilo inferior, R15 es halógeno, nitro, alquil sulfonilo inferior, ciano, alquilo inferior, OH, alcoxilo inferior, alcoxicarbonilo inferior, carboxilo, alquil aminosulfonilo inferior, perfluoro alquilo inferior, alquiltio inferior, hidroxi alquilo inferior, alcoxi alquilo inferior, halo alquilo inferior, alquiltio alquilo inferior, alquilsulfinil alquilo inferior, alquilsulfonil alquilo inferior, alquilsulfinilo inferior, alcanoilo inferior, aroilo, ariloxilo un grupo de la fórmula R17 CºC-, R16 es hidrógeno, halógeno, nitro, ciano, alquilo inferior, OH, perfluoro alquilo inferior o alquiltio inferior, R17 es hidrógeno, arilo, heteroarilo o alquilo inferior que está insustituido o sustituido por OH, arilo o heteroarilo, y a es 0 o 1.",,SIDDURI ACHYUTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH GREGORY;;CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG,,https://lens.org/090-778-877-766-224,Patent Application,no,0,0,1,1,0,,A61K31/16;;C07C233/45,,0,0,,,,PENDING
92,NZ,A,NZ 502813 A,179-151-405-090-412,2002-10-25,2002,NZ 50281398 A,1998-08-13,EP 9805135 W;;US 5671897 P,1997-08-22,N-aroylphenylalanine derivatives as inhibitors of the interaction between a4 containing integrins and VCAM-1,"Described are compounds of formula (I), wherein One of X and X' is hydrogen, halogen, or C1-6 alkyl, the other is a group of formula (II), or one of X and X' is a group of formula (III), wherein Het is a 5- or 6-membered heteroaromatic ring or Het is a 9- or 10-membered bicyclic heteroaromatic ring, or one of X and X' is a group of formula (IV), and Y is a group of formula (V), or a group selected from a 5- or 6-membered monocyclic heteroaromatic group containing 1-3 heteroatoms selected from N, O, and S or a 10-membered bicyclic heteroaromatic group containing 1-4 heteroatoms, selected from N, O, and S, wherein the heteroaromatic group is bonded via a carbon atom to the amide carbonyl, and Z is hydrogen or C1-6 alkyl. The compounds are used as medicaments for treating rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and asthma.",F,SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH G;;CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG,,https://lens.org/179-151-405-090-412,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,PENDING
93,DE,D1,DE 69416753 D1,044-560-457-229-465,1999-04-08,1999,DE 69416753 T,1994-06-24,US 9370393 A,1993-07-26,Herstellung von 3-Pentensäure und Katalysator dafür,,DU PONT,BUNEL EMILIO ENRIQUE;;D AMORE MICHAEL BRIAN;;CHIANG CHEN-CHOU;;SCHAUMANN ERIK JEFFERSON;;SCOTT LEON SINGREY,,https://lens.org/044-560-457-229-465,Granted Patent,no,0,0,6,6,0,C07C51/04;;C07C51/58;;C07C51/04;;C07C51/58,B01J31/22;;C07B61/00;;C07C51/04;;C07C51/377;;C07C51/58;;C07C57/03;;C07C57/66;;C07F15/00,,0,0,,,,EXPIRED
94,AU,A,AU 1998/093419 A,047-981-855-484-984,1999-03-16,1999,AU 1998/093419 A,1998-08-13,EP 9805144 W;;US 5692997 P,1997-08-22,N-aroylphenylalanine derivatives,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/047-981-855-484-984,Patent Application,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,EXPIRED
95,PE,A1,PE 111299 A1,083-487-617-482-993,1999-11-20,1999,PE 00076298 A,1998-08-21,US 5671897 P,1997-08-22,DERIVADOS DE N-AROILFENILALANINA,"SE REFIERE A UN COMPUESTO DE FORMULA I, UNO DE X Y X` ES H, HALOGENO o ALQUILO EL OTRO ES UN GRUPO X6, R1 ES H o ALQUILO; R15 ES HALOGENO, NITRO, ALQUILSULFONILO, ENTRE OTROS; R16 ES H, HALOGENO, NITRO, ENTRE OTROS; R17 ES H, ARILO, HETEROARILO, ENTRE OTROS; a ES 0 o 1, O UNO DE X Y X' ES UN GRUPO X7 O X10, HET ES UN MONO- O BICICLO HETEROAROMATICO, R30 ES H, ALQUILO O ESTA AUSENTE; R18 ES ALQUILO, ARILO, HETEROARILO, ENTRE OTROS; R19 ES ALQUILO, ARILO O HETEROARILO; R20 ES ALQUILO O ALCANOILO; o R19 o R20 SON TETRAMETILENO; Y ES UN GRUPO Y1 O UN MONO o BICICLO HETEROAROMATICO; R22 Y R23 SON H, ALQUILO, ALCOXILO, ENTRE OTROS; R24 ES H, OH, ALQUILO, ENTRE OTROS; o R22 Y R24 FORMAN JUNTOS BENCENO; Z ES H o ALQUILO. TAMBIEN SE REFIERE A UN METODO PARA LA PREPARACION. EL COMPUESTO I INHIBE LA UNION DE LA MOLECULA-1 DE ADHESION A LAS CELULAS VASCULARES (VCAM-1) A LA INTEGRINA VLA POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE, ENFERMEDAD INFLAMATORIA DEL INTESTINO O ASMA",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;SIDDURI ACHYUTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH GREGORY,,https://lens.org/083-487-617-482-993,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,C07C233/84;;A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/56;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/38;;C07D233/74;;C07D233/80;;C07D239/28;;C07D239/34;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/24;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
96,PE,A1,PE 107399 A1,098-308-393-790-177,1999-11-03,1999,PE 00076198 A,1998-08-21,US 5671897 P,1997-08-22,DERIVADOS DE N-ALCANOILFENILALANINA,"SE REFIERE A UN COMPUESTO I, DONDE UNO DE X o X` ES H, HALOGENO, ALQUILO Y EL OTRO ES GRUPO X6; R1 ES H o ALQUILO; R15 ES H, HALOGENO, NITRO, ALQUILSULFONILO, ENTRE OTROS; R16 ES H, HALOGENO, NITRO, CIANO, ENTRE OTROS; R17 ES H, ARILO, HETEROARILO, ENTRE OTROS; a ES 0 o 1; o UNO DE X Y X' ES GRUPO X7 o X10; HET ES UN MONO O BICICLO HETEROAROMATICO; R30 ES H o ALQUILO O NO EXISTE; R18 ES H, ALQUILO, ARILO, ENTRE OTROS; R19 ALQUILO, ARILO, HETEROARILO, ENTRE OTROS; R20 ES ALQUILO, ALCANOILO; Y ES -C(R22)(R23)(R24), GRUPO Y2; R22 Y R23 SON ARILO, HETEROARILO O ALQUILO; R24 ES ARILO, CIANO, ALQUILSULFONILO, ENTRE OTROS; R25 ES ALQUILO, ALQUENILO, R26-(CH2)e-; R26 ES ARILO, HETEROARILO, AZIDO, ENTRE OTROS; R28 ES H O ALQUILO; R29 ES H, ALQUILO, ALCOXICARBONILO, ENTRE OTROS; Q ES -(CH2)fO-, -(CH2)fS-, -(CH2)f, ENLACE; R27 ES H, ALQUILO, ARILO, ENTRE OTROS; e ES 0-4; f ES 0-3; Z ES H O ALQUILO. UN COMPUESTO PREFERIDO ES 4-[[(2,6-DICLOROFENIL)CARBONIL]AMINO]-N-[[1-[(4-METOXIFENIL)METIL]CICLOPENTIL]CARBONIL]-L-FENILALANINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I INHIBE LA UNION DE LA MOLECULA 1 DE ADHESION A LAS CELULAS VASCULARES (VCAM-1) A LA INTEGRINA VLA-4 Y PUEDE SER UTIL PARA TRATAR LA ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE, ENFERMEDAD INFLAMATORIA DEL INTESTINO O ASMA",HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;SIDDURI ACHYUTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH GREGORY,,https://lens.org/098-308-393-790-177,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,C07C229/36;;A61K31/165;;A61K31/195;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
97,PT,E,PT 1005446 E,116-554-532-742-701,2004-06-30,2004,PT 98946326 T,1998-08-13,US 5692997 P,1997-08-22,DERIVADOS DE N-AROILFENILALANINA,,HOFFMANN LA ROCHE,GUTHRIE ROBERT WILLIAM;;TILLEY JEFFERSON WRIGHT;;CHEN LI;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO,,https://lens.org/116-554-532-742-701,Granted Patent,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,EXPIRED
98,AU,C,AU 742928 C,140-208-056-125-849,2003-02-20,2003,AU 1998/093419 A,1998-08-13,EP 9805144 W;;US 5692997 P,1997-08-22,N-alkanoylphenylalanine derivatives,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/140-208-056-125-849,Amended Patent,no,1,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,EXPIRED
99,US,A1,US 2004/0210051 A1,155-255-670-833-382,2004-10-21,2004,US 82877104 A,2004-04-21,US 82877104 A;;US 11761602 A;;US 13835398 A;;US 5692997 P;;US 9459198 P,1997-08-22,N-alkanoylphenylalanine derivatives,"
    Compounds of the formula: 

   are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4. 
",CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH GREGORY,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH GREGORY,,https://lens.org/155-255-670-833-382,Patent Application,yes,1,0,4,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;C07D213/81;;C07C275/18;;C07D261/18;;C07D213/89;;C07D295/088;;C07C275/60;;C07D487/04;;C07C235/64;;C07C235/82;;C07C317/44;;C07D317/30;;C07C335/08;;C07D317/68;;C07C271/22;;C07C233/87;;C07D211/64;;C07D249/06;;C07D233/32;;C07D217/26;;C07C323/60;;C07D257/04;;C07C255/57;;C07C275/30;;C07D231/14;;C07C255/41;;C07C275/24;;C07D277/14;;C07D401/06;;C07C235/40;;C07C237/24;;C07C2601/08;;C07C2601/14,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,544/59;;544/162;;544/386;;546/225;;X5482;;548/236;;548/333.5;;X54853,0,0,,,,DISCONTINUED
100,ID,A,ID 24304 A,014-606-707-458-694,2000-07-13,2000,ID 20000344 A,1998-08-13,US 5671897 P,1997-08-22,N-ALKANOYLPHENYLALANINE DERIVATIVES,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/014-606-707-458-694,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,PENDING
101,CA,A1,CA 2301377 A1,008-285-376-891-028,1999-03-04,1999,CA 2301377 A,1998-08-13,EP 9805135 W;;US 5671897 P,1997-08-22,N-AROYLPHENYLALANINE DERIVATIVES,"Compounds of formula (1) as well as their salts and esters are disclosed wherein X, X', Z and Y are as described in the specification and which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.",HOFFMANN LA ROCHE,HUANG TAI-NANG;;HULL KENNETH G;;TILLEY JEFFERSON WRIGHT;;CHEN LI;;GUTHRIE ROBERT WILLIAM;;SIDDURI ACHYUTHARAO,,https://lens.org/008-285-376-891-028,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
102,AT,T1,AT E267801 T1,034-419-732-342-820,2004-06-15,2004,AT 98945235 T,1998-08-13,EP 9805135 W;;US 5671897 P,1997-08-22,N-ALKANOYLPHENYLALANINDERIVATE,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/034-419-732-342-820,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,PENDING
103,HR,A2,HR P20000080 A2,114-411-763-211-528,2000-12-31,2000,HR P20000080 A,2000-02-11,EP 9805135 W;;US 5671897 P,1997-08-22,N-ALKANOYLPHENYLALANINE DERIVATIVES,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/114-411-763-211-528,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,DISCONTINUED
104,UY,A1,UY 25151 A1,127-099-415-250-393,2001-01-31,2001,UY 25151 A,1998-08-21,US 5671897 P,1997-08-22,DERIVADOS DE LA N-ALQUILFENILALANINA,"La presente invención se refiere a derivados de la N-alquilfenilalanina de fórmula (I), en donde: uno de X y X' es H, halógeno, o alquilo, el otro es un grupo de la fórmula (X-6) (fig. 2) en donde: R1 es H o alquilo, R15 es H, halógeno, nitro, alquil sulfonilo, ciano, alquilo, OH, alcoxilo, alcoxicarbonilo, carboxilo, alquil aminosulfonilo, perfluoro alquilo, alquiltio, hidroxi alquilo, alcoxi alquilo, halo alquilo, alquilsulfinil alquilo, alcanoilo, aroilo, aril, ariloxilo; R16 es H, halógeno, nitro, ciano, alquilo, OH, perfluoro alquilo, alqiltio o ariloxi; a es 0 o 1; o uno de X y X' es un grupo de la fórmula (X-7) (fig. 3) en donde Het es un anillo heteroaromático de 5 o 6 miembros conteniendo 1, 2 o 3 heteroátomos elegidos entre N, O y S; o Het es un anillo heteroaromático bicíclico de 9 o 10 miembros conteniendo 1, 2, 3 o 4 heteroátomos elegidos entre N, O, y S, a, R1, R15 y R16 son como se ha indicado antes, y R30 es H o alquilo; o uno de X y X' es un grupo de la fórmula (X-10) (fig. 4) en donde R18 es alquilo, arilo, heteroarilo, arilalquilo, heteroaril alquilo, hidrógeno; R19 es alquilo, arilo o heteroarilo, y R20 es alquilo o alcanoilo, o R19 y R20 tomados juntos son tetrametileno; e Y es un grupo de fórmula (Y-1) (fig.5) en donde: R22 y R23 son independientemente H, alquilo, alcoxilo, alquilamino, arilo, arilalquilo, nitro, ciano, alquiltio, alquilsulfinilo, alquilsulfonilo, alcanoilo, halógeno, o perfluoroalquilo, y R24 es H, hidroxilo, alquilo, alcoxilo, alquilsulfonilo, amino, arilo, nitro, ciano, halógeno; Z es H o alquilo; y sus sales y ésteres farmacéuticamente aceptables. Asimismo, se refiere a un procedimiento para su preparación, a composiciones farmacéuticas que los contienen. Dichos compuestos inhiben la ligazón de VCAM-1 y fibronectina a VLA-4 en linfocitos, eosinófilos, basófilos y monocitos circulantes, y por tanto son útiles en el tratamiento de enfermedades inflamatorias crónicas, tales como artritis reumatoide, esclerosis múltiple, asma, y enfermedad intestinal inflamatoria. Ej. no limitante: N-(2-cloro-6-metilbenzoil)-4-[[(2,6-diclorofenil)carbonil]amino]-L-fenilalanina metil éster",HOFFMANN LA ROCHE,TILLEY JEFFERSON WRIGHT;;SIDDURI ACHYTHARAO;;HULL KENNETH G;;HUANG TAI-NANG;;GUTHRIE ROBERT WILLIAM;;CHEN LI,,https://lens.org/127-099-415-250-393,Patent Application,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,PENDING
105,US,A1,US 2003/0109459 A1,148-611-367-568-269,2003-06-12,2003,US 11761602 A,2002-04-05,US 11761602 A;;US 13835398 A;;US 5692997 P;;US 9459198 P,1997-08-22,N-alkanoylphenylalamine derivatives,"
    Compounds of the formula: 

   are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4. 
",CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH GREGORY,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH GREGORY,,https://lens.org/148-611-367-568-269,Patent Application,yes,0,0,4,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;C07D213/81;;C07C275/18;;C07D261/18;;C07D213/89;;C07D295/088;;C07C275/60;;C07D487/04;;C07C235/64;;C07C235/82;;C07C317/44;;C07D317/30;;C07C335/08;;C07D317/68;;C07C271/22;;C07C233/87;;C07D211/64;;C07D249/06;;C07D233/32;;C07D217/26;;C07C323/60;;C07D257/04;;C07C255/57;;C07C275/30;;C07D231/14;;C07C255/41;;C07C275/24;;C07D277/14;;C07D401/06;;C07C235/40;;C07C237/24;;C07C2601/08;;C07C2601/14,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,514/19;;514/352;;546/329;;562/426;;562/443,0,0,,,,EXPIRED
106,ZA,B,ZA 987602 B,185-168-651-593-507,1999-05-04,1999,ZA 987602 A,1998-08-21,US 5692997 P,1997-08-22,N-alkanoylphenylalanine derivatives,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYUTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/185-168-651-593-507,Granted Patent,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,EXPIRED
107,EP,B1,EP 1005446 B1,039-788-466-124-606,2004-02-25,2004,EP 98946326 A,1998-08-13,EP 9805144 W;;US 5692997 P,1997-08-22,N-AROYLPHENYLALANINE DERIVATIVES,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/039-788-466-124-606,Granted Patent,yes,2,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,2,0,,,"PATANI G A ET AL: ""BIOISOSTERISM: A RATIONAL APPROACH IN DRUG DESIGN"" CHEMICAL REVIEWS, vol. 96, no. 8, 1996, pages 3147-3176, XP000652176;;PATENT ABSTRACTS OF JAPAN vol. 013, no. 029 (C-562), 23 January 1989 & JP 63 233963 A (SHOWA DENKO KK;OTHERS: 01), 29 September 1988",EXPIRED
108,MA,A1,MA 26533 A1,145-628-134-263-095,2004-12-20,2004,MA 25221 A,1998-08-21,US 5671897 P,1997-08-22,NOUVEAUX COMPOSES UTILES POUR LE TRAITEMENT DE SYMPTOMES ET/OU LESIONS APPARENTES A LA LIAISON DE VCAM-1 AU CELLULES EXPRIMANT VLA-4,,HOFFMANN LA ROCHE,LI CHEN;;TAI-NANG HUANG;;ACHYTHARAO SIDDURI;;ROBERT WILLIAM GUTHRIE;;KENNETH G HULL;;JEFFERSON WRIGHT TILLEY,,https://lens.org/145-628-134-263-095,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C233/87;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
109,EC,A,EC SP982634 A,026-370-234-128-691,1999-02-22,1999,EC SP982634 A,1998-08-21,EC SP982634 A,1998-08-21,DERIVADOS DE N- AROILOFENIL ALANINA,"Se describen compuestos de fórmula (gráfico), los cuales tienen actividad como inhibidores de la unión entre la VCAM-1 y las células que expresan la VLA-4. Dichos compuestos son de utilidad para el tratamiento de enfermedades cuyos sintomas y/o lesiones están relacionadas con la unión de la VCAM-1 a las células que expresan la VLA-4.",,SIDDURI ACHYUTHARAO;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH GREGORY;;CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG,,https://lens.org/026-370-234-128-691,Patent Application,no,0,0,1,1,0,,A61K31/16;;C07C233/00,,0,0,,,,PENDING
110,HU,B1,HU 229362 B1,053-257-707-091-943,2013-11-28,2013,HU P0003642 A,1998-08-13,US 5671897 P;;EP 9805135 W,1997-08-22,N-ALKANOYLPHENYLALANINE DERIVATIVES,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/053-257-707-091-943,Granted Patent,no,0,0,49,85,0,C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P43/00;;C07C233/87,C07C233/87;;A61K31/165;;A61K31/198;;A61K31/216;;A61K31/27;;A61K31/277;;A61K31/33;;A61K31/41;;A61K31/4192;;A61K31/42;;A61K31/426;;A61K31/437;;A61K31/44;;A61K31/4418;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/66;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/00;;A61P29/00;;C07C235/52;;C07C235/84;;C07C237/22;;C07C237/36;;C07C275/42;;C07C311/17;;C07C311/21;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/62;;C07D211/64;;C07D213/82;;C07D215/30;;C07D215/50;;C07D233/32;;C07D233/36;;C07D233/74;;C07D233/80;;C07D239/28;;C07D249/06;;C07D257/06;;C07D261/18;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
111,SA,B1,SA 98190482 B1,112-760-980-790-91X,2006-08-20,2006,SA 98190482 A,1998-09-01,US 5692997 P,1997-08-22,N- ALKANOYLPHENYLALANINE DERIVATIVES,I الملخص: يتعلق الاختراع بمركبات جديدة لها الصيغة:وأملاحها وأستراتها المقبولة صيدليا pharmaceutically acceptable حيث X' ،X، Z و Y تكون كما يعرف فيما بعد والتي تقوم بتثبيط ارتباط 1-VCAM مع 4-VLA، طرق لتحضير تلك المركبات، الأدوية، طريقة لإنتاج تلك الأدوية والاستخدام للمركبات الجديدة في علاج الأمراض، وبالأخص أمراض الالتهاب التي فيها يؤدي هذا الاتحاد إلى إحداث المرض.,HOFFMANN LA ROCHE,GUTHRIE ROBERT WILLIAM;;SIDDURI ACHYTHARAW;;HUANG TAI NANG;;CHEN LI;;TILLEY JEFFERSON WRIGHT;;HULL KENNETH G,,https://lens.org/112-760-980-790-91X,Granted Patent,no,0,0,28,85,0,C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C323/60;;C07C335/08;;C07D211/64;;C07D213/81;;C07D213/89;;C07D217/26;;C07D231/14;;C07D233/32;;C07D249/06;;C07D257/04;;C07D261/18;;C07D277/14;;C07D295/088;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04;;C07C2601/08;;C07C2601/14;;A61P1/00;;A61P11/06;;A61P19/02;;C07C237/34,A61K31/198;;A61K31/33;;A61K31/357;;A61K31/36;;A61K31/401;;A61K31/41;;A61K31/415;;A61K31/4166;;A61K31/42;;A61K31/426;;A61K31/44;;A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/4439;;A61K31/47;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/5375;;A61K31/5377;;A61P1/00;;A61P11/06;;A61P19/02;;C07C233/81;;C07C233/87;;C07C235/40;;C07C235/64;;C07C235/82;;C07C237/24;;C07C255/41;;C07C255/57;;C07C271/22;;C07C275/18;;C07C275/24;;C07C275/30;;C07C275/60;;C07C317/44;;C07C317/50;;C07C323/39;;C07C323/60;;C07C335/08;;C07D207/16;;C07D211/64;;C07D213/81;;C07D213/82;;C07D213/89;;C07D215/50;;C07D217/26;;C07D231/14;;C07D233/32;;C07D233/38;;C07D239/28;;C07D249/06;;C07D257/04;;C07D261/08;;C07D261/18;;C07D277/14;;C07D277/20;;C07D277/56;;C07D295/08;;C07D295/088;;C07D295/14;;C07D317/30;;C07D317/68;;C07D401/06;;C07D487/04,,0,0,,,,EXPIRED
112,ES,T3,ES 2292758 T3,168-473-767-015-332,2008-03-16,2008,ES 02731094 T,2002-03-15,US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARILETIL) BENCILAMINAS COMO ANTAGONISTAS DEL RECEPTOR 5-HT6.,"Un compuesto de fórmula Formula 1 en la cual X se selecciona entre el grupo que consiste en -O-, -NH-, -S-, -SO2-, -CH2-, -CH(F)-, -CH(OH) y -C(O)-; R1 se selecciona entre el grupo que consiste en fenilo opcionalmente sustituido, naftilo opcionalmente sustituido un heterociclo aromático monocíclico de 5 a 6 miembros opcionalmente sustituido que tiene un heteroátomo seleccionado entre el grupo que consiste en nitrógeno, oxígeno y azufre, de forma que el heterociclo aromático monocíclico de 5 a 6 miembros está opcionalmente benzocondensado. R2 se selecciona entre el grupo que consiste en hidrógeno y alquilo C1-C3; R3 se selecciona entre el grupo que consiste en hidrógeno, flúor y metilo; R4 se selecciona entre el grupo que consiste en hidrógeno, alilo, alquilo C2-C4, alquilo C2-C4 fluorado, fenilo opcionalmente sustituido, fenilsulfonilo opcionalmente sustituido, bencilo opcionalmente sustituido y un heterociclo aromático monocíclico de 5 a 6 miembros opcionalmente sustituido que tiene uno o dos heteroátomos seleccionados entre el grupo que consiste en nitrógeno, oxígeno y azufre, con la condición de que R4 no es fenilsulfonilo opcionalmente sustituido cuando X es -SO2-, -CH2-, -CH(F)-, -CH(OH)- o -C(O)-; y sus sales farmacéuticamente aceptables, distintas de 3-etoxibencil-[2-(4-etoxifenil)etil]amina, 3-etoxibencil-[2-(3-etoxifenil)etil]amina, 3-etoxibencil-[2-(2-etoxifenil)etil]amina y N-[2-(3, 4-dimetoxifenil)etil]-3-fenoxibencilamina.",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY,,https://lens.org/168-473-767-015-332,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
113,SI,T1,SI 1005445 T1,189-047-283-821-880,2004-12-31,2004,SI 9830667 T,1998-08-13,EP 9805135 W;;EP 98945235 A;;US 5671897 P,1997-08-22,N-ALKANOYLPHENYLALANINE DERIVATIVES,,HOFFMANN LA ROCHE,CHEN LI;;GUTHRIE ROBERT WILLIAM;;HUANG TAI-NANG;;HULL KENNETH G;;SIDDURI ACHYTHARAO;;TILLEY JEFFERSON WRIGHT,,https://lens.org/189-047-283-821-880,Granted Patent,no,0,0,2,85,0,C07D239/28;;C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D215/50;;C07D233/36;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,A61K31/00;;C07C233/87;;C07C235/52;;C07C237/36;;C07C311/17;;C07C311/21;;C07C317/44;;C07C323/62;;C07D211/64;;C07D215/50;;C07D233/36;;C07D239/28;;C07D249/06;;C07D261/18;;C07D277/56;;C07D295/15;;C07D401/12;;C07D413/12;;C07D471/04;;C07D487/04,,0,0,,,,EXPIRED
114,US,A1,US 2020/0334416 A1,169-993-050-225-16X,2020-10-22,2020,US 202016849506 A,2020-04-15,US 202016849506 A;;US 201916386006 A,2019-04-16,COMPUTER-IMPLEMENTED NATURAL LANGUAGE UNDERSTANDING OF MEDICAL REPORTS,"A natural language understanding method begins with a radiological report text containing clinical findings. Errors in the text are corrected by analyzing character-level optical transformation costs weighted by a frequency analysis over a corpus corresponding to the report text. For each word within the report text, a word embedding is obtained, character-level embeddings are determined, and the word and character-level embeddings are concatenated to a neural network which generates a plurality of NER tagged spans for the report text. A set of linked relationships are calculated for the NER tagged spans by generating masked text sequences based on the report text and determined pairs of potentially linked NER spans. A dense adjacency matrix is calculated based on attention weights obtained from providing the one or more masked text sequences to a Transformer deep learning network, and graph convolutions are then performed over the calculated dense adjacency matrix.",COVERA HEALTH,VIANU RON;;BROWN W NATHANIEL;;DUBBIN GREGORY ALLEN;;ELGORT DANIEL ROBERT;;ODRY BENJAMIN L;;SUUTARI BENJAMIN SELLMAN;;CHEN JEFFERSON,COVERA HEALTH (2020-04-28),https://lens.org/169-993-050-225-16X,Patent Application,yes,8,72,2,15,0,G06F40/295;;G06F40/117;;G16H15/00;;G16H50/70;;G06N3/088;;G06V30/40;;G06V30/153;;G06V30/10;;G06V10/82;;G06V30/262;;G06V10/764;;G06N3/042;;G06N7/01;;G06N3/044;;G06N3/045;;G06F18/2413;;G06F40/295;;G16H15/00;;G06N3/08;;G06V30/40;;G06V30/10;;G06F40/10;;G06V10/82;;G06V30/153;;G06V30/262;;G06V10/764,G06F40/295;;G06K9/00;;G06N3/08;;G16H15/00,,2,1,050-313-679-288-072,10.1136/amiajnl-2012-000812;;22771530;;pmc3422839,"Gorinski, Philip John, et al. ""Named entity recognition for electronic health records: a comparison of rule-based and machine learning approaches."" arXiv preprint arXiv:1903.03985 (2019). (Year: 2019);;Xu, Yan, Junichi Tsujii, and Eric I-Chao Chang. ""Named entity recognition of follow-up and time information in 20 000 radiology reports."" Journal of the American Medical Informatics Association 19.5 (2012): 792-799. (Year: 2012)",ACTIVE
115,AU,A1,AU 2020/260079 A1,127-681-114-744-035,2021-11-18,2021,AU 2020/260079 A,2020-04-15,US 201916386006 A;;US 2020/0028288 W,2019-04-16,Computer-implemented natural language understanding of medical reports,"A natural language understanding method begins with a radiological report text containing clinical findings. Errors in the text are corrected by analyzing character- level optical transformation costs weighted by a frequency analysis over a corpus corresponding to the report text. For each word within the report text, a word embedding is obtained, character-level embeddings are determined, and the word and character-level embeddings are concatenated to a neural network which generates a plurality of NER tagged spans for the report text. A set of linked relationships are calculated for the NER tagged spans by generating masked text sequences based on the report text and determined pairs of potentially linked NER spans. A dense adjacency matrix is calculated based on attention weights obtained from providing the one or more masked text sequences to a Transformer deep learning network, and graph convolutions are then performed over the calculated dense adjacency matrix.",COVERA HEALTH,VIANU RON;;BROWN NATHANIEL W;;DUBBIN GREGORY ALLEN;;ELGORT DANIEL ROBERT;;ODRY BENJAMIN L;;SUUTARI BENJAMIN SELLMAN;;CHEN JEFFERSON,,https://lens.org/127-681-114-744-035,Patent Application,no,0,0,11,15,0,G16H15/00;;G16H50/70;;G16H30/40;;G16H40/20;;G06N3/084;;G06N7/01;;G06N3/044;;G06N3/045;;G16H50/70;;G16H10/60;;G06N7/01,G16H15/00,,0,0,,,,PENDING
116,EP,A1,EP 3956901 A1,075-182-553-020-169,2022-02-23,2022,EP 20724306 A,2020-04-15,US 201916386006 A;;US 2020/0028288 W,2019-04-16,COMPUTER-IMPLEMENTED NATURAL LANGUAGE UNDERSTANDING OF MEDICAL REPORTS,,COVERA HEALTH,VIANU RON;;BROWN NATHANIEL W;;DUBBIN GREGORY ALLEN;;ELGORT DANIEL ROBERT;;ODRY BENJAMIN L;;SUUTARI BENJAMIN SELLMAN;;CHEN JEFFERSON,,https://lens.org/075-182-553-020-169,Patent Application,yes,0,0,11,15,0,G16H15/00;;G16H50/70;;G16H30/40;;G16H40/20;;G06N3/084;;G06N7/01;;G06N3/044;;G06N3/045;;G16H50/70;;G16H10/60;;G06N7/01,G16H15/00,,0,0,,,,PENDING
117,US,B2,US 11790171 B2,197-903-587-388-667,2023-10-17,2023,US 202016849506 A,2020-04-15,US 202016849506 A;;US 201916386006 A,2019-04-16,Computer-implemented natural language understanding of medical reports,"A natural language understanding method begins with a radiological report text containing clinical findings. Errors in the text are corrected by analyzing character-level optical transformation costs weighted by a frequency analysis over a corpus corresponding to the report text. For each word within the report text, a word embedding is obtained, character-level embeddings are determined, and the word and character-level embeddings are concatenated to a neural network which generates a plurality of NER tagged spans for the report text. A set of linked relationships are calculated for the NER tagged spans by generating masked text sequences based on the report text and determined pairs of potentially linked NER spans. A dense adjacency matrix is calculated based on attention weights obtained from providing the one or more masked text sequences to a Transformer deep learning network, and graph convolutions are then performed over the calculated dense adjacency matrix.",COVERA HEALTH,VIANU RON;;BROWN W NATHANIEL;;DUBBIN GREGORY ALLEN;;ELGORT DANIEL ROBERT;;ODRY BENJAMIN L;;SUUTARI BENJAMIN SELLMAN;;CHEN JEFFERSON,COVERA HEALTH (2020-04-28),https://lens.org/197-903-587-388-667,Granted Patent,yes,8,0,2,15,0,G06F40/295;;G06F40/117;;G16H15/00;;G16H50/70;;G06N3/088;;G06V30/40;;G06V30/153;;G06V30/10;;G06V10/82;;G06V30/262;;G06V10/764;;G06N3/042;;G06N7/01;;G06N3/044;;G06N3/045;;G06F18/2413;;G06F40/295;;G16H15/00;;G06N3/08;;G06V30/40;;G06V30/10;;G06F40/10;;G06V10/82;;G06V30/153;;G06V30/262;;G06V10/764,G06F40/295;;G06F40/10;;G06N3/08;;G06V10/764;;G06V10/82;;G06V30/10;;G06V30/148;;G06V30/262;;G06V30/40;;G16H15/00,,7,3,050-313-679-288-072;;008-651-598-364-087;;098-405-398-975-810,10.1136/amiajnl-2012-000812;;22771530;;pmc3422839;;10.1016/j.jbi.2017.11.007;;29146561;;10.1016/j.ipm.2018.06.001,"Gorinski, Philip John, et al. “Named entity recognition for electronic health records: a comparison of rule-based and machine learning approaches.” arXiv preprint arXiv:1903.03985 (2019). (Year: 2019).;;Xu, Yan, Junichi Tsujii, and Eric I-Chao Chang. “Named entity recognition of follow-up and time information in 20 000 radiology reports.” Journal of the American Medical Informatics Association 19.5 (2012): 792-799. (Year: 2012).;;International Preliminary Report on Patenabilit in related international application No. PCT/US2020/028288 dated Aug. 6, 2021.;;Written Opinion of the International Preliminary Examining Authority in corresponding international application No. PCT/US2020/028288 dated Oct. 14, 2020.;;International Search Report and Written Opinion in corresponding international application No. PCT/US2020/028288 dated Jun. 19, 2020.;;“Recurent Neural Networks with Specialized Word Embeddings for Health-Domain Named-Entity Recognition”, Jourmal of Biomedical Informatics, vol. 76, pp. 102-109, Dec. 1, 2017.;;“Statistical Learning for OCR Error Correction”, Information Processing and Management, vol. 54, No. 6, pp. 874-887, Nov. 1, 2018.",ACTIVE
118,CA,A1,CA 3137096 A1,126-824-290-360-603,2020-10-22,2020,CA 3137096 A,2020-04-15,US 201916386006 A;;US 2020/0028288 W,2019-04-16,COMPUTER-IMPLEMENTED NATURAL LANGUAGE UNDERSTANDING OF MEDICAL REPORTS,"A natural language understanding method begins with a radiological report text containing clinical findings. Errors in the text are corrected by analyzing character- level optical transformation costs weighted by a frequency analysis over a corpus corresponding to the report text. For each word within the report text, a word embedding is obtained, character-level embeddings are determined, and the word and character-level embeddings are concatenated to a neural network which generates a plurality of NER tagged spans for the report text. A set of linked relationships are calculated for the NER tagged spans by generating masked text sequences based on the report text and determined pairs of potentially linked NER spans. A dense adjacency matrix is calculated based on attention weights obtained from providing the one or more masked text sequences to a Transformer deep learning network, and graph convolutions are then performed over the calculated dense adjacency matrix.",COVERA HEALTH,VIANU RON;;BROWN NATHANIEL W;;DUBBIN GREGORY ALLEN;;ELGORT DANIEL ROBERT;;ODRY BENJAMIN L;;SUUTARI BENJAMIN SELLMAN;;CHEN JEFFERSON,,https://lens.org/126-824-290-360-603,Patent Application,no,0,1,11,15,0,G16H15/00;;G16H50/70;;G16H30/40;;G16H40/20;;G06N3/084;;G06N7/01;;G06N3/044;;G06N3/045;;G16H50/70;;G16H10/60;;G06N7/01,G16H15/00,,0,0,,,,PENDING
119,FI,A0,FI 972101 A0,126-601-383-048-717,1997-05-16,1997,FI 972101 A,1997-05-16,US 34205394 A;;US 9515110 W,1994-11-17,Näytteenotin nesteitä varten,"An optical scheme for in situ identification of particulates in fluid such as engine oil, in which a portion of the fluid flow is tapped, fed via a conduit to a pair of optically transparent opposed plates, imaged through the plates, and the fluid returned to the main flow. Imaging is preferably done with a laser and photodetector array, and the output fed to a computer for image processing. Separation between the plates ensures that all the oil therebetween will be in the imaging system's near field. Preferably, the computer counts the number of particles in the oil, and classifies their shape, by scanning the image until it hits an object (i.e. hits an opaque pixel), using known chain code to trace the object's outline, determining the object's aspect ratio, and repeating for each object in the image. One embodiment uses a planar rotary member which is scalloped about its periphery. The scallops act to push oil continuously against an outer casing. The casing has a light source for directing coherent light at the rotary member, which is made reflective. As the rotary member moves in the casing, it carries fluid with it, and packs the fluid against the casing. The gap between the light source and the rotary member then constitutes the passageway which is imaged.",US GOV SEC NAVY,REINTJES JOHN F;;DUNCAN MICHAEL D;;MAHON RITA;;TANKERSLEY LAWRENCE L;;HOWARD PAUL L;;SCHULZ ABRAHAM;;CHEN VICTOR;;WILLEY JEFFERSON,,https://lens.org/126-601-383-048-717,Patent Application,no,0,0,13,15,0,G01N15/0227;;G01N2015/0294;;G01N15/0227;;G01N2015/0294,G01N15/02,,0,0,,,,EXPIRED
120,FI,B,FI 117065 B,186-175-908-227-409,2006-05-31,2006,FI 972101 A,1997-05-16,US 34205394 A;;US 9515110 W,1994-11-17,Juoksevien aineiden näytteenotin,"An optical scheme for in situ identification of particulates in fluid such as engine oil, in which a portion of the fluid flow is tapped, fed via a conduit to a pair of optically transparent opposed plates, imaged through the plates, and the fluid returned to the main flow. Imaging is preferably done with a laser and photodetector array, and the output fed to a computer for image processing. Separation between the plates ensures that all the oil therebetween will be in the imaging system's near field. Preferably, the computer counts the number of particles in the oil, and classifies their shape, by scanning the image until it hits an object (i.e. hits an opaque pixel), using known chain code to trace the object's outline, determining the object's aspect ratio, and repeating for each object in the image. One embodiment uses a planar rotary member which is scalloped about its periphery. The scallops act to push oil continuously against an outer casing. The casing has a light source for directing coherent light at the rotary member, which is made reflective. As the rotary member moves in the casing, it carries fluid with it, and packs the fluid against the casing. The gap between the light source and the rotary member then constitutes the passageway which is imaged.",US GOV SEC NAVY,REINTJES JOHN F;;DUNCAN MICHAEL D;;MAHON RITA;;TANKERSLEY LAWRENCE L;;HOWARD PAUL L;;SCHULZ ABRAHAM;;CHEN VICTOR;;WILLEY JEFFERSON,,https://lens.org/186-175-908-227-409,Patent Application,no,0,0,13,15,0,G01N15/0227;;G01N2015/0294;;G01N15/0227;;G01N2015/0294,G01N15/02,,0,0,,,,EXPIRED
121,EP,B1,EP 0792449 B1,014-664-611-007-165,2005-05-11,2005,EP 95943334 A,1995-11-17,US 9515110 W;;US 34205394 A,1994-11-17,FLUID SAMPLER,"An optical scheme for in situ identification of particulates in fluid such as engine oil, in which a portion of the fluid flow is tapped, fed via a conduit to a pair of optically transparent opposed plates, imaged through the plates, and the fluid returned to the main flow. Imaging is preferably done with a laser and photodetector array, and the output fed to a computer for image processing. Separation between the plates ensures that all the oil therebetween will be in the imaging system's near field. Preferably, the computer counts the number of particles in the oil, and classifies their shape, by scanning the image until it hits an object (i.e. hits an opaque pixel), using known chain code to trace the object's outline, determining the object's aspect ratio, and repeating for each object in the image. One embodiment uses a planar rotary member which is scalloped about its periphery. The scallops act to push oil continuously against an outer casing. The casing has a light source for directing coherent light at the rotary member, which is made reflective. As the rotary member moves in the casing, it carries fluid with it, and packs the fluid against the casing. The gap between the light source and the rotary member then constitutes the passageway which is imaged.",US GOV SEC NAVY,REINTJES JOHN F;;DUNCAN MICHAEL D;;MAHON RITA;;TANKERSLEY LAWRENCE L;;HOWARD PAUL L;;SCHULTZ ABRAHAM;;CHEN VICTOR;;WILLEY JEFFERSON,,https://lens.org/014-664-611-007-165,Granted Patent,yes,4,1,13,15,0,G01N15/0227;;G01N2015/0294;;G01N15/0227;;G01N2015/0294,G01N15/02,,0,0,,,,EXPIRED
122,FI,A,FI 972101 A,022-500-870-492-053,1997-07-09,1997,FI 972101 A,1997-05-16,US 34205394 A;;US 9515110 W,1994-11-17,Näytteenotin nesteitä varten,"An optical scheme for in situ identification of particulates in fluid such as engine oil, in which a portion of the fluid flow is tapped, fed via a conduit to a pair of optically transparent opposed plates, imaged through the plates, and the fluid returned to the main flow. Imaging is preferably done with a laser and photodetector array, and the output fed to a computer for image processing. Separation between the plates ensures that all the oil therebetween will be in the imaging system's near field. Preferably, the computer counts the number of particles in the oil, and classifies their shape, by scanning the image until it hits an object (i.e. hits an opaque pixel), using known chain code to trace the object's outline, determining the object's aspect ratio, and repeating for each object in the image. One embodiment uses a planar rotary member which is scalloped about its periphery. The scallops act to push oil continuously against an outer casing. The casing has a light source for directing coherent light at the rotary member, which is made reflective. As the rotary member moves in the casing, it carries fluid with it, and packs the fluid against the casing. The gap between the light source and the rotary member then constitutes the passageway which is imaged.",US GOV SEC NAVY,REINTJES JOHN F;;DUNCAN MICHAEL D;;MAHON RITA;;TANKERSLEY LAWRENCE L;;HOWARD PAUL L;;SCHULZ ABRAHAM;;CHEN VICTOR;;WILLEY JEFFERSON,,https://lens.org/022-500-870-492-053,Patent Application,no,0,0,13,15,0,G01N15/0227;;G01N2015/0294;;G01N15/0227;;G01N2015/0294,G01N15/02,,0,0,,,,EXPIRED
123,WO,A1,WO 1996/016325 A1,123-735-052-785-856,1996-05-30,1996,US 9515110 W,1995-11-17,US 34205394 A,1994-11-17,FLUID SAMPLER,"An optical scheme for in situ identification of particulates in fluid such as engine oil (12), in which a portion of the fluid flow is tapped, fed via a conduit (14) to a pair of optically transparent opposed plates (23, 25), imaged through the plates, and the fluid returned to the main flow (12). Imaging is preferably done with a laser (20) and photodetector array (26), and the output fed to a computer for image processing. Separation between the plates ensures all the oil therebetween will be in the imaging system's near field. Preferably, the computer counts the number of particles in the oil, and classifies their shape, by scanning the image until it hits an object (fig. 6), using known chain code to trace the object's outline, determining the object's aspect ratio, and repeating for each object in the image.",US NAVY,REINTJES JOHN F;;DUNCAN MICHAEL D;;MAHON RITA;;TANKERSLEY LAWRENCE L;;HOWARD PAUL L;;SCHULTZ ABRAHAM;;CHEN VICTOR;;WILLEY JEFFERSON,,https://lens.org/123-735-052-785-856,Patent Application,yes,2,5,13,15,0,G01N15/0227;;G01N2015/0294;;G01N15/0227;;G01N2015/0294,G01N15/02,,0,0,,,,PATENTED
124,CA,C,CA 2204509 C,182-938-351-771-147,2007-04-10,2007,CA 2204509 A,1995-11-17,US 34205394 A;;US 9515110 W,1994-11-17,FLUID SAMPLER,"An optical scheme for in situ identification of particulates in fluid such a s engine oil (12), in which a portion of the fluid flow is tapped, fed via a conduit (14) to a pair of optically transparent opposed plates (23, 25), imaged through the plates, and the fluid returned to the main flow (12). Imaging is preferably done with a laser (20) and photodetector array (26), and the output fed to a computer for image processing. Separation between the plates ensures all the oil therebetween will be in the imaging system's near field. Preferably, the computer counts the number of particles in the oil, and classifies their shape, by scanning the image until it hits an object (fig. 6), using known chain code to trace the object's outline, determining the object's aspect ratio, and repeating for each object in the image.",US NAVY,HOWARD PAUL L;;REINTJES JOHN F;;TANKERSLEY LAWRENCE L;;DUNCAN MICHAEL D;;WILLEY JEFFERSON;;CHEN VICTOR;;MAHON RITA;;SCHULTZ ABRAHAM,,https://lens.org/182-938-351-771-147,Granted Patent,no,0,0,2,15,0,G01N15/0227;;G01N2015/0294,G01N15/14;;G01M15/00;;G01N1/20;;G01N15/02,,0,0,,,,EXPIRED
125,EP,A1,EP 0792449 A1,044-548-445-934-245,1997-09-03,1997,EP 95943334 A,1995-11-17,US 9515110 W;;US 34205394 A,1994-11-17,FLUID SAMPLER,"An optical scheme for in situ identification of particulates in fluid such as engine oil, in which a portion of the fluid flow is tapped, fed via a conduit to a pair of optically transparent opposed plates, imaged through the plates, and the fluid returned to the main flow. Imaging is preferably done with a laser and photodetector array, and the output fed to a computer for image processing. Separation between the plates ensures that all the oil therebetween will be in the imaging system's near field. Preferably, the computer counts the number of particles in the oil, and classifies their shape, by scanning the image until it hits an object (i.e. hits an opaque pixel), using known chain code to trace the object's outline, determining the object's aspect ratio, and repeating for each object in the image. One embodiment uses a planar rotary member which is scalloped about its periphery. The scallops act to push oil continuously against an outer casing. The casing has a light source for directing coherent light at the rotary member, which is made reflective. As the rotary member moves in the casing, it carries fluid with it, and packs the fluid against the casing. The gap between the light source and the rotary member then constitutes the passageway which is imaged.",US GOV SEC NAVY,REINTJES JOHN F;;DUNCAN MICHAEL D;;MAHON RITA;;TANKERSLEY LAWRENCE L;;HOWARD PAUL L;;SCHULTZ ABRAHAM;;CHEN VICTOR;;WILLEY JEFFERSON,,https://lens.org/044-548-445-934-245,Patent Application,yes,0,0,13,15,0,G01N15/0227;;G01N2015/0294;;G01N15/0227;;G01N2015/0294,G01N15/02,,0,0,,,,EXPIRED
126,EP,A4,EP 0792449 A4,119-077-626-324-607,1999-02-24,1999,EP 95943334 A,1995-11-17,US 9515110 W;;US 34205394 A,1994-11-17,FLUID SAMPLER,"An optical scheme for in situ identification of particulates in fluid such as engine oil, in which a portion of the fluid flow is tapped, fed via a conduit to a pair of optically transparent opposed plates, imaged through the plates, and the fluid returned to the main flow. Imaging is preferably done with a laser and photodetector array, and the output fed to a computer for image processing. Separation between the plates ensures that all the oil therebetween will be in the imaging system's near field. Preferably, the computer counts the number of particles in the oil, and classifies their shape, by scanning the image until it hits an object (i.e. hits an opaque pixel), using known chain code to trace the object's outline, determining the object's aspect ratio, and repeating for each object in the image. One embodiment uses a planar rotary member which is scalloped about its periphery. The scallops act to push oil continuously against an outer casing. The casing has a light source for directing coherent light at the rotary member, which is made reflective. As the rotary member moves in the casing, it carries fluid with it, and packs the fluid against the casing. The gap between the light source and the rotary member then constitutes the passageway which is imaged.",US GOV SEC NAVY,REINTJES JOHN F;;DUNCAN MICHAEL D;;MAHON RITA;;TANKERSLEY LAWRENCE L;;HOWARD PAUL L;;SCHULTZ ABRAHAM;;CHEN VICTOR;;WILLEY JEFFERSON,,https://lens.org/119-077-626-324-607,Search Report,no,2,0,13,15,0,G01N15/0227;;G01N2015/0294;;G01N15/0227;;G01N2015/0294,G01N15/02,,0,0,,,,EXPIRED
127,US,A,US 5572320 A,130-879-022-198-489,1996-11-05,1996,US 34205394 A,1994-11-17,US 34205394 A,1994-11-17,Fluid sampler utilizing optical near-field imaging,"An optical scheme for in situ identification of particulates in fluid such s engine oil, in which a portion of the fluid flow is tapped, fed via a conduit to a pair of optically transparent opposed plates, imaged through the plates, and the fluid returned to the main flow. Imaging is preferably done with a laser and photodetector array, and the output fed to a computer for image processing. Separation between the plates ensures that all the oil therebetween will be in the imaging system's near field. Preferably, the computer counts the number of particles in the oil, and classifies their shape, by scanning the image until it hits an object (i.e. hits an opaque pixel), using known chain code to trace the object's outline, determining the object's aspect ratio, and repeating for each object in the image. One embodiment uses a planar rotary member which is scalloped about its periphery. The scallops act to push oil continuously against an outer casing. The casing has a light source for directing coherent light at the rotary member, which is made reflective. As the rotary member moves in the casing, it carries fluid with it, and packs the fluid against the casing. The gap between the light source and the rotary member then constitutes the passageway which is imaged.",US ARMY,REINTJES JOHN F;;HOWARD PAUL L;;DUNCAN MICHAEL D;;MAHON RITA;;TANKERSLEY LAWRENCE L;;SCHULTZ ABRAHAM;;CHEN VICTOR;;WILLEY JEFFERSON,,https://lens.org/130-879-022-198-489,Granted Patent,yes,2,63,13,15,0,G01N15/0227;;G01N2015/0294;;G01N15/0227;;G01N2015/0294,G01N15/02,356/335;;356/336;;356/246;;356/70,0,0,,,,EXPIRED
128,AT,T1,AT E295534 T1,004-279-540-308-759,2005-05-15,2005,AT 95943334 T,1995-11-17,US 34205394 A;;US 9515110 W,1994-11-17,ENTNEHMER EINER FLÜSSIGKEITSPROBE,"An optical scheme for in situ identification of particulates in fluid such as engine oil, in which a portion of the fluid flow is tapped, fed via a conduit to a pair of optically transparent opposed plates, imaged through the plates, and the fluid returned to the main flow. Imaging is preferably done with a laser and photodetector array, and the output fed to a computer for image processing. Separation between the plates ensures that all the oil therebetween will be in the imaging system's near field. Preferably, the computer counts the number of particles in the oil, and classifies their shape, by scanning the image until it hits an object (i.e. hits an opaque pixel), using known chain code to trace the object's outline, determining the object's aspect ratio, and repeating for each object in the image. One embodiment uses a planar rotary member which is scalloped about its periphery. The scallops act to push oil continuously against an outer casing. The casing has a light source for directing coherent light at the rotary member, which is made reflective. As the rotary member moves in the casing, it carries fluid with it, and packs the fluid against the casing. The gap between the light source and the rotary member then constitutes the passageway which is imaged.",US GOV SEC NAVY,REINTJES JOHN F;;DUNCAN MICHAEL D;;MAHON RITA;;TANKERSLEY LAWRENCE L;;HOWARD PAUL L;;SCHULTZ ABRAHAM;;CHEN VICTOR;;WILLEY JEFFERSON,,https://lens.org/004-279-540-308-759,Granted Patent,no,0,0,13,15,0,G01N15/0227;;G01N2015/0294;;G01N15/0227;;G01N2015/0294,G01N15/02,,0,0,,,,DISCONTINUED
129,EP,B1,EP 3176184 B1,055-268-144-529-337,2020-02-19,2020,EP 16194064 A,2011-11-09,US 45664210 P;;US 41831010 P;;US 41885010 P;;US 201061426425 P;;EP 11785551 A;;US 2011/0059964 W,2010-11-10,ANTI-BACE1 ANTIBODIES FOR NEURAL DISEASE IMMUNOTHERAPY,,HOFFMANN LA ROCHE,ATWAL JASVINDER;;CHEN YONGMEI;;CHIU CECILIA PUI CHI;;LAZARUS ROBERT A;;WANG WEIRU;;WATTS RYAN JEFFERSON;;WU YAN;;ZHANG YINGNAN,,https://lens.org/055-268-144-529-337,Granted Patent,yes,4,0,34,35,0,A61K2039/505;;A61K47/6871;;C07K16/40;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/28;;A61P27/06;;A61P43/00;;A61P9/10;;C07K16/18;;A61K39/395;;C07K2317/76;;C07K2317/56;;C07K2317/565;;A61K39/3955;;A61K47/6871;;A61K2039/505;;C07K16/40;;G01N33/573;;C07K2317/51;;C07K2317/515;;C07K2317/92;;C12P21/005,C07K16/40;;A61K39/395;;A61P25/28,,5,0,,,"ATWAL JASVINDER K ET AL: ""A therapeutic antibody targeting BACE1 inhibits amyloid-[beta] production in vivo"", SCIENCE / SCIENCE TRANSLATIONAL MEDICINE, WASHINGTON, DC : AAAS, US, vol. 3, no. 84, 25 May 2011 (2011-05-25), XP009155719, ISSN: 1946-6242;;H. SHIMIZU ET AL: ""Crystal Structure of an Active Form of BACE1, an Enzyme Responsible for Amyloid Protein Production"", MOLECULAR AND CELLULAR BIOLOGY, vol. 28, no. 11, 1 June 2008 (2008-06-01), pages 3663-3671, XP055017116, ISSN: 0270-7306, DOI: 10.1128/MCB.02185-07;;COLE SARAH L ET AL: ""BACE1 structure and function in health and Alzheimer's disease"", CURRENT ALZHEIMER RESEARCH, SAIF ZONE, SHARJAH [U.A.] : BENTHAM, AE, vol. 5, no. 2, 1 April 2008 (2008-04-01), pages 100-120, XP009155715, ISSN: 1567-2050;;MOHAMMAD TABRIZI ET AL: ""Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease"", THE AAPS JOURNAL, vol. 12, no. 1, 1 March 2010 (2010-03-01), pages 33-43, XP055071451, ISSN: 1550-7416, DOI: 10.1208/s12248-009-9157-5;;RICHARD T FRANK ET AL: ""Strategies for enhancing antibody delivery to the brain"", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1816, no. 2, 3 July 2011 (2011-07-03) , pages 191-198, XP028392590, ISSN: 0304-419X, DOI: 10.1016/J.BBCAN.2011.07.002 [retrieved on 2011-07-08]",ACTIVE
130,EP,A1,EP 3176184 A1,138-874-818-709-027,2017-06-07,2017,EP 16194064 A,2011-11-09,US 45664210 P;;US 41831010 P;;US 41885010 P;;US 201061426425 P;;EP 11785551 A;;US 2011/0059964 W,2010-11-10,ANTI-BACE1 ANTIBODIES FOR NEURAL DISEASE IMMUNOTHERAPY,The invention provides antibodies to specific neural proteins and methods of using the same.,HOFFMANN LA ROCHE,ATWAL JASVINDER;;CHEN YONGMEI;;CHIU CECILIA PUI CHI;;LAZARUS ROBERT A;;WANG WEIRU;;WATTS RYAN JEFFERSON;;WU YAN;;ZHANG YINGNAN,,https://lens.org/138-874-818-709-027,Patent Application,yes,116,0,34,35,210,A61K2039/505;;A61K47/6871;;C07K16/40;;A61P21/00;;A61P21/02;;A61P25/00;;A61P25/02;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/28;;A61P27/06;;A61P43/00;;A61P9/10;;C07K16/18;;A61K39/395;;C07K2317/76;;C07K2317/56;;C07K2317/565;;A61K39/3955;;A61K47/6871;;A61K2039/505;;C07K16/40;;G01N33/573;;C07K2317/51;;C07K2317/515;;C07K2317/92;;C12P21/005,C07K16/40;;A61K39/395;;A61P25/28,,143,118,102-324-860-705-668;;007-360-280-813-595;;132-175-267-818-962;;013-453-389-408-905;;096-412-408-809-705;;005-277-927-658-347;;122-728-056-221-351;;000-308-875-407-438;;035-771-281-418-062;;074-773-324-604-214;;006-110-332-415-858;;134-937-617-174-812;;030-654-551-353-066;;049-134-753-209-354;;051-208-529-712-079;;002-490-451-363-036;;000-090-177-789-978;;015-239-659-590-870;;094-061-985-800-335;;001-779-867-387-972;;044-522-255-085-902;;107-783-742-795-839;;110-088-048-889-302;;030-607-398-087-475;;042-204-626-457-327;;030-323-674-660-051;;064-667-501-146-970;;022-023-983-891-895;;006-338-973-732-491;;004-601-819-239-79X;;009-746-604-420-355;;093-067-181-692-392;;009-483-512-107-343;;069-144-826-896-138;;015-395-754-996-662;;106-032-800-597-23X;;001-256-484-369-395;;003-570-249-164-056;;010-953-281-569-514;;048-564-471-521-204;;003-984-734-905-938;;170-311-024-328-514;;006-895-260-696-111;;107-330-806-519-859;;034-345-578-106-977;;030-630-100-818-462;;034-331-211-704-877;;020-855-322-534-259;;005-283-943-871-819;;079-666-119-599-514;;039-981-636-470-013;;054-876-950-584-376;;022-133-574-143-973;;072-378-691-723-546;;032-071-991-081-664;;117-775-899-628-564;;031-063-853-127-197;;005-112-559-456-657;;104-212-297-137-759;;035-232-534-898-963;;022-375-749-274-329;;034-345-578-106-977;;018-694-084-068-187;;012-268-510-926-843;;037-445-639-149-821;;009-275-403-380-31X;;156-501-805-490-709;;116-831-294-654-564;;022-725-321-473-914;;017-695-622-077-055;;008-274-774-541-556;;070-280-057-407-994;;013-584-945-188-940;;012-900-923-946-056;;020-126-213-879-311;;054-717-629-774-351;;068-264-897-850-380;;011-842-849-963-456;;060-301-220-665-473;;020-126-164-125-029;;035-796-690-562-525;;008-587-496-850-953;;065-430-968-783-392;;021-430-782-622-770;;051-940-176-386-905;;024-242-524-715-107;;018-318-373-327-73X;;033-482-863-511-642;;036-848-648-380-064;;002-495-630-767-098;;027-670-963-287-976;;061-970-204-106-123;;079-144-966-327-175;;004-850-131-529-307;;065-996-283-702-791;;018-221-719-733-102;;117-906-457-481-371;;019-055-424-431-057;;065-684-269-783-203;;066-516-608-807-593;;048-563-040-470-615;;031-210-358-563-650;;054-876-950-584-376;;032-110-387-855-191;;079-666-119-599-514;;060-459-542-715-007;;027-949-576-705-03X;;050-513-346-896-80X;;045-573-849-077-607;;002-289-887-981-383;;134-937-617-174-812;;004-766-081-679-603;;075-416-515-543-38X;;039-911-698-743-730;;028-340-655-656-340;;075-416-515-543-38X;;022-183-615-558-047;;064-346-851-411-108,10.1126/scitranslmed.3002254;;21613622;;10.1128/mcb.02185-07;;18378702;;pmc2423307;;10.2174/156720508783954758;;18393796;;10.1208/s12248-009-9157-5;;pmc2811642;;19924542;;21767610;;10.1016/j.bbcan.2011.07.002;;10.1523/jneurosci.3657-09.2009;;19828790;;pmc2879048;;10.1093/hmg/10.12.1317;;11406613;;17616527;;10.1074/jbc.m611687200;;10.1016/s0896-6273(03)00810-9;;14715132;;10.1523/jneurosci.2766-05.2005;;pmc2564291;;16354928;;10.1038/nature07767;;19225519;;pmc2677572;;18457381;;10.1021/jm800138h;;16114893;;10.1021/bi050932l;;10.1016/0022-2836(87)90412-8;;3681981;;17981654;;10.2741/2786;;17161664;;10.1016/j.jchromb.2006.11.018;;10.1126/science.286.5440.735;;010531052;;10531052;;10.4049/jimmunol.150.3.880;;8423344;;15628850;;10.1021/bi048106k;;10.1006/jmbi.1999.3192;;10543973;;9377574;;12514726;;10.1038/nm0103-129;;10.1007/978-3-642-78432-3_11;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;3127726;;10.1038/332323a0;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;15848072;;10.1016/j.ymeth.2005.01.003;;10.1016/0161-5890(91)90163-e;;1905784;;15848074;;10.1016/j.ymeth.2005.01.005;;15848075;;10.1016/j.ymeth.2005.01.006;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;7688398;;10.4049/jimmunol.151.4.2296;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;8360482;;10.4049/jimmunol.151.5.2623;;9099717;;10.1074/jbc.272.16.10678;;10.1074/jbc.271.37.22611;;8798431;;11470598;;10.1016/s1367-5931(00)00216-7;;18606226;;10.1016/j.coi.2008.06.004;;10.1038/nbt1135;;16151405;;10.4049/jimmunol.133.6.3001;;6092464;;10.4049/jimmunol.147.1.86;;2051030;;16505368;;10.1073/pnas.0511285103;;pmc1383494;;15944943;;10.14670/hh-20.927;;10.1358/mf.2005.27.3.890876;;15834451;;11968478;;10.1385/1-59259-240-6:001;;10.1038/348552a0;;2247164;;10.1038/352624a0;;1907718;;1748994;;10.1016/0022-2836(91)90498-u;;15066433;;10.1016/j.jmb.2004.02.050;;15236968;;10.1016/j.jmb.2004.05.051;;15306681;;10.1073/pnas.0401786101;;pmc515084;;14736422;;10.1016/j.jim.2003.11.001;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90894-p;;1404359;;10.1038/305537a0;;6137772;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;10.1126/science.3925553;;3925553;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.152.11.5368;;8189055;;1675655;;10.4049/jimmunol.147.1.60;;11968478;;10.1385/1-59259-240-6:001;;10.1126/science.2471267;;2471267;;15037082;;10.3410/f.1020100.229441;;10.1016/j.jmb.2004.01.007;;10.1016/0003-9861(86)90031-7;;2428310;;16609957;;10.1002/bit.20880;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;10.1073/pnas.83.18.7059;;pmc386652;;3462743;;pmc397290;;3856277;;10.1073/pnas.82.5.1499;;3500259;;pmc2189658;;10.1084/jem.166.5.1351;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;9107305;;10.1016/s0022-1759(97)00002-1;;10.1182/blood-2002-06-1761;;12393541;;14551143;;10.1182/blood-2003-06-2031;;17077181;;10.1093/intimm/dxl110;;10.4049/jimmunol.164.8.4178;;10754313;;10.4049/jimmunol.117.2.587;;950463;;3258649;;10.1038/332738a0;;16087878;;pmc1187972;;10.1073/pnas.0502680102;;14970501;;10.1385/1-59259-666-5:245;;10.1038/nbt1028;;15529166;;886304;;10.1099/0022-1317-36-1-59;;10.1095/biolreprod23.1.243;;6774781;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;17536186;;10.1159/000103250;;17341681;;10.1096/fj.06-7685com;;15192085;;10.1124/jpet.104.071027;;pmc2666934;;10.1097/fbp.0b013e3282da278d;;17762506;;8324745;;9679947;;10.2174/092986706776055751;;16515518;;10.1016/j.bmcl.2005.09.081;;16275070;;10.1021/bc050039z;;15898742;;10639165;;10.1073/pnas.97.2.829;;pmc15416;;10.1016/s0960-894x(02)00194-4;;12031335;;12213074;;10.1021/jm020149g;;3317828;;10.1126/science.3317828;;1727373;;11960316;;10.1038/sj.gt.3301664;;10.1038/news030324-12;;12669033;;10.1038/nm850;;10.1007/978-1-4613-0701-3;;14736422;;10.1016/j.jim.2003.11.001;;17196977;;10.1016/j.jmb.2006.11.021;;15236968;;10.1016/j.jmb.2004.05.051;;10.1021/jm00035a001;;8176700;;17825836;;10.1016/j.jmb.2007.08.005;;10.1016/0076-6879(87)54085-x;;3323813;;10.1016/s0076-6879(00)28406-1;;10.1016/s0076-6879(13)60005-1;;11075354;;20383388;;10.1039/b927393j;;18457381;;10.1021/jm800138h;;pmc2148376;;18077410;;10.1073/pnas.0708251104;;11021803;;10.1126/science.290.5489.150;;10.2210/pdb1fkn/pdb;;10.1107/s0907444904019158;;15572765;;10.1107/s0907444996012255;;15299926;;11021803;;10.1126/science.290.5489.150;;10.2210/pdb1fkn/pdb;;pmc26455;;10.1073/pnas.97.4.1456;;10677483;;3581475;;10.1016/0009-8981(87)90250-6,"ATWAL JASVINDER K ET AL: ""A therapeutic antibody targeting BACE1 inhibits amyloid-[beta] production in vivo"", SCIENCE / SCIENCE TRANSLATIONAL MEDICINE, WASHINGTON, DC : AAAS, US, vol. 3, no. 84, 25 May 2011 (2011-05-25), XP009155719, ISSN: 1946-6242;;H. SHIMIZU ET AL: ""Crystal Structure of an Active Form of BACE1, an Enzyme Responsible for Amyloid Protein Production"", MOLECULAR AND CELLULAR BIOLOGY, vol. 28, no. 11, 1 June 2008 (2008-06-01), pages 3663 - 3671, XP055017116, ISSN: 0270-7306, DOI: 10.1128/MCB.02185-07;;COLE SARAH L ET AL: ""BACE1 structure and function in health and Alzheimer's disease"", CURRENT ALZHEIMER RESEARCH, SAIF ZONE, SHARJAH [U.A.] : BENTHAM, AE, vol. 5, no. 2, 1 April 2008 (2008-04-01), pages 100 - 120, XP009155715, ISSN: 1567-2050;;MOHAMMAD TABRIZI ET AL: ""Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease"", THE AAPS JOURNAL, vol. 12, no. 1, 1 March 2010 (2010-03-01), pages 33 - 43, XP055071451, ISSN: 1550-7416, DOI: 10.1208/s12248-009-9157-5;;RICHARD T FRANK ET AL: ""Strategies for enhancing antibody delivery to the brain"", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1816, no. 2, 3 July 2011 (2011-07-03), pages 191 - 198, XP028392590, ISSN: 0304-419X, [retrieved on 20110708], DOI: 10.1016/J.BBCAN.2011.07.002;;VASSAR ET AL., J. NEUROSCI, vol. 29, 2009, pages 12787 - 12794;;VASSAR ET AL., J. NEUROSCI., vol. 29, 2009, pages 12787 - 12794;;ROBERDS ET AL., HUMAN MOL. GENETICS, vol. 10, 2001, pages 1317 - 1324;;MCCONLOGUE ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 26326 - 26334;;OHNO ET AL., NEURON, vol. 41, 2004, pages 27 - 33;;LAIRD ET AL., J. NEUROSCI., vol. 25, 2005, pages 11693 - 11709;;NIKOLAEV ET AL., NATURE, vol. 457, 2009, pages 981 - 989;;CHARRIER ET AL., J. MED. CHEM., vol. 51, 2008, pages 3313 - 3317;;KORNACKER ET AL., BIOCHEMISTRY, vol. 44, 2005, pages 11567 - 11572;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NATIONAL INSTITUTES OF HEALTH;;KABAT ET AL.: ""Sequences ofProteins of Immunological Interest"", vol. 1-3, 1991, NIH PUBLICATION 91-3242;;CHOTHIA; LESK, J. MOL. BIOL, vol. 196, 1987, pages 901 - 917;;KABAT ET AL.: ""Sequences ofProteins of Immunological Interest"", 1991, NATIONAL INSTITUTES OF HEALTH;;ALMAGRO; FRANSSON, FRONT. BIOSCI., vol. 13, 2008, pages 1619 - 1633;;FLATMAN ET AL., J. CHROMATOGR. B, vol. 848, 2007, pages 79 - 87;;VASSAR ET AL., SCIENCE, vol. 286, 1999, pages 735 - 741;;KINDT ET AL.: ""Kuby Immunology"", 2007, W.H. FREEMAN AND CO., pages: 91;;PORTOLANO ET AL., J. IMMUNOL., vol. 150, 1993, pages 880 - 887;;CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;TURNER ET AL., BIOCHEMISTRY, vol. 44, 2005, pages 105 - 112;;KOMACKER ET AL., BIOCHEM., vol. 44, 2005, pages 11567 - 11573;;CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881;;PRESTA ET AL., CANCER RES., vol. 57, 1997, pages 4593 - 4599;;HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134;;PLUCKTHUN: ""The Pharmacology of Monoclonal Antibodies"", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315;;HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;QUEEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033;;KASHMIRI ET AL., METHODS, vol. 36, 2005, pages 25 - 34;;PADLAN, MOL. IMMUNOL., vol. 28, 1991, pages 489 - 498;;DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 43 - 60;;OSBOURN ET AL., METHODS, vol. 36, 2005, pages 61 - 68;;KLIMKA ET AL., BR. J. CANCER, vol. 83, 2000, pages 252 - 260;;SIMS ET AL., J. IMMUNOL., vol. 151, 1993, pages 2296;;CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285;;PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623;;BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684;;ROSOK ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 22611 - 22618;;VAN DIJK; VAN DE WINKEL, CURR. OPIN. PHARMACOL, vol. 5, 2001, pages 368 - 374;;LONBERG, CURR. OPIN. IMMUNOL, vol. 20, 2008, pages 450 - 459;;LONBERG, NAT. BIOTECH, vol. 23, 2005, pages 1117 - 1125;;KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001;;BRODEUR ET AL.: ""Monoclonal Antibody Production Techniques and Applications"", 1987, MARCEL DEKKER, INC., pages: 51 - 63;;BOERNER ET AL., J. IMMUNOL., vol. 147, 1991, pages 86;;LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562;;NI, XIANDAI MIANYIXUE, vol. 26, no. 4, 2006, pages 265 - 268;;VOLLMERS; BRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, vol. 20, no. 3, 2005, pages 927 - 937;;VOLLMERS; BRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 27, no. 3, 2005, pages 185 - 191;;HOOGENBOOM ET AL.: ""Methods in Molecular Biology"", vol. 178, 2001, HUMAN PRESS, pages: 1 - 37;;MCCAFFERTY ET AL., NATURE, vol. 348, pages 552 - 554;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1992, pages 581 - 597;;MARKS; BRADBURY: ""Methods in Molecular Biology"", vol. 248, 2003, HUMAN PRESS, pages: 161 - 175;;SIDHU ET AL., J. MOL. BIOL., vol. 338, no. 2, 2004, pages 299 - 310;;LEE ET AL., J. MOL. BIOL., vol. 340, no. 5, 2004, pages 1073 - 1093;;FELLOUSE, PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 2004, pages 12467 - 12472;;LEE ET AL., J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132;;WINTER ET AL., ANN. REV. IMMUNOL., vol. 12, 1994, pages 433 - 455;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1992, pages 381 - 388;;MILSTEIN; CUELLO, NATURE, vol. 305, 1983, pages 537;;TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553;;GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368;;TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60;;CHOWDHURY, METHODS MOL. BIOL., vol. 207, 2008, pages 179 - 196;;HOOGENBOOM ET AL.: ""Methods in Molecular Biology"", vol. 178, 2001, HUMAN PRESS, pages: 1 - 37;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;WRIGHT ET AL., TIBTECH, vol. 15, 1997, pages 26 - 32;;OKAZAKI ET AL., J. MOL. BIOL., vol. 336, 2004, pages 1239 - 1249;;YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., vol. 87, 2004, pages 614;;RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS, vol. 249, 1986, pages 533 - 545;;KANDA, Y. ET AL., BIOTECHNOL. BIOENG., vol. 94, no. 4, 2006, pages 680 - 688;;RAVETCH; KINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457 - 492;;HELLSTROM, I. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 83, 1986, pages 7059 - 7063;;HELLSTROM, I ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 1499 - 1502;;BRUGGEMANN, M. ET AL., J. EXP. MED., vol. 166, 1987, pages 1351 - 1361;;CLYNES ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 652 - 656;;GAZZANO-SANTORO ET AL., , J. IMMUNOL. METHODS, vol. 202, 1996, pages 163;;CRAGG, M.S. ET AL., BLOOD, vol. 101, 2003, pages 1045 - 1052;;CRAGG, M.S.; M.J. GLENNIE, BLOOD, vol. 103, 2004, pages 2738 - 2743;;PETKOVA, S.B. ET AL., INTL. IMMUNOL, vol. 18, no. 12, 2006, pages 1759 - 1769;;SHIELDS ET AL., J. BIOL. CHEM., vol. 9, no. 2, 2001, pages 6591 - 6604;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184;;GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587;;KIM ET AL., J. IMMUNOL., vol. 24, 1994, pages 249;;DUNCAN; WINTER, NATURE, vol. 322, 1988, pages 738 - 740;;KAM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 11600 - 11605;;CHARLTON: ""Methods in Molecular Biology"", vol. 248, 2003, HUMANA PRESS, pages: 245 - 254;;GERNGROSS, NAT. BIOTECH., vol. 22, 2004, pages 1409 - 1414;;LI ET AL., NAT. BIOTECH, vol. 24, 2006, pages 210 - 215;;GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59;;MATHER, BIOL. REPROD, vol. 23, 1980, pages 243 - 251;;MATHER ET AL.: ""Annals N. Y. Acad. Sci"", vol. 383, 1982, pages: 44 - 68;;URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216;;YAZAKI; WU: ""Methods in Molecular Biology"", vol. 248, 2003, HUMANA PRESS, pages: 255 - 268;;MORRIS: ""Methods in Molecular Biology"", vol. 66, 1996, HUMANA PRESS, article ""Epitope Mapping Protocols"";;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY;;RAKOVER ET AL., NEURODEGENER. DIS., vol. 4, no. 5, 2007, pages 392 - 402;;MOURI ET AL., FASEB J., vol. 21, no. 9, July 2007 (2007-07-01), pages 2135 - 2148;;MINKEVICIENE ET AL., J. PHARMACOL. EXP. THER., vol. 311, no. 2, November 2004 (2004-11-01), pages 677 - 682;;YUEDE ET AL., BEHAV PHARMACOL., vol. 18, no. 5-6, September 2007 (2007-09-01), pages 347 - 363;;HINMAN ET AL., CANCER RES., vol. 53, 1993, pages 3336 - 3342;;LODE ET AL., CANCER RES., vol. 58, 1998, pages 2925 - 2928;;KRATZ ET AL., CURRENT MED. CHEM., vol. 13, 2006, pages 477 - 523;;JEFFREY ET AL., BIOORGANIC & MED. CHEM. LETTERS, vol. 16, 2006, pages 358 - 362;;TORGOV ET AL., BIOCONJ. CHEM, vol. 16, 2005, pages 717 - 721;;NAGY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 829 - 834;;DUBOWCHIK ET AL., BIOORG. & MED. CHEM. LETTERS, vol. 12, 2002, pages 1529 - 1532;;KING ET AL., J. MED. CHEM., vol. 45, 2002, pages 4336 - 4343;;VITETTA ET AL., SCIENCE, vol. 238, 1987, pages 1098;;CHARI ET AL., CANCER RES., vol. 52, 1992, pages 127 - 131;;OSOL A.: ""Remington's Pharmaceutical Sciences, 16th ed."", 1980;;PAPANASTASSIOU ET AL., GENE THERAPY, vol. 9, 2002, pages 398 - 406;;GILL ET AL., NATURE MED, vol. 9, 2003, pages 589 - 595;;NEUWELT, E. A.: ""Implication of the Blood-Brain Barrier and its Manipulation"", vol. 1 & 2, 1989, PLENUM PRESS;;LEE ET AL., J. IMMUNOL. METH., vol. 284, 2004, pages 119 - 132;;LIANG ET AL., J. MOL. BIOL., vol. 366, 2007, pages 815 - 829;;LEE ET AL., J. MOL. BIOL., vol. 340, 2004, pages 1073 - 1093;;GALLOP ET AL., J. MED. CHEM., vol. 37, 1994, pages 1233 - 1251;;FELLOUSE, F.A. ET AL., J. MOL. BIOL., vol. 373, 2007, pages 924 - 940;;KUNKEL, T.A. ET AL., METHODS ENZYMOL., vol. 154, 1987, pages 367 - 382;;SIDHU, S.S. ET AL., METHODS ENZYMOL., vol. 328, 2000, pages 333 - 363;;BIRTALAN, S. ET AL., MOL BIOSYST, vol. 6, 2010, pages 1186 - 1194;;MARQUARDT, D. W., SIAMJ. APPL. MATH., vol. 11, 1963, pages 431 - 441;;CHARRIER, N. ET AL., J. MED. CHEM., vol. 51, 2008, pages 3313 - 3317;;KOMACKER ET AL., BIOCHEMISTRY, vol. 44, 2005, pages 11567 - 11572;;WU, Y. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 104, 2007, pages 19784 - 19789;;HONG, L. ET AL., SCIENCE, vol. 290, 2000, pages 150 - 153;;EMSLEY; COWTAN, ACTA. CRYST., vol. D60, 2004, pages 2126 - 2132;;MURSHUDOV, G.N. ET AL., ACTA CRYST., vol. D53, 1997, pages 240 - 255;;ADAMS, P.D. ET AL., ACTA. CRYST., vol. D66, 2010, pages 213 - 221;;HONG ET AL., , SCIENCE, vol. 290, 2000, pages 150 - 153;;HONG ET AL., SCIENCE, vol. 290, 2000, pages 150 - 153;;LIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 1456 - 1460;;REIBER; FELGENHAUER, CLIN. CHIM. ACTA., vol. 163, 1987, pages 319 - 328",ACTIVE
131,CA,A1,CA 2204509 A1,041-842-710-557-03X,1996-05-30,1996,CA 2204509 A,1995-11-17,US 34205394 A;;US 9515110 W,1994-11-17,FLUID SAMPLER,"An optical scheme for in situ identification of particulates in fluid such as engine oil (12), in which a portion of the fluid flow is tapped, fed via a conduit (14) to a pair of optically transparent opposed plates (23, 25), imaged through the plates, and the fluid returned to the main flow (12). Imaging is preferably done with a laser (20) and photodetector array (26), and the output fed to a computer for image processing. Separation between the plates ensures all the oil therebetween will be in the imaging system's near field. Preferably, the computer counts the number of particles in the oil, and classifies their shape, by scanning the image until it hits an object (fig. 6), using known chain code to trace the object's outline, determining the object's aspect ratio, and repeating for each object in the image.",US NAVY,TANKERSLEY LAWRENCE L;;HOWARD PAUL L;;MAHON RITA;;WILLEY JEFFERSON;;DUNCAN MICHAEL D;;SCHULTZ ABRAHAM;;CHEN VICTOR;;REINTJES JOHN F,,https://lens.org/041-842-710-557-03X,Patent Application,no,0,2,2,15,0,G01N15/0227;;G01N2015/0294,G01N15/02,,0,0,,,,EXPIRED
132,HR,B1,HR P20030771 B1,031-164-436-484-487,2008-10-31,2008,HR P20030771 A,2003-09-24,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT<SUB>6</SUB> RECEPTOR,"Spoj formulenaznačen time, štoX je odabran iz skupine koju sačinjavaju -O-, -NH-, -S-, -SO2-, -CH2-, -CH(F)-, -CH(OH)-, i-C(O)-; R1 je odabran iz skupine koju sačinjavaju po potrebi supstituirani fenil, po potrebi supstituirani naftil, po potrebi supstituirani 5 do 6 člani monociklički aromatski heterocikl koji ima jedan heteroatom odabran iz skupine koju sačinjavaju dušik, kisik, i sumpor i koji5 do 6 člani monociklički aromatski heterocikl jepo potrebi benzokondenziran; R2 je odabran iz skupine koju sačinjavaju vodik i C1-C3 alkil; R3 je odabran iz skupine koju sačinjavaju vodik, fluor, imetil; R4 je odabran iz skupine koju sačinjavaju vodik, alil, C2-C4 alkil, fluorirani C2-C4 alkil, po potrebi supstituirani fenil, po potrebi supstituirani fenilsulfonil, po potrebi supstituirani benzil, i po potrebi supstituirani 5 do 6 člani monociklički aromatski heterocikl koji ima jedan ili dva heteroatoma odabrana iz skupine koju sačinjavajudušik, kisik, i sumpor, pod uvjetom da R4 nije popotrebi supstituirani fenilsulfonil kad X je -SO2-, -CH2-, CH(F)-, - CH(OH)-, ili-C(O)-; gdje ""po potrebi supstituirani fenil"" označava radikal formulegdje je Ra iz 1 do 3 skupine koje se nezavisno biraju iz skupine koja se sastoji iz vodika, hidroksilne, C1-C4 alkilne, C1-C4 alkoksi, halogena, benziloksi, karboksi, C1-C4 alkoksikarbonil, amido, N-(C1-C4 alkil)amido, sulfonilamido, cijano, trifluorometil, trifluorometoksi, nitro i fenil supstituiran ili nesupstituiran s C1-C4 alkil, C1-C4 alkoksi, halogen, cijano ili trifluorometil; ""po potrebi supstituiran naftil"" označava radikal formulegdje je Rc iz 1 do 2 skupine nezavisno birane iz skupine koja se sastoji iz vodika, C1-C4 alkil, C1-C4alkoksi, halogen, cijano, trifluorometil i nitro;""po potrebi supstituirani 5 do 6 člani monociklički aromatski heterocikl koji ima jedan heteroatom odabran iz skupine koja se sastoji iz dušika, kisika, sumpora i kod kojeg po potrebi 5 do 6 člani monociklički aromatski heterocikl je po potrebi benzokondenziran"" označava radikal formule gdje se se Q1 odabire iz skupine koja se sastoji od -O-, -S-,i -NRg- gdje se Rg bira iz skupine koja se sastoji od vodika i C1-C4 alkila; Q2 je -N=, Rd, svaki Re i Rf nezavisno odabrani iz skupine koja se sastoji od vodika, C1-C4 alkila, C1-C4 alkoksi, halogena, cijano, i trifluorometila i Rd i Re (ili jedan od Re) uzetih zajedno s atomima na koje su pričvršćeni stvarajuću benzenski prsten kod kojih je benzenski prsten nesupstituiran ili supstituiran s 1 do 4 supstituenta nezavisno biranih iz skupine kojase sastoji iz vodika, hidroksi, C1-C4 alkila, C1-C4 alkoksi, trifluorometoksi, 2,2,2-trifluoroetoksi, trifluorometila, halogena, karboksi, C1-C4 alkoksikarbonila, amido, N-(C1-C4 alkil)amido, amino, (C1-C4 alkil)amino, acilamino gdje se acilna skupina bira iz skupine koja se sastoji iz C1-C4 alkilai fenila; cijano, nitro, sulfonilamido, fenil nesupstituirani i supstituirani s C1-C4 alkilom, C1-C4 alkoksi, halogenom, cijano ili trifluorometilom;fenoksi, be",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/031-164-436-484-487,Granted Patent,no,2,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
133,CN,B,CN 102686587 B,040-366-356-077-189,2015-05-27,2015,CN 201080056772 A,2010-12-13,EP 2010069455 W;;US 28611609 P,2009-12-14,Azaindole glucokinase activators,,HOFFMANN LA ROCHE,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/040-366-356-077-189,Granted Patent,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D471/04;;A61K31/437,,0,0,,,,INACTIVE
134,HU,B1,HU 230322 B1,083-846-890-025-672,2016-01-28,2016,HU P0303651 A,2002-03-15,US 32944901 P;;US 0205115 W;;US 27992801 P,2001-03-29,N-(2-arylethyl)-benzylamines as antagonists of the 5-ht6 receptor and pharmaceutical compositions containing them,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/083-846-890-025-672,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
135,NZ,A,NZ 527815 A,100-296-248-794-977,2005-05-27,2005,NZ 52781502 A,2002-03-15,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor,"Compounds of formula (I) and pharmaceutically acceptable salts thereof, which are antagonists of the 5-HT6 receptor are disclosed, wherein: X is selected from the group consisting of -O-, -NH-, -S-, -SO2-, -CH2-, -CH(F)-, -CH(OH)-, and -C(O)-; R1 is selected from the group consisting of optionally substituted phenyl provided that R1 is not C1-C4 alkoxy optionally substituted phenyl, optionally substituted naphthyl, optionally substituted 5 to 6 membered monocyclic aromatic heterocycle having one heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur and which 5 to 6 membered monocyclic aromatic heterocycle is optionally benzofused; R2 is selected from the group consisting of hydrogen and C1-C3 alkyl; R3 is selected from the group consisting of hydrogen, fluoro, and methyl; R4 is selected from the group consisting of hydrogen, allyl,C2-C4 alkyl, fluorinated C2-C4 alkyl, optionally substituted phenyl, optionally substituted phenylsulfonyl, optionally substituted benzyl, and optionally substituted 5 to 6 membered monocyclic aromatic heterocycle having one or two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, provided that R4 is not optionally substituted phenylsulfonyl when X is -SO2-, -CH2-, CH(F)-, - CH(OH)-, or -C(O)-.",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/100-296-248-794-977,Patent Application,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07D233/64;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,DISCONTINUED
136,US,A1,US 2009/0306110 A1,113-293-600-070-942,2009-12-10,2009,US 50424209 A,2009-07-16,US 50424209 A;;US 60892206 A;;US 47274104 A;;US 0205115 W;;US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,"The present invention provides compounds of formula (I), which are antagonists of the 5-HT 6 receptor.",CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/113-293-600-070-942,Patent Application,yes,1,5,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/404;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/435;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/445;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,514/269;;514/415;;514/297;;514/319,0,0,,,,EXPIRED
137,BR,A8,BR 112012014463 A8,136-080-608-780-346,2017-12-26,2017,BR 112012014463 A,2010-12-13,EP 2010069455 W;;US 28611609 P,2009-12-14,ativadores de glucoquinase azaindol,"ativadores de glucoquinase azaindol. são providos aquim compostos da fórmula (i): bem como os sais farmceuticamente aceitáveis dos mesmos, em que os substituintes são como aqueles revelados no relatório descritivo. estes compostos, e as composições farmacêuticas que os contêm, são úteis para o tratamento de doenças ou de distúrbios do metabolismo tais como, por exemplo, diabete mellitus do tipo ii.",F HOFFMANN LA ROCHE AG T,JEFFERSON WRIGHT TILLEY;;LI CHEN;;LICHUN FENG;;NANCY-ELLEN HAYNES;;ROBERT FRANCIS KESTER;;STEVEN JOSEPH BERTHEL;;SUNG-SAU SO;;WENDY LEA CORBETT,,https://lens.org/136-080-608-780-346,Patent Application,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D471/04;;A61K31/437,,0,0,,,,DISCONTINUED
138,ZA,B,ZA 200306795 B,172-427-059-336-087,2005-02-23,2005,ZA 200306795 A,2003-08-29,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,,LILLY CO ELI,ZHAOGEN CHEN;;MATTHEW JOSEPH FISHER;;JAMES RONALD GILLIG;;SHAWN CHRISTOPHER MILLER;;MICHAEL PHILIP COHEN;;BRUNO GIETHLEN;;JEFFERSON RAY MCCOWAN;;JOHN MEHNERT SCHAUS,,https://lens.org/172-427-059-336-087,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K/;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P/;;A61P25/18;;A61P25/22;;A61P25/28;;C07C/;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D/;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
139,US,A1,US 2004/0132800 A1,171-363-972-312-310,2004-07-08,2004,US 47274104 A,2004-02-27,US 47274104 A;;US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor,"
    The present invention provides compounds of formula (I), which are antagonists of the 5-HT ₆ receptor. 
",CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/171-363-972-312-310,Patent Application,yes,2,4,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/137;;A61K31/18;;C07D233/64;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,514/419;;548/503,0,0,,,,EXPIRED
140,SI,T1,SI 1859798 T1,040-592-802-114-169,2016-07-29,2016,SI 200231068 A,2002-03-15,US 27992801 P;;US 32944901 P;;EP 07015058 A,2001-03-29,N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT;;GIETHLEN BRUNO,,https://lens.org/040-592-802-114-169,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/00;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/00;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/00;;C07C317/32;;C07C317/34;;C07C323/00;;C07C323/32;;C07D209/00;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/00;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/00;;C07D233/24;;C07D239/00;;C07D239/34;;C07D277/00;;C07D277/20;;C07D277/34;;C07D307/00;;C07D307/91;;C07D333/00;;C07D333/20;;C07D401/00;;C07D401/12;;C07D403/00;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
141,PL,B1,PL 220721 B1,089-535-522-430-148,2015-12-31,2015,PL 36445802 A,2002-03-15,US 0205115 W;;US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/089-535-522-430-148,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,C07D209/16;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/30;;C07D209/32;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
142,BR,A,BR 0208179 A,174-110-203-832-649,2004-03-02,2004,BR 0208179 A,2002-03-15,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,"Composto, composição farmacêutica, métodos para tratar distúrbios associados com o receptor 5-ht6, distúrbios cognitivos, distúrbios da mémoria, psicose, esquizofrenia, e ansiedade, e, uso de um composto","""COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA TRATAR DISTúRBIOS ASSOCIADOS COM O RECEPTOR 5-HT~ 6~, DISTúRBIOS COGNITIVOS DISTúRBIOS DA MEMóRIA PSICOSE ESQUIZOFRENIA, E ANSIEDADE, E, USO DE UM COMPOSTO"". A presente invenção proporciona compostos de fórmula (I), que são antagonistas do receptor 5-HT~ 6~.",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/174-110-203-832-649,Patent Application,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,C07D233/64;;A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,DISCONTINUED
143,EP,A2,EP 1379239 A2,010-214-856-278-701,2004-01-14,2004,EP 02731094 A,2002-03-15,US 0205115 W;;US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/010-214-856-278-701,Patent Application,yes,0,9,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07D233/64;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
144,SK,A3,SK 12052003 A3,079-694-705-072-553,2004-09-08,2004,SK 12052003 A,2002-03-15,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-arylethyl) benzylamines as antagonists of 5-HT6 receptor,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/079-694-705-072-553,Patent Application,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07D233/64;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
145,NO,L,NO 20034289 L,097-883-270-783-975,2003-11-28,2003,NO 20034289 A,2003-09-25,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-aryletyl)benzylaminer som antagonister av 5-HT6- reseptoren,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/097-883-270-783-975,Abstract,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
146,DK,T3,DK 1859798 T3,147-057-685-996-865,2016-03-21,2016,DK 07015058 T,2002-03-15,US 27992801 P;;US 32944901 P;;EP 02731094 A,2001-03-29,N-(2-ARYLETHYL) -BENZYLAMINER SOM ANTAGONISTER AF 5-HT6-RECEPTOREN,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT;;GIETHLEN BRUNO,,https://lens.org/147-057-685-996-865,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
147,HK,A1,HK 1171226 A1,134-077-870-013-337,2013-03-22,2013,HK 12112005 A,2012-11-23,EP 2010069455 W;;US 28611609 P,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;NANCY-ELLEN HAYNES;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/134-077-870-013-337,Patent Application,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,A61K/;;C07D/,,0,0,,,,DISCONTINUED
148,HR,A2,HR P20030771 A2,098-297-765-810-802,2005-08-31,2005,HR P20030771 A,2003-09-24,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT<SUB>6</SUB> RECEPTOR,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/098-297-765-810-802,Patent Application,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07D233/64;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
149,CZ,A3,CZ 20032614 A3,062-207-414-610-368,2004-03-17,2004,CZ 20032614 A,2002-03-15,US 27992801 P;;US 32944901 P,2001-03-29,CZ 20032614 A3,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/062-207-414-610-368,Patent Application,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07D233/64;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
150,EP,A1,EP 1859798 A1,077-298-429-129-869,2007-11-28,2007,EP 07015058 A,2002-03-15,EP 02731094 A;;US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,"The present invention relates to the use compounds of formula I
  
which are antagonists of the 5-HT 6  receptor, for treating a cognitive disorder selected from the group consisting of age-related cognitive decline, mild cognitive impairment and dementia",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT;;GIETHLEN BRUNO,,https://lens.org/077-298-429-129-869,Patent Application,yes,2,2,3,58,0,A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07F7/0812,A61K31/4045;;C07D233/64;;A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07F7/08,,0,0,,,,EXPIRED
151,WO,A1,WO 2011/073117 A1,125-800-565-716-734,2011-06-23,2011,EP 2010069455 W,2010-12-13,US 28611609 P,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS,"Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.",HOFFMANN LA ROCHE;;BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/125-800-565-716-734,Patent Application,yes,5,2,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,A61K31/437;;C07D471/04,,16,14,056-206-411-978-675;;106-170-725-806-657;;061-893-046-790-102;;040-526-770-522-399;;098-019-860-572-873;;002-463-604-557-082;;047-763-655-227-523;;074-121-168-885-806;;016-865-549-924-168;;081-609-796-032-196;;060-895-089-314-256;;041-561-940-793-141;;002-463-604-557-082;;041-656-638-510-229,10.1016/s1874-6047(08)60113-4;;10.1146/annurev.nutr.13.1.463;;10.1146/annurev.nu.13.070193.002335;;8369155;;6364828;;10.1152/ajpendo.1984.246.1.e1;;7553875;;10.1016/0092-8674(95)90235-x;;10.1096/fasebj.10.10.8751724;;8751724;;pmc1135815;;7619052;;10.1042/bj3090167;;9435328;;10.1056/nejm199801223380404;;17987520;;10.1021/cr068006f;;17973536;;10.1002/ejoc.200700391;;10.1021/cr050992x;;17305399;;17212474;;10.1021/cr0505674;;pmc1135815;;7619052;;10.1042/bj3090167;;2337595;;10.1021/bi00455a026,"COLOWICK, S.P.: ""The Enzymes"", vol. 9, 1973, ACADEMIC PRESS, pages: 1 - 48;;CHIPKIN, S.R.; KELLY, K.L.; RUDERMAN, N.B.: ""Joslin's Diabetes"", 1994, LEA AND FEBIGER, pages: 97 - 115;;PRINTZ, R.G.; MAGNUSON, M.A.; GRANNER, D.K.: ""Ann. Rev. Nutrition"", vol. 13, 1993, ANNUAL REVIEW, INC., pages: 463 - 496;;MEGLASSON, M.D.; MATSCHINSKY, F.M., AMER. J. PHYSIOL., vol. 246, 1984, pages E1 - E13;;GRUPE, A.; HULTGREN, B.; RYAN, A. ET AL., CELL, vol. 83, 1995, pages 69 - 78;;FERRIE, T.; RIU, E.; BOSCH, F. ET AL., FASEB J., vol. 10, 1996, pages 1213 - 1218;;LIANG, Y.; KESAVAN, P.; WANG, L. ET AL., BIOCHEM. J., vol. 309, 1995, pages 167 - 173;;GLASER, B.; KESAVAN, P.; HEYMAN, M. ET AL., NEW ENGLAND J. MED., vol. 338, 1998, pages 226 - 230;;GREENE, T. W.: ""Protective Groups in Organic Synthesis"", 1991, JOHN WILEY & SONS, INC.;;DOUCET, H.; HIERSO, J.-C., CURR. OPIN. DRUG DISCOVERY DEV., vol. 10, 2007, pages 672 - 690;;BECCALLI, E. M.; BROGGINI, G.; MARTINELLI, M.; OTTOCORNOLA, S., CHEM. REV., vol. 107, 2007, pages 5318 - 5365;;KIENLE, M.; DUBBAKA, S. R.; BRADE, K.; KNOCHEL, P., EUR. J. ORG. CHEM., 2007, pages 4166 - 4176;;CHINCHILLA, R.; NAJERA, C., CHEM. REV, vol. 107, 2007, pages 874 - 922;;YIN, L.; LIEBSCHER, J., CHEM. REV., vol. 107, 2007, pages 133 - 173;;LIANG, Y.; KESAVAN, P.; WANG, L.; NISWENDER, K.; TANIZAWA, Y.; PERMUT, M. A.; MAGNUSON, M.; MATSCHINSKY, F. M.: ""Variable effects ofmaturity-onset-diabetes-of- youth (MODY)-associated glucokinase mutations on the substrate interactions and stability of the enzyme"", BIOCHEM. J., vol. 309, 1995, pages 167 - 173;;NEET, K.; KEENAN, R. P.; TIPPETT, P.S.: ""Observation of a kinetic slow transition in monomeric glucokinase"", BIOCHEMISTRY, vol. 29, 1990, pages 770 - 777",PENDING
152,MX,A,MX 2012006287 A,035-075-495-162-657,2012-07-03,2012,MX 2012006287 A,2010-12-13,US 28611609 P;;EP 2010069455 W,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS.,"Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.",HOFFMANN LA ROCHE,CORBETT WENDY LEA;;TILLEY JEFFERSON WRIGHT;;KESTER ROBERT FRANCIS;;CHEN LI;;HAYNES NANCY-ELLEN;;BERTHEL STEVEN JOSEPH;;FENG LICHUN;;SO SUNG-SAU,,https://lens.org/035-075-495-162-657,Patent Application,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,A61K31/437;;C07D471/04,,0,0,,,,ACTIVE
153,US,B2,US 8044090 B2,126-397-173-683-67X,2011-10-25,2011,US 50424209 A,2009-07-16,US 50424209 A;;US 60892206 A;;US 47274104 A;;US 0205115 W;;US 27992801 P;;US 32944901 P,2001-03-29,N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor,"The present invention provides compounds of formula (I), which are antagonists of the 5-HT 6 receptor.",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/126-397-173-683-67X,Granted Patent,yes,19,12,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,514/418;;514/654;;548/503,17,11,083-585-927-346-056;;112-610-281-471-879;;157-279-218-008-692;;047-306-566-051-286;;126-095-024-405-293;;025-016-564-757-660;;000-896-608-204-760;;005-636-205-780-457;;023-674-069-451-316;;134-360-960-183-43X;;000-755-952-293-257,10.1016/s0223-5234(00)01209-5;;11311747;;7616396;;11163639;;10.1016/s0166-4328(00)00316-8;;10.1007/s002130100840;;11702084;;8027974;;10.1021/jm00039a004;;10.1021/ja01283a038;;11055342;;10.1016/s0960-894x(00)00453-4;;11140741;;11140722;;11140733;;11140734;;10.1016/s0960-894x(00)00597-7;;10937732;;10.1016/s0960-894x(00)00320-6;;10.1039/jr9630004545;;10.1007/bf00629975,"ACS Chemcats 2000:1020106, Order No. STOCK1S-08349, CAS Registry No. 302795-49-9.;;Bos et al., ""5-HT6 receptor antagonists: lead optimization and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides,"" Eur J. Med. Chem., vol. 36, pp. 165-178 (2001).;;Bourson et al, ""Determination of the Role of the 5-ht6 Receptor in the Rat Brain: A Study using Antisense Oligonucleotides,"" J. of Pharm. and Experimental Therapeutics, vol. 274, No. 1, pp. 173-180 (1995).;;Meneses, Alfredo, ""Effects of the 5-HT6 receptor antagonist Ro 04-6790 on learning consolidation,"" Behavioral Brain Research, vol. 118, pp. 107-110 (2001).;;Rogers et al., ""5-HT6 receptor antagonists enhance retention of a water maze task in the rat,"" PsvchopharmacoloEy, vol. 158, pp. 114-119 (2001).;;Glennon, et al. ""Influence of Amine Substituents on 5-HT2A versus 5-HT2C-Binding of Phenylakllyl- and Indolylalkylamines"" J. Med. Chem., 1994, 37, 1929-1935.;;Glennon, et al., 5-HT6 Serotonin Receptor Binding of Indolealkylamines: A Preliminary Structure-Affinity Investigation. Med. Chem. Res., 1999, 9, 108-117.;;Ide et al. ""Pharmacologically Active Compounds from Alkoxy-B-phenylethylamines"" Journal of the American Chemical Society 1937, 726-731.;;Tsai et al. ""N1-(Benzenesulfonyl)tryptamines as Novel 5-HT6 Antagonists"" Bioorganic & Medicinal Chemistry Letters 2000, 2295-2299.;;Bromidge et al. ""Phenyl Benzenesulfonamides are Novel and Selective 5-HT6 Antagonists: Identification of . . . "" Bioorganic & Medicinal Chemistry Letters 2001, 55-58.;;Isaac et al. ""6-Bicyclopiperazinyl-1-arylsulfonylindoles and 6-Bicyclopiperidinyl-1-arylsulfonylindoles Derivatives as Novel, Potent, and Selective 5-HT6 Receptor Antagonists"" Bioorganic & Medicinal Chemistry Letters 2000, 1719-1721.;;Database Crossfire Beilstein Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(3-ethoxy-phenethyl)-amine), Database accession No. 3365863: XP002209140, 1992.;;Database Crossfire Beilstein Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(4-ethoxy-phenethyl)-amine), IDE, BUCK: Database accession No. 3365864; XP002209139, 1992.;;Database Crossfire Beilstein Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(2-ethoxy-henethyl)-amine), IDE, BUCK: Database accession No. 3380345; XP002209141, 1992.;;Barton, et al., ""886. Phenol Oxidation and Biosynthesis. Part VI. The Biogenesis of Amaryllidaceae Alkaloids,"" Barton, Kirby, Taylor and Thomas, pp. 4545-4558 (1963).;;Vinogradova, et al., ""Synthesis Based on b-Phenylethylamines. IV. Synthesis and Antiarrhythmic Activity of Substituted Phenylalkylamines and N-Benzyltetrahydroisoquinolines,"" vol. 29, No. 3, pp. 259-414 (1993).;;Vinogradova, et al., ""Syntheses Based on b-Ethylamines. VIII. Synthesis of Substituted 2-Benzyltetrahydroisoquinolines and Their Influence on Bile Secretion,"" vol. 30, No. 3, pp. 368-370 (1994).",EXPIRED
154,WO,A2,WO 2002/078693 A2,166-191-225-915-127,2002-10-10,2002,US 0205115 W,2002-03-15,US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,"The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.",LILLY CO ELI;;CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/166-191-225-915-127,Patent Application,yes,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07D233/64;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,PATENTED
155,US,A9,US 2006/0009511 A9,000-023-086-025-956,2006-01-12,2006,US 47274104 A,2004-02-27,US 47274104 A;;US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor,"The present invention provides compounds of formula (I), which are antagonists of the 5-HT 6 receptor.",CHEN ZHAOGEN;;COHEN MICHAEL P;;FISHER MATTHEW J;;GIETHLEN BRUNO;;GILLIG JAMES R;;MCCOWAN JEFFERSON R;;MILLER SHAWN C;;SCHAUS JOHN M,CHEN ZHAOGEN;;COHEN MICHAEL P;;FISHER MATTHEW J;;GIETHLEN BRUNO;;GILLIG JAMES R;;MCCOWAN JEFFERSON R;;MILLER SHAWN C;;SCHAUS JOHN M,,https://lens.org/000-023-086-025-956,Amended Application,yes,2,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,C07D209/04;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/404;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,514/419;;548/503,0,0,,,,EXPIRED
156,EP,A1,EP 2513103 A1,029-368-087-381-916,2012-10-24,2012,EP 10792890 A,2010-12-13,US 28611609 P;;EP 2010069455 W,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/029-368-087-381-916,Patent Application,yes,0,1,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D401/06;;C07D403/10;;C07D405/06;;C07D471/04,,0,0,,,,DISCONTINUED
157,EP,B1,EP 1859798 B1,182-295-063-596-878,2015-12-30,2015,EP 07015058 A,2002-03-15,EP 02731094 A;;US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT;;GIETHLEN BRUNO,,https://lens.org/182-295-063-596-878,Granted Patent,yes,2,1,3,58,0,A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07F7/0812,A61K31/4045;;C07D233/64;;A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07F7/08,,0,0,,,,EXPIRED
158,CZ,B6,CZ 305838 B6,057-992-222-239-379,2016-04-06,2016,CZ 20032614 A,2002-03-15,US 27992801 P;;US 32944901 P,2001-03-29,N-(2-arylethyl)benzylamines as 5-HT6 receptor antagonists,"The present invention relates to a compound, which is N-(2-(6-fluoro-1H-indol-3-yl)ethyl)-3-(2,2,3,3-tetrafluoropropoxy)benzylamine or pharmaceutically acceptable salt thereof",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/057-992-222-239-379,Granted Patent,no,2,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,C07D233/64;;A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,1,1,025-016-564-757-660,10.1021/ja01283a038,"Ide, W. S., et al: J. Am. Chem. Soc. 1937 (59), 726 - 731",EXPIRED
159,WO,A3,WO 2002/078693 A3,081-873-567-496-088,2002-12-05,2002,US 0205115 W,2002-03-15,US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,"The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.",LILLY CO ELI;;CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/081-873-567-496-088,Search Report,yes,2,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07D233/64;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,3,0,,,"DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; IDE, BUCK, XP002209139, Database accession no. 3365864;;DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002209140, Database accession no. 3365863;;DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; IDE, BUCK, XP002209141, Database accession no. 3380345",PATENTED
160,US,A1,US 2007/0099909 A1,106-790-617-242-978,2007-05-03,2007,US 60892206 A,2006-12-11,US 60892206 A;;US 47274104 A;;US 0205115 W;;US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,"The present invention provides compounds of formula (I), which are antagonists of the 5-HT 6 receptor.",CHEN ZHAOGEN;;COHEN MICHAEL P;;FISHER MATTHEW J;;GIETHLEN BRUNO;;GILLIG JAMES R;;MCCOWAN JEFFERSON R;;MILLER SHAWN C;;SCHAUS JOHN M,CHEN ZHAOGEN;;COHEN MICHAEL P;;FISHER MATTHEW J;;GIETHLEN BRUNO;;GILLIG JAMES R;;MCCOWAN JEFFERSON R;;MILLER SHAWN C;;SCHAUS JOHN M,,https://lens.org/106-790-617-242-978,Patent Application,yes,6,10,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/54;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/405;;A61K31/417;;A61K31/4172;;A61K31/421;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/445;;A61K31/495;;A61K31/505;;A61K31/506;;A61K31/5375;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,514/227.5;;514/237.5;;514/252.12;;514/317;;514/365;;514/374;;514/400;;514/408;;514/649;;544/59;;544/399;;546/229;;544/162;;548/205;;548/235;;548/335.5;;548/561;;564/373;;514/419;;548/495,0,0,,,,DISCONTINUED
161,CN,A,CN 102686587 A,140-008-675-240-268,2012-09-19,2012,CN 201080056772 A,2010-12-13,EP 2010069455 W;;US 28611609 P,2009-12-14,Azaindole glucokinase activators,"Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.",HOFFMANN LA ROCHE,JOSEPH BERTHEL STEVEN;;LI CHEN;;LEA CORBETT WENDY;;LICHUN FENG;;NANCY-ELLEN HAYNES;;FRANCIS KESTER ROBERT;;SUNG-SAU SO;;WRIGHT TILLEY JEFFERSON,,https://lens.org/140-008-675-240-268,Patent Application,no,2,1,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D471/04;;A61K31/437,,0,0,,,,INACTIVE
162,HU,A2,HU P0303651 A2,198-430-429-124-964,2004-03-01,2004,HU P0303651 A,2002-03-15,US 32944901 P;;US 0205115 W;;US 27992801 P,2001-03-29,N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM,"A találmány (I) általános képletű - ahol X jelentése oxigén-, kénatom,-NH-, -SO2-, -CH2-, -CH(F)-, -CH(OH)- vagy -C(O)képletű csoport; R1jelentése adott esetben helyettesített fenilcsoport, adott esetbenhelyettesített naftilcsoport vagy adott esetben helyettesített, 5-6tagú, egygyűrűs, aromás, egy heteroatomot - mely lehet nitrogén-,oxigén- vagy kénatom - tartalmazó heterociklusos csoport, mely adottesetben benzolgyűrűvel kondenzált; R2 jelentése hidrogénatom vagy 1-3szénatomos alkilcsoport; R3 jelentése hidrogénatom, fluoratom vagy metilcsoport; R4jelentése hidrogénatom, allil-, 2-4 szénatomos alkil-, fluorozott, 2-4szénatomos alkil-, adott esetben helyettesített fenil-, adott esetbenhelyettesített fenil-szulfonil-, adott esetben helyettesítettbenzilcsoport vagy adott esetben helyettesített, 5-6 tagú, egygyűrűs,aromás, egy vagy két heteroatomot - mely lehet nitrogén-, oxigén- vagykénatom - tartalmazó heterociklusos csoport; azzal a feltétellel, hogyamikor X jelentése -SO2-, -CH2-, -CH(F)-, -CH(OH)- vagy -C(O)- képletűcsoport, R4 jelentése nem lehet adott esetben helyettesített fenil-szulfonil-csoport - vegyületekkel foglalkozik, melyek 5-HT6receptorantagonisták. A találmány kiterjed a vegyületeket tartalmazógyógyszerkészítményekre is. Ó",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/198-430-429-124-964,Patent Application,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/137;;A61K31/18;;C07D233/64;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
163,US,B2,US 8222416 B2,080-526-956-888-891,2012-07-17,2012,US 94353910 A,2010-11-10,US 94353910 A;;US 28611609 P,2009-12-14,Azaindole glucokinase activators,"Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.",BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT;;HOFFMANN LA ROCHE,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/080-526-956-888-891,Granted Patent,yes,45,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D471/02;;A61K31/545,546/113;;514/200,1,0,,,"International Search Report for PCT/EP2010/069455 dated Mar. 15, 2011.",INACTIVE
164,NO,B1,NO 326160 B1,187-739-403-246-767,2008-10-13,2008,NO 20034289 A,2003-09-25,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-aryletyl)benzylaminer som antagonister av 5-HT6-reseptoren,,LILLY CO ELI,MCCOWAN JEFFERSON RAY;;FISHER MATTHEW JOSEPH;;SCHAUS JOHN MEHNERT;;CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MILLER SHAWN CHRISTOPHER,,https://lens.org/187-739-403-246-767,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,C07D209/16;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
165,US,A1,US 2011/0144105 A1,192-871-183-843-939,2011-06-16,2011,US 94353910 A,2010-11-10,US 94353910 A;;US 28611609 P,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS,"Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.",BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/192-871-183-843-939,Patent Application,yes,3,2,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,A61K31/437;;A61K31/5377;;A61P3/00;;A61P3/10;;C07D471/04,514/234.5;;514/300;;544/127;;546/113,0,0,,,,INACTIVE
166,SK,B6,SK 287463 B6,004-019-283-179-261,2010-10-07,2010,SK 12052003 A,2002-03-15,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-arylethyl) benzylamines as antagonists of 5-HT6 receptor,"Disclosed are compounds of a general formula (I) and (II), their use in the manufacture of medicaments for the treatment of 5-HT6 receptor mediated diseases and pharmaceutical compositions containing them.",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/004-019-283-179-261,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,C07D209/00;;A61K31/00;;C07D233/64;;A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/00;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/00;;C07C317/32;;C07C317/34;;C07C323/00;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/00;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/00;;C07D239/34;;C07D277/00;;C07D277/20;;C07D277/34;;C07D307/00;;C07D307/91;;C07D333/00;;C07D333/20;;C07D401/00;;C07D401/12;;C07D403/00;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
167,KR,A,KR 20120104357 A,033-530-766-464-454,2012-09-20,2012,KR 20127018375 A,2010-12-13,US 28611609 P,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS,,HOFFMANN LA ROCHE,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/033-530-766-464-454,Patent Application,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,A61K31/437;;A61P3/10,,0,0,,,,DISCONTINUED
168,ES,T3,ES 2566056 T3,057-883-845-589-647,2016-04-08,2016,ES 07015058 T,2002-03-15,US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6,"Un compuesto de estructura:**Fórmula** en la que X está seleccionado del grupo que consiste en -O-, -NH-, -S-, -SO2-, -CH2-, -CH(F)-, -CH(OH)- y -C(O)-; R1 está seleccionado del grupo que consiste en fenilo opcionalmente sustituido, naftilo opcionalmente sustituido, heterociclo aromático monocíclico de 5 a 6 miembros opcionalmente sustituido que tiene un heteroátomo seleccionado del grupo que consiste en nitrógeno, oxígeno y azufre y el heterociclo aromático monocíclico de 5 a 6 miembros está opcionalmente benzocondensado; donde el término ""fenilo opcionalmente sustituido"" se refiere a un radical de la fórmula**Fórmula** en la que Ra es de 1 a 3 grupos seleccionados independientemente del grupo que consiste en hidrógeno, hidroxi, alquilo C1-C4, alcoxi C1-C4, halógeno, benciloxi, carboxi, alcoxicarbonilo C1-C4, amido, N-(alquil C1-C4)amido, sulfonilamido, ciano, trifluorometilo, trifluorometoxi, nitro y fenilo opcionalmente sustituido con alquilo C1-C4, alcoxi C1-C4, halógeno, ciano y trifluorometilo; donde el término ""naftilo opcionalmente sustituido"" se refiere a un radical de la fórmula**Fórmula** en la que Rc es de 1 a 2 grupos seleccionados independientemente del grupo que consiste en hidrógeno, alquilo C1- C4, alcoxi C1-C4, halógeno, ciano, trifluorometilo y nitro; donde el término ""heterociclo aromático monocíclico de 5 a 6 miembros opcionalmente sustituido que tiene un heteroátomo seleccionado del grupo que consiste en nitrógeno, oxígeno y azufre y el heterociclo aromático monocíclico de 5 a 6 miembros está opcionalmente benzocondensado"" se refiere a radicales de la fórmula**Fórmula** en la que Q1 está seleccionado del grupo que consiste en -O-, -S- y -NRg- donde Rg está seleccionado del grupo que consiste en hidrógeno y alquilo C1-C4; y Q2 es -N>=, Rd, cada uno de Re y Rf están seleccionado independientemente del grupo que consiste en hidrógeno, alquilo C1-C4, alcoxi C1-C4, halógeno, ciano y trifluorometilo, o Rd y Re (o uno de Re) se toman junto con los átomos a los que están unidos formando un anillo benzo, anillo benzo que está opcionalmente sustituido con 1 a 4 sustituyentes seleccionados independientemente del grupo que consiste en hidrógeno, hidroxi, alquilo C1-C4, alcoxi C1-C4, trifluorometoxi, 2,2,2-trifluoroetoxi, trifluorometilo, halógeno, carboxi, alcoxicarbonilo C1-C4, amido, N-(alquil C1-C4)amido, amino, (alquil C1-C4)amino, acilamino donde el grupo acilo está seleccionado del grupo que consiste en alquilo C1-C4 y fenilo; ciano, nitro, sulfonilamido, fenilo opcionalmente sustituido con alquilo C1-C4, alcoxi C1-C4, halógeno, ciano y trifluorometilo; fenoxi, benciloxi, -NHS(O)2Rh, donde Rh está seleccionado del grupo que consiste en alquilo C1-C4 y fenilo; y -S(O)pRi, donde p es 0, 1 o 2 y Ri está seleccionado del grupo que consiste en alquilo C1-C4 y fenilo opcionalmente sustituido con alquilo C1-C4, alcoxi C1-C4, halógeno, ciano y trifluorometilo; y Rf está seleccionado del grupo que consiste en hidrógeno, alquilo C1-C4, alcoxi C1-C4, trifluorometilo y halógeno; R2 está seleccionado del grupo que consiste en hidrógeno y alquilo C1-C3; R3 está seleccionado del grupo que consiste en hidrógeno, fluoro y metilo; y R4 está seleccionado del grupo que consiste en hidrógeno, alilo, alquilo C2-C4, alquilo C2-C4 fluorado, fenilo opcionalmente sustituido, fenilsulfonilo opcionalmente sustituido, bencilo opcionalmente sustituido y heterociclo aromático monocíclico de 5 a 6 miembros opcionalmente sustituido que tiene uno o dos heteroátomos seleccionados del grupo que consiste en nitrógeno, oxígeno y azufre, con la condición de que R4 no es fenilsulfonilo opcionalmente sustituido cuando X es -SO2-, -CH2-, - CH(F)-, -CH(OH)- o -C(O)-; donde el término ""fenilsulfonilo opcionalmente sustituido"" se refiere a un radical de la fórmula**Fórmula** en la que Rj es de 1 a 3 grupos seleccionados independientemente del grupo que consiste en hidrógeno, alquilo C1- C4, alcoxi C1-C4, halógeno, ciano, trifluorometilo, nitro y fenilo; donde el término bencilo opcionalmente sustituido"" se refiere a un radical de la fórmula**Fórmula** en la que Rk es de 1 a 3 grupos seleccionados independientemente del grupo que consiste en hidrógeno, alquilo C1- C4, alcoxi C1-C4, ciano, nitro, trifluorometilo y halógeno; donde el término ""heterociclo aromático monocíclico de 5 a 6 miembros opcionalmente sustituido que tiene uno o dos heteroátomos seleccionados del grupo que consiste en nitrógeno, oxígeno y azufre"" se refiere a radicales de la fórmula**Fórmula** en la que Q3 está seleccionado del grupo que consiste en -O-,-S- y -NRg'- donde Rg' está seleccionado del grupo que consiste en hidrógeno y alquilo C1-C4; y Q4 y Q5 son -CRm, donde cada Rm está seleccionado independientemente del grupo que consiste en hidrógeno, alquilo C1-C4, halógeno y trifluorometilo o uno o ambos de Q4 y Q5 es -N>=; y donde uno o dos de Q6 son -N>=, mientras que el resto son -CRn; donde cada Rn está seleccionado independientemente del grupo que consiste en hidrógeno, alquilo C1-C4, alcoxi C1-C4, halógeno, ciano, nitro y trifluorometilo; o una sal farmacéuticamente aceptable del mismo, para su uso en un procedimiento de tratamiento de demencia o un trastorno cognitivo seleccionado del grupo que consiste en deterioro cognitivo relacionado con la edad y deficiencia cognitiva leve.",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT;;GIETHLEN BRUNO,,https://lens.org/057-883-845-589-647,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
169,HK,A1,HK 1061649 A1,159-132-937-631-620,2004-09-30,2004,HK 04104659 A,2004-06-29,US 32944901 P;;US 27992801 P;;US 0205115 W,2001-03-29,N-(2-arylethyl) benzylamines as antagonists of the5-ht6 receptor,,LILLY CO ELI,ZHAOGEN CHEN;;PHILIP COHEN MICHAEL;;JOSEPH FISHER MATTHEW;;BRUNO GIETHLEN;;RONALD GILLING JAMES;;RAY MCCOWAN JEFFERSON;;CHRISTOPHER MILLER SHAWN;;MEHNERT SCHAUS JOHN,,https://lens.org/159-132-937-631-620,Patent Application,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K/;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P/;;A61P25/18;;A61P25/22;;A61P25/28;;C07C/;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D/;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,DISCONTINUED
170,PT,E,PT 1379239 E,190-924-484-915-397,2007-12-06,2007,PT 02731094 T,2002-03-15,US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,,LILLY CO ELI,SCHAUS JOHN MEHNERT;;GILLIG JAMES RONALD;;FISHER MATTHEW JOSEPH;;MILLER SHAWN CHRISTOPHER;;COHEN MICHAEL PHILIP;;CHEN ZHAOGEN;;GIETHLEN BRUNO;;MCCOWAN JEFFERSON RAY,,https://lens.org/190-924-484-915-397,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
171,CA,C,CA 2442114 C,040-723-142-685-19X,2011-06-21,2011,CA 2442114 A,2002-03-15,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,"The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/040-723-142-685-19X,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,C07D209/14;;C07D233/64;;A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/395;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/26;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/36;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
172,CY,T1,CY 1117548 T1,060-935-394-788-726,2017-04-26,2017,CY 161100250 T,2016-03-24,EP 07015058 A;;US 27992801 A;;US 32944901 A,2001-03-29,Ν-(2-ΑΡΥΛΑΙΘΥΛΟ)ΒΕΝΖΥΛΑΜΙΝΕΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΤΟΥ 5-ΗT6 ΥΠΟΔΟΧΕΑ,"Η παρούσα εφεύρεση σχετίζεται με τη χρήση ενώσεων του τύπου (I), οι οποίες είναι ανταγωνιστές του 5-ΗΤ6 υποδοχέα, για αντιμετώπιση μιας γνωσιακής διαταραχής επιλεγμένης από την ομάδα η οποία αποτελείται από σχετιζόμενη με την ηλικία γνωσιακή έκπτωση, ήπια γνωσιακή βλάβη και άνοια.",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT;;GIETHLEN BRUNO,,https://lens.org/060-935-394-788-726,Granted Patent,no,0,0,1,1,0,,A61K31/4045;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/506;;A61P25/18;;A61P25/28;;C07C217/54;;C07C317/14;;C07C323/01;;C07D209/14;;C07D209/16;;C07D213/64;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/12,,0,0,,,,ACTIVE
173,EA,B1,EA 007493 B1,069-319-160-721-092,2006-10-27,2006,EA 200301073 A,2002-03-15,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HTRECEPTOR,"The present invention provides compounds of formula (I), which are antagonists of the 5-HTreceptor.",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLING JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/069-319-160-721-092,Granted Patent,no,2,1,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,3,0,,,"DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(4-ethoxy-phenethyl)-ami ne), IDE, BUCK: Database accession no. 3365864, XP002209139, abstract & J.AM.CHEM.SOC, vol. 59, 1937, page 726ff;;DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(3-ethoxy-phenethyl-amine), Database accession no. 3365863, XP002209140, abstract & IDE, BUCK: J.AM.CHEM.SOC, vol. 59, 1937, page 726ff;;DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(2-ethoxy-phenethyl)-ami ne), IDE, BUCK: Database accession no. 3380345 XP002209141, abstract & J.AM.CHEM.SOC, vol. 59, 1937, page 726ff",EXPIRED
174,PL,A1,PL 364458 A1,111-584-448-587-310,2004-12-13,2004,PL 36445802 A,2002-03-15,US 0205115 W;;US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/111-584-448-587-310,Patent Application,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;C07D233/64;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
175,AU,B2,AU 2002/303094 B2,119-355-946-725-706,2006-11-23,2006,AU 2002/303094 A,2002-03-15,US 32944901 P;;US 27992801 P;;US 0205115 W,2001-03-29,N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor,,LILLY CO ELI,MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT;;FISHER MATTHEW JOSEPH;;MCCOWAN JEFFERSON RAY;;GILLIG JAMES RONALD;;CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;GIETHLEN BRUNO,,https://lens.org/119-355-946-725-706,Granted Patent,no,2,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;C07D233/64;;A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,1,0,,,"J. Am. Chem. Soc. 1937, pp726 -731",EXPIRED
176,US,B2,US 7157488 B2,103-941-301-267-964,2007-01-02,2007,US 47274104 A,2004-02-27,US 47274104 A;;US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor,"The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HT 6 receptor. The present invention further provides a method of treating disorders associated with 5-HT 6 receptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/103-941-301-267-964,Granted Patent,yes,7,28,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/00;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,514/418;;514/654;;548/503;;564/503,16,10,000-896-608-204-760;;005-636-205-780-457;;023-674-069-451-316;;025-016-564-757-660;;134-360-960-183-43X;;000-755-952-293-257;;083-585-927-346-056;;112-610-281-471-879;;157-279-218-008-692;;047-306-566-051-286,11055342;;10.1016/s0960-894x(00)00453-4;;11140741;;11140722;;11140733;;11140734;;10.1016/s0960-894x(00)00597-7;;10937732;;10.1016/s0960-894x(00)00320-6;;10.1021/ja01283a038;;10.1039/jr9630004545;;10.1007/bf00629975;;10.1016/s0223-5234(00)01209-5;;11311747;;7616396;;11163639;;10.1016/s0166-4328(00)00316-8;;10.1007/s002130100840;;11702084,"Database Crossfire Beilstein Online! Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main DE; (3-ethoxy-benzyl)-(3-ethoxy-phenethyl)-amine), Database accession No. 3365863: XP002209140.;;Tsai et al. ""N1-(Benzenesulfonyl)tryptamines as Novel 5-HT6 Antagonists"" Bioorganic & Medicinal Chemistry Letters 2000, 2295-2299.;;Bromidge et al. ""Phenyl Benzenesulfonamides are Novel and Selective 5-HT6 Antagonists: Identification of . . . "" Bioorganic & Medicinal Chemistry Letters, 2001, 55-58.;;Isaac et al. ""6-Bicyclopiperazinyl-1-arylsulfonylindoles and 6-Bicyclopiperidinyl-1-arylsulfonylindoles Derivatives as Novel, Potent, and Selective 5-HT6 Receptor Antagonists"" Bioorganic & Medicinal Chemistry Letters 2000, 1719-1721.;;Ide et al. ""Pharmacologically Active Compounds from Alkoxy-B-phenylethylamines"" Journal of the American Chemical Society 1937, 726-731.;;Database Crossfire Beilstein Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(4-ethoxy-phenethyl)-amine), IDE, BUCK: Database accession No. 3365864; XP002209139.;;Database Crossfire Beilstein Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(3-ethoxy-phenethyl)-amine), Database accession No. 3365863; XP002209140.;;Database Crossfire Beilstein Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(2-ethoxy-henethyl)-amine), IDE, BUCK: Database accession No. 3380345; XP002209141.;;Barton, et al., ""886. Phenol Oxidation and Biosynthesis. Part VI. The Biogenesis of Amaryllidaceae Alkaloids,"" Barton, Kirby, Taylor and Thomas, pp. 4545-4558 (1963).;;Vinogradova, et al., ""Synthesis Based on b-Phenylethylamines. IV. Synthesis and Antiarrhythmic Activity of Substituted Phenylalkylamines and N-Benzyltetrahydroisoquinolines,"" vol. 29, No. 3, pp. 259-414 (1993).;;Vinogradova, et al., ""Syntheses Based on b-Ethylamines. VIII. Synthesis of Substituted 2-Benzyltetrahydroisoquinolines and Their Influence on Bile Secretion,"" vol. 30, No. 3, pp. 368-370 (1994).;;ACS Chemcats 2000:1020106, Order No. STOCK1S-08349, CAS Registry No. 302795-49-9.;;Bos et al., ""5-HT6 receptor antagonists: lead optimization and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides,"" Eur J. Med. Chem., vol. 36, pp. 165-178 (2001).;;Bourson et al., ""Determination of the Role of the 5-ht6 Receptor in the Rat Brain: A Study using Antisense Oligonucleotides,"" J. of Pharm. And Experimental Therapeutics, vol. 274, No. 1, pp. 173-180 (1995).;;Meneses, Alfredo, ""Effects of the 5-HT6 receptor antagonist Ro 04-6790 on learning consolidation,"" Behavioral Brain Research, vol. 118, pp. 107-110 (2001).;;Rogers et al., ""5-HT6 receptor antagonists enhance retention of a water maze task in the rat,"" Psychopharmacology, vol. 158, pp. 114-119 (2001).",EXPIRED
177,EP,B1,EP 1379239 B1,163-068-881-384-229,2007-09-12,2007,EP 02731094 A,2002-03-15,US 0205115 W;;US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/163-068-881-384-229,Granted Patent,yes,2,4,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,3,0,,,"DATABASE CROSSFIRE BEILSTEIN [Online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(4-ethoxy-phenethyl)-ami ne), IDE, BUCK: Database accession no. 3365864 XP002209139 & J.AM.CHEM.SOC., vol. 59, 1937, page 726ff;;DATABASE CROSSFIRE BEILSTEIN [Online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(3-ethoxy-phenethyl)-ami ne), Database accession no. 3365863 XP002209140 & IDE, BUCK: J.AM.CHEM.SOC, vol. 59, 1937, page 726ff;;DATABASE CROSSFIRE BEILSTEIN [Online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; (3-ethoxy-benzyl)-(2-ethoxy-phenethyl)-ami ne), IDE, BUCK: Database accession no. 3380345 XP002209141 & J.AM.CHEM.SOC., vol. 59, 1937, page 726ff",EXPIRED
178,CY,T1,CY 1110362 T1,176-001-243-687-407,2015-04-29,2015,CY 071101516 T,2007-11-27,EP 02731094 A;;US 27992801 P;;US 32944901 P,2001-03-29,Ν-(2-ΑΡΥΛΑΙΘΥΛΟ)ΒΕΝΖΥΛΑΜΙΝΕΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΤΟΥ 5-ΗΤ6 ΥΠΟΔΟΧΕΑ,"Η παρούσα εφεύρεση παρέχει ενώσεις του τύπου (Ι), οι οποίες είναι ανταγωνιστές του 5-ΗΤ6 υποδοχέα.",LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/176-001-243-687-407,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;C07D233/64;;A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,ACTIVE
179,BR,A2,BR 112012014463 A2,170-429-627-662-232,2017-03-14,2017,BR 112012014463 A,2010-12-13,EP 2010069455 W;;US 28611609 P,2009-12-14,ativadores de glucoquinase azaindol,"ativadores de glucoquinase azaindol. são providos aquim compostos da fórmula (i): bem como os sais farmceuticamente aceitáveis dos mesmos, em que os substituintes são como aqueles revelados no relatório descritivo. estes compostos, e as composições farmacêuticas que os contêm, são úteis para o tratamento de doenças ou de distúrbios do metabolismo tais como, por exemplo, diabete mellitus do tipo ii.",F HOFFMANN-LA ROCHE AG (T),JEFFERSON WRIGHT TILLEY;;LI CHEN;;LICHUN FENG;;NANCY-ELLEN HAYNES;;ROBERT FRANCIS KESTER;;STEVEN JOSEPH BERTHEL;;SUNG-SAU SO;;WENDY LEA CORBETT,,https://lens.org/170-429-627-662-232,Patent Application,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D471/04;;A61K31/437,,0,0,,,,DISCONTINUED
180,EC,A,EC SP034781 A,011-130-456-962-393,2003-12-01,2003,EC SP034781 A,2003-09-26,US 27992801 P,2001-03-29,N-(2-ARILETIL) BENCILAMINAS COMO ANTAGONISTAS DEL RECEPTOR 5-HT6,"Un compuesto de fórmula (Grafico) en el que X se selecciona del grupo constituido por -O-, -NH-, -S-, -SO2-, -CH2-, -CH(F)-, CH(OH)-,Y-C(O)-;R1 se selecciona del grupo constituido por fenilo opcionalmente sustituido, heterociclo aromático monociclito de 5 a 6 miembros opccionalmente sustituido que tiene un heteroátomo seleccionado del grupo constituido por nitrógeno, oxigeno y azufre y dicho heterociclo aromático monociclico de 5 a 6 miembros está opcionalmente benzocondensado; R2 se selecciona del grupo constituido por hidrogeno y alquilo C1-C3; R3 se selecciona del grupo constituido por hidrogeno, fluoro, y metilo; R4 se selecciona del grupo constituido por hidrógeno, alilo, alquilo C2- C4, alquilo C2-C4 fluorado, fenilo opcionalmente sustituido, fenilsulfonilo opcionalmente sustituido, bencilo opcionalmente sustituido, y heterociclo aromático monociclico de 5 a 6 miembros opcionalmente sustituido que tiene uno o dos heteroátomos seleccionados del grupo constituido por nitrógeno, oxigeno, y azúfre, con la condición de que R4 no sea fenilsulfonilo opcionalmente sustituido cuando X es -S02-; -CH2-, -CH(F)-, -CH(OH)-, 0- C(0)-; y sales farmacéuticamente aceptables del mismo.",LILLY CO ELI,COHEN MICHAEL PHILIP;;GIETHLEN BRUNO;;MILLER SHAWN CHRISTOPHER;;CHEN ZHAOGEN;;FISHER MATTHEW JOSEPH;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;SCHAUS JOHN MEHNERT,,https://lens.org/011-130-456-962-393,Patent Application,no,0,0,2,58,0,,A61K/;;A61P/;;C07C/;;C07D/;;C07D209/14;;C07D213/64;;C07D233/24;;C07D233/34;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20,,0,0,,,,PENDING
181,PT,E,PT 1859798 E,057-087-382-798-209,2016-03-31,2016,PT 07015058 T,2002-03-15,US 27992801 P;;US 32944901 P,2001-03-29,N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,,LILLY CO ELI,JOHN MEHNERT SCHAUS;;JAMES RONALD GILLIG;;MATTHEW JOSEPH FISHER;;SHAWN CHRISTOPHER MILLER;;MICHAEL PHILIP COHEN;;ZHAOGEN CHEN;;BRUNO GIETHLEN;;JEFFERSON RAY MCCOWAN,,https://lens.org/057-087-382-798-209,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
182,NO,D0,NO 20034289 D0,071-748-677-185-998,2003-09-25,2003,NO 20034289 A,2003-09-25,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-aryletylbenzylaminer som antagonister av 5-HT6- reseptoren,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/071-748-677-185-998,Patent Application,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
183,CA,A1,CA 2442114 A1,094-724-615-084-09X,2002-10-10,2002,CA 2442114 A,2002-03-15,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,"The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.",LILLY CO ELI,SCHAUS JOHN MEHNERT;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;CHEN ZHAOGEN,,https://lens.org/094-724-615-084-09X,Patent Application,no,0,2,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,C07D233/64;;A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
184,DE,T2,DE 60222396 T2,013-783-237-100-743,2008-05-15,2008,DE 60222396 T,2002-03-15,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-ARYLETHYL) BENZYLAMINE ALS 5-HT6 REZEPTOR-ANTAGONISTE,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/013-783-237-100-743,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
185,CA,A1,CA 2782172 A1,071-231-712-530-004,2011-06-23,2011,CA 2782172 A,2010-12-13,US 28611609 P;;EP 2010069455 W,2009-12-14,AZAINDOLE GLUCOKINASE ACTIVATORS,"Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.",HOFFMANN LA ROCHE,BERTHEL STEVEN JOSEPH;;CHEN LI;;CORBETT WENDY LEA;;FENG LICHUN;;HAYNES NANCY-ELLEN;;KESTER ROBERT FRANCIS;;SO SUNG-SAU;;TILLEY JEFFERSON WRIGHT,,https://lens.org/071-231-712-530-004,Patent Application,no,0,0,16,16,0,C07D471/04;;C07D401/06;;C07D403/10;;C07D405/06;;C07C2601/04;;C07C2601/06;;A61P3/00;;A61P43/00;;A61P3/10;;A61K31/437;;C07D471/04;;C07C2601/06;;C07C2601/04;;C07D471/04;;C07D401/06;;C07D405/06;;C07D403/10;;C07C2601/04;;C07C2601/06,C07D471/04;;A61K31/437,,0,0,,,,DISCONTINUED
186,AT,T1,AT E419848 T1,052-208-199-471-212,2009-01-15,2009,AT 05819201 T,2005-10-26,US 62320304 P,2004-10-29,CYCLOALKYL-LACTAM-DERIVATE ALS INHIBITOREN VON 11-BETA-HYDROXYSTEROIDDEHYDROGENASE 1,"The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.",LILLY CO ELI,AICHER THOMAS;;CHICARELLI MARK;;HINKLIN RONALD;;TIAN HONGQI;;WALLACE OWEN;;CHEN ZHAOGEN;;MABRY THOMAS;;MCCOWAN JEFFERSON;;SNYDER NANCY;;WINNEROSKI LEONARD;;ALLEN JOHN GORDON,,https://lens.org/052-208-199-471-212,Granted Patent,no,0,0,13,13,0,C07D207/26;;C07D207/267;;C07D207/273;;C07D211/76;;C07D401/10;;C07D401/12;;C07D403/10;;C07D403/12;;C07D405/04;;C07D409/04;;C07D409/10;;A61P3/00;;A61P3/04;;A61P3/10;;C07D403/12;;C07D405/04;;C07D207/26;;C07D211/76;;C07D401/10;;C07D207/267;;C07D409/04;;C07D409/10;;C07D207/273;;C07D403/10;;C07D401/12,,,0,0,,,,ACTIVE
187,DK,T3,DK 1379239 T3,011-584-075-165-653,2008-01-07,2008,DK 02731094 T,2002-03-15,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO PRESTWICK;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/011-584-075-165-653,Granted Patent,no,0,1,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/4045;;A61K31/137;;C07D233/64;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/14;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
188,DE,D1,DE 60222396 D1,187-068-341-364-244,2007-10-25,2007,DE 60222396 T,2002-03-15,US 27992801 P;;US 32944901 P;;US 0205115 W,2001-03-29,N-(2-ARYLETHYL) BENZYLAMINE ALS 5-HT6 REZEPTOR-ANTAGONISTE,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO PRESTWICK CH;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/187-068-341-364-244,Granted Patent,no,0,0,53,58,0,C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/0812;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;A61P43/00;;C07D209/14;;C07D213/64;;C07C217/58;;C07D213/65;;C07C211/56;;C07D209/14;;C07D209/16;;C07C311/37;;C07D471/04;;C07D233/24;;C07D333/20;;C07D307/91;;C07C211/52;;C07C217/60;;C07D239/34;;C07D213/68;;C07D213/74;;C07C225/16;;C07D209/08;;C07D277/34;;C07D417/12;;C07D403/06;;C07D213/38;;C07F7/0812;;C07C317/34;;C07C323/32;;C07D401/12;;C07D403/12;;C07D209/86;;C07D405/12,A61K31/137;;A61K31/4045;;A61K31/18;;C07D233/64;;A61K31/343;;A61K31/381;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/54;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/32;;C07C317/34;;C07C323/01;;C07C323/32;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D209/86;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/20;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07D471/04;;C07F7/08,,0,0,,,,EXPIRED
189,SI,T1,SI 1379239 T1,087-907-563-663-88X,2008-02-29,2008,SI 200230644 T,2002-03-15,US 27992801 P;;US 32944901 P;;US 0205115 W;;EP 02731094 A,2001-03-29,N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR,,LILLY CO ELI,CHEN ZHAOGEN;;COHEN MICHAEL PHILIP;;FISHER MATTHEW JOSEPH;;GIETHLEN BRUNO PRESTWICK CHEMI;;GILLIG JAMES RONALD;;MCCOWAN JEFFERSON RAY;;MILLER SHAWN CHRISTOPHER;;SCHAUS JOHN MEHNERT,,https://lens.org/087-907-563-663-88X,Granted Patent,no,0,0,3,58,0,A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C217/58;;C07C217/60;;C07C225/16;;C07C311/37;;C07C317/34;;C07C323/32;;C07D209/08;;C07D209/14;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/24;;C07D239/34;;C07D277/34;;C07D307/91;;C07D333/20;;C07D401/12;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07F7/0812,A61K31/00;;C07D233/64;;A61K31/137;;A61K31/18;;A61K31/343;;A61K31/381;;A61K31/4045;;A61K31/417;;A61K31/426;;A61K31/427;;A61K31/4402;;A61K31/4406;;A61K31/4409;;A61K31/4439;;A61K31/505;;A61K31/506;;A61P25/00;;A61P25/18;;A61P25/22;;A61P25/28;;C07C211/52;;C07C211/56;;C07C215/32;;C07C215/50;;C07C217/00;;C07C217/58;;C07C217/60;;C07C225/16;;C07C309/73;;C07C311/37;;C07C317/00;;C07C317/32;;C07C317/34;;C07C323/00;;C07C323/32;;C07D209/00;;C07D209/00;;C07D209/08;;C07D209/14;;C07D209/16;;C07D213/00;;C07D213/30;;C07D213/38;;C07D213/63;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/74;;C07D233/00;;C07D233/24;;C07D239/00;;C07D239/34;;C07D277/00;;C07D277/20;;C07D277/34;;C07D307/00;;C07D307/91;;C07D333/00;;C07D333/20;;C07D401/00;;C07D401/12;;C07D403/00;;C07D403/06;;C07D403/12;;C07D405/12;;C07D417/12;;C07F7/08,,0,0,,,,EXPIRED
190,ES,T3,ES 2435115 T3,013-930-795-345-689,2013-12-18,2013,ES 07760877 T,2007-04-19,US 74531106 P;;US 2007/0066921 W,2006-04-21,Derivados de bifenilamida-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1,"compuesto estructuralmente representado por la fórmula:**Fórmula** en la que: R1 es**Fórmula** en los que la línea de trazos representa el punto de unión a la posición R1 en la fórmula I; R2 es -H, -halógeno, -CH3 (opcionalmente sustituido con 1 a 3 halógenos), o -O-CH3 (opcionalmente sustituidocon 1 a 3 halógenos); R3 es -halógeno, -CH3 (opcionalmente sustituido con 1 a 3 halógenos), o -O-CH3 (opcionalmente sustituido con 1a 3 halógenos); R4 es -H o -halógeno; R5 es**Fórmula**",LILLY CO ELI,AICHER THOMAS;;CHEN ZHAOGEN;;HINKLIN RONALD;;HITE GARY;;KRASUTSKY ALEXEI;;LI RENHUA;;MCCOWAN JEFFERSON;;SAEED ASHRAF;;SNYDER NANCY;;TOTH JAMES;;WALLACE OWEN;;WINNEROSKI JUNIOR;;XU YANPING;;YORK JEREMY,,https://lens.org/013-930-795-345-689,Granted Patent,no,0,0,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,C07D207/12;;A61K31/4015;;A61P3/10;;C07D401/10;;C07D401/12;;C07D403/10;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/04,,0,0,,,,ACTIVE
191,US,A1,US 2023/0319110 A1,110-877-708-371-712,2023-10-05,2023,US 202217709318 A,2022-03-30,US 202217709318 A,2022-03-30,EVENT-LEVEL DATA PRIVACY FOR STREAMING POST ANALYTICS DATA,"Technologies for providing event-level data privacy for streaming post analytics data include, in some embodiments, receiving a data stream that includes instances of count data collected over a time interval, computing a true count breakdown that includes a set of sub-counts of non-public user interface interactions on the post, creating a noisy count breakdown by applying at least one differential privacy mechanism to the set of sub-counts, and streaming the noisy count breakdown instead of the true count breakdown to a computing device. At least one of the sub-counts is a count that is associated with a particular value of an attribute that has different possible values. The attribute is associated with the non-public user interface interactions on the post.",MICROSOFT TECHNOLOGY LICENSING LLC,ROGERS RYAN M;;SUBRAMANIAM SUBBU;;CESAR MARK B;;RIVERA CARDOSO ADRIAN;;CHEN YU;;LAI JEFFERSON;;MADDI VINYAS;;XU LIN;;UATHAVIKUL GAVIN CASTRO;;JAIN NEHA;;SAHAY SHRADDHA;;AHAMMAD PARVEZ;;TANDRA RAHUL,MICROSOFT TECHNOLOGY LICENSING LLC (2022-04-04),https://lens.org/110-877-708-371-712,Patent Application,yes,0,0,1,1,0,H04L63/20;;H04L63/20,H04L9/40,,1,1,050-201-067-549-669,10.1145/3269206.3272031,Krishnaram Kenthapadi et al. PriPeARL: A Framework for Privacy-Preserving Analytics and Reporting at LinkedIn. (Year: 2018),PENDING
192,US,A1,US 2008/0275043 A1,107-920-364-045-480,2008-11-06,2008,US 71811105 A,2005-10-26,US 71811105 A;;US 62320304 P;;US 2005/0038369 W,2004-10-29,Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1,"The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Fomula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.",AICHER THOMAS DANIEL;;CHICARELLI MARK JOSEPH;;HINKLIN RONALD JAY;;TIAN HONGQI;;WALLACE OWEN BRENDAN;;ALLEN JOHN GORDON;;CHEN ZHAOGEN;;MABRY THOMAS EDWARD;;MCCOWAN JEFFERSON RAY;;SNYDER NANCY JUNE;;WINNEROSKI LEONARD LARRY,AICHER THOMAS DANIEL;;CHICARELLI MARK JOSEPH;;HINKLIN RONALD JAY;;TIAN HONGQI;;WALLACE OWEN BRENDAN;;ALLEN JOHN GORDON;;CHEN ZHAOGEN;;MABRY THOMAS EDWARD;;MCCOWAN JEFFERSON RAY;;SNYDER NANCY JUNE;;WINNEROSKI LEONARD LARRY,ARRAY BIOPHARMA INC (2006-02-19);;ELI LILLY AND COMPANY (2006-02-13),https://lens.org/107-920-364-045-480,Patent Application,yes,0,18,13,13,0,C07D207/26;;C07D207/267;;C07D207/273;;C07D211/76;;C07D401/10;;C07D401/12;;C07D403/10;;C07D403/12;;C07D405/04;;C07D409/04;;C07D409/10;;A61P3/00;;A61P3/04;;A61P3/10;;C07D403/12;;C07D405/04;;C07D207/26;;C07D211/76;;C07D401/10;;C07D207/267;;C07D409/04;;C07D409/10;;C07D207/273;;C07D403/10;;C07D401/12,A61K31/5377;;A61K31/4015;;A61K31/4439;;A61K31/496;;A61P3/10;;C07D207/12;;C07D401/08;;C07D403/08;;C07D413/12,514/235.5;;548/543;;514/424;;514/254.01;;544/372;;546/278.4;;514/343;;544/141,0,0,,,,INACTIVE
193,DE,D1,DE 602005012306 D1,158-592-985-781-018,2009-02-26,2009,DE 602005012306 T,2005-10-26,US 62320304 P;;US 2005/0038369 W,2004-10-29,CYCLOALKYL-LACTAM-DERIVATE ALS INHIBITOREN VON 11-BETA-HYDROXYSTEROIDDEHYDROGENASE 1,"The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.",LILLY CO ELI,AICHER THOMAS D;;CHICARELLI MARK JOSEPH;;HINKLIN RONALD JAY;;TIAN HONGQI;;WALLACE OWEN BRENDAN;;CHEN ZHAOGEN;;MABRY THOMAS EDWARD;;MCCOWAN JEFFERSON RAY;;SNYDER NANCY JUNE;;WINNEROSKI LEONARD LARRY;;ALLEN JOHN GORDON,,https://lens.org/158-592-985-781-018,Granted Patent,no,0,0,13,13,0,C07D207/26;;C07D207/267;;C07D207/273;;C07D211/76;;C07D401/10;;C07D401/12;;C07D403/10;;C07D403/12;;C07D405/04;;C07D409/04;;C07D409/10;;A61P3/00;;A61P3/04;;A61P3/10;;C07D403/12;;C07D405/04;;C07D207/26;;C07D211/76;;C07D401/10;;C07D207/267;;C07D409/04;;C07D409/10;;C07D207/273;;C07D403/10;;C07D401/12,A61K31/4015;;A61K31/4025;;A61K31/4412;;A61P3/04;;C07D207/27;;C07D211/76;;C07D401/10;;C07D403/10;;C07D409/10,,0,0,,,,ACTIVE
194,SI,T1,SI 1807072 T1,196-500-917-758-155,2009-06-30,2009,SI 200530646 T,2005-10-26,US 62320304 P;;EP 05819201 A,2004-10-29,CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1,"The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.",LILLY CO ELI,AICHER THOMAS D;;CHICARELLI MARK JOSEPH;;HINKLIN RONALD JAY;;TIAN HONGQI;;WALLACE OWEN BRENDAN;;CHEN ZHAOGEN;;MABRY THOMAS EDWARD;;MCCOWAN JEFFERSON RAY;;SNYDER NANCY JUNE;;WINNEROSKI LEONARD LARRY JUNIOR;;ALLEN JOHN GORDON,,https://lens.org/196-500-917-758-155,Granted Patent,no,0,0,13,13,0,C07D207/26;;C07D207/267;;C07D207/273;;C07D211/76;;C07D401/10;;C07D401/12;;C07D403/10;;C07D403/12;;C07D405/04;;C07D409/04;;C07D409/10;;A61P3/00;;A61P3/04;;A61P3/10;;C07D403/12;;C07D405/04;;C07D207/26;;C07D211/76;;C07D401/10;;C07D207/267;;C07D409/04;;C07D409/10;;C07D207/273;;C07D403/10;;C07D401/12,A61K31/00;;A61P3/00;;C07D207/00;;C07D211/00;;C07D401/00;;C07D403/00;;C07D409/00,,0,0,,,,ACTIVE
195,WO,A1,WO 2006/049952 A1,069-227-591-392-341,2006-05-11,2006,US 2005/0038369 W,2005-10-26,US 62320304 P,2004-10-29,CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1,"The present invention discloses compounds of Formula I: (I) having 11beta -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Fomula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.",LILLY CO ELI;;AICHER THOMAS D;;CHICARELLI MARK JOSEPH;;HINKLIN RONALD JAY;;TIAN HONGQI;;WALLACE OWEN BRENDAN;;CHEN ZHAOGEN;;MABRY THOMAS EDWARD;;MCCOWAN JEFFERSON RAY;;SNYDER NANCY JUNE;;WINNEROSKI LEONARD LARRY JUNIO;;ALLEN JOHN GORDON,AICHER THOMAS D;;CHICARELLI MARK JOSEPH;;HINKLIN RONALD JAY;;TIAN HONGQI;;WALLACE OWEN BRENDAN;;CHEN ZHAOGEN;;MABRY THOMAS EDWARD;;MCCOWAN JEFFERSON RAY;;SNYDER NANCY JUNE;;WINNEROSKI LEONARD LARRY JUNIO;;ALLEN JOHN GORDON,,https://lens.org/069-227-591-392-341,Patent Application,yes,5,104,13,13,0,C07D207/26;;C07D207/267;;C07D207/273;;C07D211/76;;C07D401/10;;C07D401/12;;C07D403/10;;C07D403/12;;C07D405/04;;C07D409/04;;C07D409/10;;A61P3/00;;A61P3/04;;A61P3/10;;C07D403/12;;C07D405/04;;C07D207/26;;C07D211/76;;C07D401/10;;C07D207/267;;C07D409/04;;C07D409/10;;C07D207/273;;C07D403/10;;C07D401/12,A61K31/4015;;A61K31/4025;;A61K31/4412;;A61P3/04;;C07D207/27;;C07D211/76;;C07D401/10;;C07D403/10;;C07D409/10,,2,1,138-880-096-253-638,10.1016/s0040-4039(00)60921-8,"KONNO ; AKINORI; NAITO, WATARU, FUCHIGAMI, TOSCHIO: ""Electrolytic Partial Fluorination of Organic Compounds. 6.1 Highly Regioselective Electrochemical Monofluorination of Aliphatic Nitrogen-Containing Heterocycles"", TETRAHEDRON LETT., vol. 33, no. 46, 1992, pages 7017 - 7020, XP002370306;;J AM. CHEM. SOC., vol. 69, 1947, pages 715 - 716",PENDING
196,PT,E,PT 1807072 E,066-427-348-488-72X,2009-02-16,2009,PT 05819201 T,2005-10-26,US 62320304 P,2004-10-29,CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1,"The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.",LILLY CO ELI,WALLACE OWEN BRENDAN;;AICHER THOMAS DANIEL;;MCCOWAN JEFFERSON RAY;;HINKLIN RONALD JAY;;CHICARELLI MARK JOSEPH;;TIAN HONGQI;;ALLEN JOHN GORDON;;CHEN ZHAOGEN;;MABRY THOMAS EDWARD;;SNYDER NANCY JUNE;;WINNEROSKI LEONARD LARRY JUNIO,,https://lens.org/066-427-348-488-72X,Granted Patent,no,0,0,13,13,0,C07D207/26;;C07D207/267;;C07D207/273;;C07D211/76;;C07D401/10;;C07D401/12;;C07D403/10;;C07D403/12;;C07D405/04;;C07D409/04;;C07D409/10;;A61P3/00;;A61P3/04;;A61P3/10;;C07D403/12;;C07D405/04;;C07D207/26;;C07D211/76;;C07D401/10;;C07D207/267;;C07D409/04;;C07D409/10;;C07D207/273;;C07D403/10;;C07D401/12,A61K31/4015;;A61K31/4025;;A61K31/4412;;A61P3/04;;C07D207/27;;C07D211/76;;C07D401/10;;C07D403/10;;C07D409/10,,0,0,,,,ACTIVE
197,DK,T3,DK 1807072 T3,103-268-640-176-744,2009-03-16,2009,DK 05819201 T,2005-10-26,US 62320304 P;;US 2005/0038369 W,2004-10-29,Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1,"The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.",LILLY CO ELI,AICHER THOMAS D;;CHICARELLI MARK JOSEPH;;HINKLIN RONALD JAY;;TIAN HONGQI;;WALLACE OWEN BRENDAN;;MCCOWAN JEFFERSON RAY;;SNYDER NANCY JUNE;;WINNEROSKI LEONARD LARRY JUNIO;;MABRY THOMAS EDWARD;;ALLEN JOHN GORDON;;CHEN ZHAOGEN,,https://lens.org/103-268-640-176-744,Granted Patent,no,0,0,13,13,0,C07D207/26;;C07D207/267;;C07D207/273;;C07D211/76;;C07D401/10;;C07D401/12;;C07D403/10;;C07D403/12;;C07D405/04;;C07D409/04;;C07D409/10;;A61P3/00;;A61P3/04;;A61P3/10;;C07D403/12;;C07D405/04;;C07D207/26;;C07D211/76;;C07D401/10;;C07D207/267;;C07D409/04;;C07D409/10;;C07D207/273;;C07D403/10;;C07D401/12,A61K31/4015;;A61K31/4025;;A61K31/4412;;A61P3/04;;C07D207/27;;C07D211/76;;C07D401/10;;C07D403/10;;C07D409/10,,0,0,,,,ACTIVE
198,US,B2,US 7713979 B2,146-094-299-204-870,2010-05-11,2010,US 71811105 A,2005-10-26,US 71811105 A;;US 62320304 P;;US 2005/0038369 W,2004-10-29,Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1,"The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.",LILLY CO ELI,AICHER THOMAS DANIEL;;CHICARELLI MARK JOSEPH;;HINKLIN RONALD JAY;;TIAN HONGQI;;WALLACE OWEN BRENDAN;;ALLEN JOHN GORDON;;CHEN ZHAOGEN;;MABRY THOMAS EDWARD;;MCCOWAN JEFFERSON RAY;;SNYDER NANCY JUNE;;WINNEROSKI JR LEONARD LARRY,ARRAY BIOPHARMA INC (2006-02-19);;ELI LILLY AND COMPANY (2006-02-13),https://lens.org/146-094-299-204-870,Granted Patent,yes,5,3,13,13,0,C07D207/26;;C07D207/267;;C07D207/273;;C07D211/76;;C07D401/10;;C07D401/12;;C07D403/10;;C07D403/12;;C07D405/04;;C07D409/04;;C07D409/10;;A61P3/00;;A61P3/04;;A61P3/10;;C07D403/12;;C07D405/04;;C07D207/26;;C07D211/76;;C07D401/10;;C07D207/267;;C07D409/04;;C07D409/10;;C07D207/273;;C07D403/10;;C07D401/12,C07D207/00;;A61K31/40;;A61K31/445;;A61K31/497;;C07D211/06;;C07D403/00,514/254.02;;514/326;;514/424;;544/372;;546/226;;548/543,1,1,138-880-096-253-638,10.1016/s0040-4039(00)60921-8,"Konno et al., Electrolytic Partial Fluorination of Organic Compounds 6.1 Highly Regioselective Electrochemical Monofluorination of Aliphatic Nitrogen-Containing Heterocycles, Tetrahedron Letters, 1992, pp. 7017-7020, vol. 33, No. 46.",INACTIVE
199,EP,B1,EP 1807072 B1,063-464-933-386-541,2009-01-07,2009,EP 05819201 A,2005-10-26,US 2005/0038369 W;;US 62320304 P,2004-10-29,CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1,"The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.",LILLY CO ELI,AICHER THOMAS D;;CHICARELLI MARK JOSEPH;;HINKLIN RONALD JAY;;TIAN HONGQI;;WALLACE OWEN BRENDAN;;CHEN ZHAOGEN;;MABRY THOMAS EDWARD;;MCCOWAN JEFFERSON RAY;;SNYDER NANCY JUNE;;WINNEROSKI LEONARD LARRY JUNIO;;ALLEN JOHN GORDON,,https://lens.org/063-464-933-386-541,Granted Patent,yes,5,0,13,13,0,C07D207/26;;C07D207/267;;C07D207/273;;C07D211/76;;C07D401/10;;C07D401/12;;C07D403/10;;C07D403/12;;C07D405/04;;C07D409/04;;C07D409/10;;A61P3/00;;A61P3/04;;A61P3/10;;C07D403/12;;C07D405/04;;C07D207/26;;C07D211/76;;C07D401/10;;C07D207/267;;C07D409/04;;C07D409/10;;C07D207/273;;C07D403/10;;C07D401/12,A61K31/4015;;A61K31/4025;;A61K31/4412;;A61P3/04;;C07D207/27;;C07D211/76;;C07D401/10;;C07D403/10;;C07D409/10,,1,0,,,"KONNO ; AKINORI; NAITO, WATARU, FUCHIGAMI, TOSCHIO: ""Electrolytic Partial Fluorination of Organic Compounds. 6.1 Highly Regioselective Electrochemical Monofluorination of Aliphatic Nitrogen-Containing Heterocycles"" TETRAHEDRON LETT., vol. 33, no. 46, 1992, pages 7017-7020, XP002370306",ACTIVE
200,EP,A1,EP 1807072 A1,142-299-405-400-634,2007-07-18,2007,EP 05819201 A,2005-10-26,US 2005/0038369 W;;US 62320304 P,2004-10-29,CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1,"The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.",LILLY CO ELI,AICHER THOMAS D;;CHICARELLI MARK JOSEPH;;HINKLIN RONALD JAY;;TIAN HONGQI;;WALLACE OWEN BRENDAN;;CHEN ZHAOGEN;;MABRY THOMAS EDWARD;;MCCOWAN JEFFERSON RAY;;SNYDER NANCY JUNE;;WINNEROSKI LEONARD LARRY JUNIO;;ALLEN JOHN GORDON,,https://lens.org/142-299-405-400-634,Patent Application,yes,0,0,13,13,0,C07D207/26;;C07D207/267;;C07D207/273;;C07D211/76;;C07D401/10;;C07D401/12;;C07D403/10;;C07D403/12;;C07D405/04;;C07D409/04;;C07D409/10;;A61P3/00;;A61P3/04;;A61P3/10;;C07D403/12;;C07D405/04;;C07D207/26;;C07D211/76;;C07D401/10;;C07D207/267;;C07D409/04;;C07D409/10;;C07D207/273;;C07D403/10;;C07D401/12,A61K31/4015;;A61K31/4025;;A61K31/4412;;A61P3/04;;C07D207/27;;C07D211/76;;C07D401/10;;C07D403/10;;C07D409/10,,0,0,,,,ACTIVE
201,US,A1,US 2010/0184764 A1,056-626-294-292-770,2010-07-22,2010,US 72787110 A,2010-03-19,US 72787110 A;;US 71811107 A;;US 2005/0038369 W;;US 62320304 P,2004-10-29,CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1,"The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.",LILLY CO ELI,AICHER THOMAS DANIEL;;CHICARELLI MARK JOSEPH;;HINKLIN RONALD JAY;;TIAN HONGQI;;WALLACE OWEN BRENDAN;;ALLEN JOHN GORDON;;CHEN ZHAOGEN;;MABRY THOMAS EDWARD;;MCCOWAN JEFFERSON RAY;;SNYDER NANCY JUNE;;WINNEROSKI JR LEONARD LARRY,,https://lens.org/056-626-294-292-770,Patent Application,yes,0,0,13,13,0,C07D207/26;;C07D207/267;;C07D207/273;;C07D211/76;;C07D401/10;;C07D401/12;;C07D403/10;;C07D403/12;;C07D405/04;;C07D409/04;;C07D409/10;;A61P3/00;;A61P3/04;;A61P3/10;;C07D403/12;;C07D405/04;;C07D207/26;;C07D211/76;;C07D401/10;;C07D207/267;;C07D409/04;;C07D409/10;;C07D207/273;;C07D403/10;;C07D401/12,A61K31/40;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/506;;A61K31/5377;;C07D207/26;;C07D207/273;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/10;;C07D413/12,514/235.5;;548/543;;548/544;;544/372;;546/208;;546/278.4;;544/335;;544/336;;544/141;;546/194;;514/424;;514/254.01;;514/326;;514/343;;514/256;;514/255.05;;514/318,0,0,,,,DISCONTINUED
202,PL,T3,PL 1807072 T3,189-355-537-666-740,2009-06-30,2009,PL 05819201 T,2005-10-26,US 62320304 P;;EP 05819201 A;;US 2005/0038369 W,2004-10-29,CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1,"The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.",LILLY CO ELI,AICHER THOMAS D;;CHICARELLI MARK JOSEPH;;HINKLIN RONALD JAY;;TIAN HONGQI;;WALLACE OWEN BRENDAN;;CHEN ZHAOGEN;;MABRY THOMAS EDWARD;;MCCOWAN JEFFERSON RAY;;SNYDER NANCY JUNE;;WINNEROSKI LEONARD LARRY JUNIOR;;ALLEN JOHN GORDON,,https://lens.org/189-355-537-666-740,Patent Application,no,0,0,13,13,0,C07D207/26;;C07D207/267;;C07D207/273;;C07D211/76;;C07D401/10;;C07D401/12;;C07D403/10;;C07D403/12;;C07D405/04;;C07D409/04;;C07D409/10;;A61P3/00;;A61P3/04;;A61P3/10;;C07D403/12;;C07D405/04;;C07D207/26;;C07D211/76;;C07D401/10;;C07D207/267;;C07D409/04;;C07D409/10;;C07D207/273;;C07D403/10;;C07D401/12,A61K31/4015;;A61K31/4025;;A61K31/4412;;A61P3/04;;C07D207/27;;C07D211/76;;C07D401/10;;C07D403/10;;C07D409/10,,0,0,,,,PENDING
203,BR,A2,BR PI0710246 A2,022-409-878-843-164,2011-08-09,2011,BR PI0710246 A,2007-04-19,US 74531106 P;;US 2007/0066921 W,2006-04-21,"composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica.","<B>COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, E, COMPOSIçãO FARMACêUTICA<D> A presente invenção diz respeito a compostos inéditos de fórmula 1: que possuem atividade antagonista de 11 <225>-HSD tipo 1, bem como métodos para preparar tais compostos. Em uma outra modalidade, a invenção diz respeito a composições farmacêuticas compreendendo compostos de fórmula 1 bem como métodos de usar os compostos e composições para tratar diabetes, hiperglicemia, obesidade, hipertensão, hiperlipidemia, síndrome metabólica, distúrbio cognitivo e outras condições associadas a atividade de 11 <225>-HSD tipo 1.",LILLY CO ELI,AICHER THOMAS DANIEL;;CHEN ZHAOGEN;;HINKLIN RONALD JAY;;HITE GARY ALAN;;PAVLOVYCH ALEXEI;;LI RENHUA;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;SNYDER NANCY JUNE;;TOTH JAMES LEE;;WALLACE OWEN BRENDAN;;WINNEROSKI LEONARD LARRY;;XU YANPING;;YORK JEREMY SCHULENBURG,,https://lens.org/022-409-878-843-164,Patent Application,no,0,0,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08,,0,0,,,,DISCONTINUED
204,EP,A1,EP 2016047 A1,016-741-792-102-469,2009-01-21,2009,EP 07760877 A,2007-04-19,US 2007/0066921 W;;US 74531106 P,2006-04-21,BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1,,LILLY CO ELI,AICHER THOMAS DANIEL;;CHEN ZHAOGEN;;HINKLIN RONALD JAY;;HITE GARY ALAN;;KRASUTSKY ALEXEI PAVLOVYCH;;LI RENHUA;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;SNYDER NANCY JUNE;;TOTH JAMES LEE;;WALLACE OWEN BRENDAN;;WINNEROSKI JUNIOR LEONARD LARRY;;XU YANPING;;YORK JEREMY SCHULENBURG,,https://lens.org/016-741-792-102-469,Patent Application,yes,0,0,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,C07D207/12;;A61K31/4015;;A61P3/10;;C07D401/10;;C07D401/12;;C07D403/10;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/04,,0,0,,,,ACTIVE
205,WO,A8,WO 2007/124337 A8,139-620-969-137-261,2009-06-18,2009,US 2007/0066921 W,2007-04-19,US 74531106 P,2006-04-21,BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1,"The present invention discloses novel compounds of Formula I: possessing 11 ß-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 ß -HSD type 1 activity.",LILLY CO ELI;;AICHER THOMAS DANIEL;;CHEN ZHAOGEN;;HINKLIN RONALD JAY;;HITE GARY ALAN;;KRASUTSKY ALEXEI PAVLOVYCH;;LI RENHUA;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;SNYDER NANCY JUNE;;TOTH JAMES LEE;;WALLACE OWEN BRENDAN;;WINNEROSKI JUNIOR LEONARD LARR;;XU YANPING;;YORK JEREMY SCHULENBURG,AICHER THOMAS DANIEL;;CHEN ZHAOGEN;;HINKLIN RONALD JAY;;HITE GARY ALAN;;KRASUTSKY ALEXEI PAVLOVYCH;;LI RENHUA;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;SNYDER NANCY JUNE;;TOTH JAMES LEE;;WALLACE OWEN BRENDAN;;WINNEROSKI JUNIOR LEONARD LARRY;;XU YANPING;;YORK JEREMY SCHULENBURG,,https://lens.org/139-620-969-137-261,Amended Application,yes,0,0,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,C07D207/12;;A61K31/4015;;A61P3/10;;C07D401/10;;C07D401/12;;C07D403/10;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/04,,0,0,,,,PENDING
206,WO,A1,WO 2007/124337 A1,180-321-835-677-031,2007-11-01,2007,US 2007/0066921 W,2007-04-19,US 74531106 P,2006-04-21,BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1,"The present invention discloses novel compounds of Formula I: possessing 11 ß-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 ß -HSD type 1 activity.",LILLY CO ELI;;AICHER THOMAS DANIEL;;CHEN ZHAOGEN;;HINKLIN RONALD JAY;;HITE GARY ALAN;;KRASUTSKY ALEXEI PAVLOVYCH;;LI RENHUA;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;SNYDER NANCY JUNE;;TOTH JAMES LEE;;WALLACE OWEN BRENDAN;;WINNEROSKI JUNIOR LEONARD LARR;;XU YANPING;;YORK JEREMY SCHULENBURG,AICHER THOMAS DANIEL;;CHEN ZHAOGEN;;HINKLIN RONALD JAY;;HITE GARY ALAN;;KRASUTSKY ALEXEI PAVLOVYCH;;LI RENHUA;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;SNYDER NANCY JUNE;;TOTH JAMES LEE;;WALLACE OWEN BRENDAN;;WINNEROSKI JUNIOR LEONARD LARR;;XU YANPING;;YORK JEREMY SCHULENBURG,,https://lens.org/180-321-835-677-031,Patent Application,yes,5,45,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,C07D207/12;;A61K31/4015;;A61P3/10;;C07D401/10;;C07D401/12;;C07D403/10;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/04,,1,0,,,"DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ""Preparation of 3-benzylpyrrolidin-2-one and N-benzylimidazolidin-2-one derivaties as prophylactic/therapeutic agents for diabetes"", XP002449024",PENDING
207,MX,A,MX 2008013485 A,188-553-060-478-371,2008-10-30,2008,MX 2008013485 A,2007-04-19,US 74531106 P;;US 2007/0066921 W,2006-04-21,BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1.,"The present invention discloses novel compounds of Formula I: possessing 11 Ã¿-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 Ã¿ -HSD type 1 activity.",LILLY CO ELI,SNYDER NANCY JUNE;;SAEED ASHRAF;;HINKLIN RONALD JAY;;WALLACE OWEN BRENDAN;;AICHER THOMAS DANIEL;;XU YANPING;;LI RENHUA;;KRASUTSKY ALEXEI PAVLOVYCH;;WINNEROSKI LEONARD LARRY JUNIOR;;CHEN ZHAOGEN;;HITE GARY ALAN;;MCCOWAN JEFFERSON RAY;;TOTH JAMES LEE;;YORK JEREMY SCHULENBURG,,https://lens.org/188-553-060-478-371,Patent Application,no,0,0,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,C07D207/12;;A61K31/4015;;A61P3/10;;C07D401/10;;C07D401/12;;C07D403/10;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/04,,0,0,,,,ACTIVE
208,US,A1,US 2009/0156571 A1,002-978-692-355-546,2009-06-18,2009,US 29734907 A,2007-04-19,US 29734907 A;;US 74531106 P;;US 2007/0066921 W,2006-04-21,BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1,"The present invention discloses novel compounds of Formula I: possessing 11 β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 β-HSD type 1 activity.",AICHER THOMAS DANIEL;;CHEN ZHAOGEN;;HINKLIN RONALD JAY;;HITE GARY ALAN;;KRASUTSKY ALEXEI PAVLOVYCH;;LI RENHUA;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;SNYDER NANCY JUNE;;TOTH JAMES LEE;;WALLACE OWEN BRENDAN;;WINNEROSKI JR LEONARD LARRY;;XU YANPING;;YORK JEREMY SCHULENBURG,AICHER THOMAS DANIEL;;CHEN ZHAOGEN;;HINKLIN RONALD JAY;;HITE GARY ALAN;;KRASUTSKY ALEXEI PAVLOVYCH;;LI RENHUA;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;SNYDER NANCY JUNE;;TOTH JAMES LEE;;WALLACE OWEN BRENDAN;;WINNEROSKI JR LEONARD LARRY;;XU YANPING;;YORK JEREMY SCHULENBURG,ELI LILLY AND COMPANY (2007-04-02),https://lens.org/002-978-692-355-546,Patent Application,yes,13,14,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,A61K31/453;;A61K31/497;;A61K31/5377;;A61K31/541;;A61K31/553;;C07D403/08;;C07D405/14;;C07D413/08;;C07D417/08,514/210.2;;546/194;;544/372;;544/141;;544/60;;540/544;;514/326;;514/254.01;;514/235.5;;514/227.8;;514/211.15,0,0,,,,INACTIVE
209,CA,C,CA 2649741 C,068-675-899-587-949,2013-08-27,2013,CA 2649741 A,2007-04-19,US 74531106 P;;US 2007/0066921 W,2006-04-21,BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1,"The present invention discloses novel compounds of Formula I: possessing 11 ß-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 ß -HSD type 1 activity.",LILLY CO ELI,AICHER THOMAS DANIEL;;CHEN ZHAOGEN;;HINKLIN RONALD JAY;;HITE GARY ALAN;;KRASUTSKY ALEXEI PAVLOVYCH;;LI RENHUA;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;SNYDER NANCY JUNE;;TOTH JAMES LEE;;WALLACE OWEN BRENDAN;;WINNEROSKI JUNIOR LEONARD LARRY;;XU YANPING;;YORK JEREMY SCHULENBURG,,https://lens.org/068-675-899-587-949,Granted Patent,no,0,0,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,C07D207/12;;A61K31/4015;;A61P3/10;;C07D401/10;;C07D401/12;;C07D403/10;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/04,,0,0,,,,INACTIVE
210,AU,A1,AU 2007/240458 A1,072-727-982-531-723,2007-11-01,2007,AU 2007/240458 A,2007-04-19,US 74531106 P;;US 2007/0066921 W,2006-04-21,Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1,,LILLY CO ELI,KRASUTSKY ALEXEI PAVLOVYCH;;AICHER THOMAS DANIEL;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;XU YANPING;;HINKLIN RONALD JAY;;HITE GARY ALAN;;CHEN ZHAOGEN;;WINNEROSKI JUNIOR LEONARD LARR;;LI RENHUA;;YORK JEREMY SCHULENBURG;;WALLACE OWEN BRENDAN;;SNYDER NANCY JUNE;;TOTH JAMES LEE,,https://lens.org/072-727-982-531-723,Patent Application,no,0,0,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,C07D207/12;;A61K31/4015;;A61P3/10;;C07D401/10;;C07D401/12;;C07D403/10;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/04,,0,0,,,,INACTIVE
211,EP,B1,EP 2016047 B1,196-240-474-545-303,2013-08-28,2013,EP 07760877 A,2007-04-19,US 2007/0066921 W;;US 74531106 P,2006-04-21,BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1,,LILLY CO ELI,AICHER THOMAS DANIEL;;CHEN ZHAOGEN;;HINKLIN RONALD JAY;;HITE GARY ALAN;;KRASUTSKY ALEXEI PAVLOVYCH;;LI RENHUA;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;SNYDER NANCY JUNE;;TOTH JAMES LEE;;WALLACE OWEN BRENDAN;;WINNEROSKI JUNIOR LEONARD LARRY;;XU YANPING;;YORK JEREMY SCHULENBURG,,https://lens.org/196-240-474-545-303,Granted Patent,yes,2,0,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,C07D207/12;;A61K31/4015;;A61P3/10;;C07D401/10;;C07D401/12;;C07D403/10;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/04,,1,0,,,"DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ""Preparation of 3-benzylpyrrolidin-2-one and N-benzylimidazolidin-2-one derivaties as prophylactic/therapeutic agents for diabetes"" XP002449024 & WO 2006/104280 A (TAKEDA PHARMACEUTICAL COMPANY [JP]; CHO NOBUO [JP]; KASAI SHIZUO [JP];) 5 October 2006 (2006-10-05)",ACTIVE
212,CA,A1,CA 2649741 A1,116-512-134-870-964,2007-11-01,2007,CA 2649741 A,2007-04-19,US 74531106 P;;US 2007/0066921 W,2006-04-21,BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1,,LILLY CO ELI,SNYDER NANCY JUNE;;TOTH JAMES LEE;;SAEED ASHRAF;;MCCOWAN JEFFERSON RAY;;LI RENHUA;;CHEN ZHAOGEN;;AICHER THOMAS DANIEL;;HINKLIN RONALD JAY;;WALLACE OWEN BRENDAN;;XU YANPING;;HITE GARY ALAN;;YORK JEREMY SCHULENBURG;;KRASUTSKY ALEXEI PAVLOVYCH;;WINNEROSKI JUNIOR LEONARD LARRY,,https://lens.org/116-512-134-870-964,Patent Application,no,0,0,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,C07D207/12;;A61K31/4015;;A61P3/10;;C07D401/10;;C07D401/12;;C07D403/10;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/04,,0,0,,,,INACTIVE
213,US,B2,US 8088776 B2,132-789-177-659-095,2012-01-03,2012,US 29734907 A,2007-04-19,US 29734907 A;;US 74531106 P;;US 2007/0066921 W,2006-04-21,Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1,"The present invention discloses novel compounds of Formula I: possessing 11 β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 β-HSD type 1 activity.",AICHER THOMAS DANIEL;;CHEN ZHAOGEN;;HINKLIN RONALD JAY;;HITE GARY ALAN;;KRASUTSKY ALEXEI PAVLOVYCH;;LI RENHUA;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;SNYDER NANCY JUNE;;TOTH JAMES LEE;;WALLACE OWEN BRENDAN;;WINNEROSKI JR LEONARD LARRY;;XU YANPING;;YORK JEREMY SCHULENBURG;;LILLY CO ELI,AICHER THOMAS DANIEL;;CHEN ZHAOGEN;;HINKLIN RONALD JAY;;HITE GARY ALAN;;KRASUTSKY ALEXEI PAVLOVYCH;;LI RENHUA;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;SNYDER NANCY JUNE;;TOTH JAMES LEE;;WALLACE OWEN BRENDAN;;WINNEROSKI JR LEONARD LARRY;;XU YANPING;;YORK JEREMY SCHULENBURG,ELI LILLY AND COMPANY (2007-04-02),https://lens.org/132-789-177-659-095,Granted Patent,yes,34,0,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,A61K31/496;;A61K31/453;;C07D403/02;;C07D405/14,514/254.01;;514/326;;544/372;;546/208,4,4,035-230-547-171-641;;065-859-751-287-752;;015-524-538-071-794;;138-880-096-253-638,10.1021/cr950066q;;11848856;;10.1016/j.bmcl.2006.08.034;;16931002;;10.1021/jm0600794;;16759088;;10.1016/s0040-4039(00)60921-8,"Patani et al., Bioisosterism: A Rational Approach in Drug Design, 1996, Chem. Rev., 96, 3147-3176.;;Yeh et al.: Discovery of orally active butyrolactam 11 beta-HSD1 inhibitors, Bioorganic & Medicinal Chemistry Letters, Nov. 1, 2006, 16(21), pp. 5555-5560.;;Schuster, Daniela et al.: The Discovery of New 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors by Common Feature Pharmacophore Modeling and Virtual Screening, J. Medicinal Chemistry, 2006, 49, pp. 3454-3466.;;Konno et al.: Electrolytic Partial Fluorination of Organic Compounds. 6. Highly Regioselective Eletrochemical Monofluorination of Aliphatic Nitrogen-Containing Heterocycles, Tetrahedron Letters, 1992, vol. 33, No. 46, pp. 7017-7020.",INACTIVE
214,CN,B,CN 101541747 B,162-616-712-948-183,2012-11-14,2012,CN 200780014316 A,2007-04-19,US 2007/0066921 W;;US 74531106 P,2006-04-21,Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1,"The present invention discloses novel compounds of Formula I: possessing 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11beta-HSD type 1 activity.",LILLY CO ELI,PAVLOVYCH KRASUTSKY ALEXEI;;RENHUA LI;;LEE TOTH JAMES;;ASHRAF SAEED;;JAY HINKLIN RONALD;;RAY MCCOWAN JEFFERSON;;BRENDAN WALLACE OWEN;;LARR WINNEROSKI JUNIOR LEONARD;;ALAN HITE GARY;;JUNE SNYDER NANCY;;SCHULENBURG YORK JEREMY;;YANPING XU;;DANIEL AICHER THOMAS;;ZHAOGEN CHEN,,https://lens.org/162-616-712-948-183,Granted Patent,no,0,0,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,C07D207/12;;A61K31/4015;;A61P3/10;;C07D401/10;;C07D401/12;;C07D403/10;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/04,,0,0,,,,INACTIVE
215,EA,B1,EA 014718 B1,142-179-369-753-005,2011-02-28,2011,EA 200870462 A,2007-04-19,US 74531106 P;;US 2007/0066921 W,2006-04-21,BIPHENYL AMIDELACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1,"The present invention discloses novel compounds of Formula I:possessing 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11β-HSD type 1 activity.",LILLY CO ELI,AICHER THOMAS DANIEL;;CHEN ZHAOGEN;;HINKLIN RONALD JAY;;HITE GARY ALAN;;KRASUTSKY ALEXEI PAVLOVICH;;LI RENHUA;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;SNYDER NANCY JUNE;;TOTH JAMES LEE;;WALLACE OWEN BRENDAN;;WINNEROSKI JUNIOR LEONARD LARRY;;XU YANPING;;YORK JEREMY SCHULENBURG,,https://lens.org/142-179-369-753-005,Granted Patent,no,3,0,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,C07D207/12;;A61K31/4015;;A61P3/10;;C07D401/10;;C07D401/12;;C07D403/10;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/04,,1,0,,,"DATABASE CAPLUS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ""Preparation of 3-benzylpyrrolidin-2-one and N-benzylimidazolidin-2-one derivaties as prophylactic/therapeutic agents for diabetes"", XP002449024, abstract; compounds RN 911722-70-8 and RN911724-34-0, abstract",ACTIVE
216,AU,B2,AU 2007/240458 B2,039-810-526-395-239,2012-03-15,2012,AU 2007/240458 A,2007-04-19,US 74531106 P;;US 2007/0066921 W,2006-04-21,Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1,"The present invention discloses novel compounds of Formula I: possessing 11 ß-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 ß -HSD type 1 activity.",LILLY CO ELI,KRASUTSKY ALEXEI PAVLOVYCH;;AICHER THOMAS DANIEL;;MCCOWAN JEFFERSON RAY;;SAEED ASHRAF;;XU YANPING;;HINKLIN RONALD JAY;;HITE GARY ALAN;;CHEN ZHAOGEN;;WINNEROSKI JUNIOR LEONARD LARRY;;LI RENHUA;;YORK JEREMY SCHULENBURG;;WALLACE OWEN BRENDAN;;SNYDER NANCY JUNE;;TOTH JAMES LEE,,https://lens.org/039-810-526-395-239,Granted Patent,no,2,0,19,19,0,C07D207/12;;C07D401/10;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;A61P3/04;;A61P3/06;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D207/12;;C07D405/14;;C07D401/10;;C07D413/10;;C07D417/10;;C07D491/10;;C07D487/08;;C07D471/04;;C07D403/10;;C07D491/08;;C07D401/12;;C07D417/14;;C07D487/04,C07D207/12;;A61K31/4015;;A61P3/10;;C07D401/10;;C07D401/12;;C07D403/10;;C07D413/10;;C07D417/10;;C07D417/14;;C07D471/04;;C07D487/04;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/04,,0,0,,,,INACTIVE
217,EP,A1,EP 3156466 A1,006-276-691-912-039,2017-04-19,2017,EP 15189956 A,2015-10-15,EP 15189956 A,2015-10-15,MULTILAYER PRESSURE SENSITIVE ADHESIVE FOAM TAPE FOR OUTDOOOR APPLICATIONS,"The present disclosure relates to a method of adhering a first part to a second part, wherein the first part and the second part are used for outdoor applications and comprise a thermoplastic or a thermosetting organic polymer. The present disclosure is also directed to a composite assembly comprising: 
a) a first part and a second part used for outdoor applications and comprising a thermoplastic or a thermosetting organic polymer; and 
b) a multilayer pressure sensitive adhesive foam tape as described in the present disclosure, wherein the first pressure sensitive adhesive layer is adhered to the first part, and the second pressure sensitive adhesive layer is adhered to the second part.",3M INNOVATIVE PROPERTIES CO,ECKHARDT DOREEN;;TORRE CLAUDIA;;SIKORA REGINA;;UNVERHAU KERSTIN;;WIENEKE JAN;;KUESTER FRANK;;HEIMINK JAN;;FORSTER JAN DANIEL;;RADEK BETTINA;;CHASTEK THOMAS Q;;DEVOLDER ROSS JOHN;;WANG SHUJUN S J;;WAID ROBERT DENNIS;;ZOLLER PANU K;;WILLETT PEGGY SPERL;;GADBOIS GREGORY BERNARD;;DEL UNRUH JEREMY;;BRAY STEVEN DEAN;;WILLIAMS JACK JEFFERSON;;CHEN ZHONG,,https://lens.org/006-276-691-912-039,Patent Application,yes,46,11,5,5,0,C09J5/00;;C09J2400/243;;C09J2433/00;;C09J2453/00;;C09J7/38;;C09J7/22;;C09J2301/1242;;C09J2301/414;;C09J5/00;;C09J2400/243;;C09J2433/00;;C09J2453/00;;C09J7/38;;C09J7/22;;C09J2301/408;;C09J2301/414;;C09J2301/1242;;C09J7/387;;C09J7/385;;C09J7/26;;B29C48/21;;B29K2033/08;;B29K2105/0097;;B32B5/18;;B32B7/12;;B32B27/08;;B32B2405/00;;C08J5/128;;C09J11/06;;C09J2433/006,B60R13/02;;C03C27/04;;C09J5/00;;C09J7/22;;C09J7/26;;C09J7/38;;E04B1/38,,2,0,,,"A.V. POCIUS: ""Adhesion and Adhesives Technology: An Introduction"", 2002, HANSER GARDNER PUBLICATION;;""Mixing in Polymer Processing"", 1991, MARCEL DEKKER INC., article ""Mixing in Single-Screw Extruders"", pages: 129,176 - 177,185-",ACTIVE
218,EP,B1,EP 3156466 B1,022-138-692-902-363,2020-11-25,2020,EP 15189956 A,2015-10-15,EP 15189956 A,2015-10-15,MULTILAYER PRESSURE SENSITIVE ADHESIVE FOAM TAPE FOR OUTDOOOR APPLICATIONS,,3M INNOVATIVE PROPERTIES CO,HEIMINK JAN;;FORSTER JAN DANIEL;;RADEK BETTINA;;ECKHARDT DOREEN;;TORRE CLAUDIA;;SIKORA REGINA;;UNVERHAU KERSTIN;;WIENEKE JAN;;KUESTER FRANK;;CHASTEK THOMAS Q;;DEVOLDER ROSS JOHN;;WANG SHUJUN S J;;WAID ROBERT DENNIS;;ZOLLER PANU K;;WILLETT PEGGY SPERL;;GADBOIS GREGORY BERNARD;;DEL UNRUH JEREMY;;BRAY STEVEN DEAN;;WILLIAMS JACK JEFFERSON;;CHEN ZHONG,,https://lens.org/022-138-692-902-363,Granted Patent,yes,6,0,5,5,0,C09J5/00;;C09J2400/243;;C09J2433/00;;C09J2453/00;;C09J7/38;;C09J7/22;;C09J2301/1242;;C09J2301/414;;C09J5/00;;C09J2400/243;;C09J2433/00;;C09J2453/00;;C09J7/38;;C09J7/22;;C09J2301/408;;C09J2301/414;;C09J2301/1242;;C09J7/387;;C09J7/385;;C09J7/26;;B29C48/21;;B29K2033/08;;B29K2105/0097;;B32B5/18;;B32B7/12;;B32B27/08;;B32B2405/00;;C08J5/128;;C09J11/06;;C09J2433/006,C09J5/00;;C09J7/22;;C09J7/26;;C09J7/38,,0,0,,,,ACTIVE
219,EP,A1,EP 3156465 A1,153-899-110-591-777,2017-04-19,2017,EP 15189946 A,2015-10-15,EP 15189946 A,2015-10-15,MULTILAYER PRESSURE SENSITIVE ADHESIVE FOAM TAPE FOR OUTDOOOR APPLICATIONS,"The present disclosure relates to a method of adhering a first part to a second part, wherein the first part and the second part are used for outdoor applications and comprise a thermoplastic or a thermosetting organic polymer. The present disclosure is also directed to a composite assembly comprising: 
a) a first part and a second part used for outdoor applications and comprising a thermoplastic or a thermosetting organic polymer; and 
b) a multilayer pressure sensitive adhesive foam tape as described in the present disclosure, wherein the first pressure sensitive adhesive layer is adhered to the first part, and the second pressure sensitive adhesive layer is adhered to the second part.",3M INNOVATIVE PROPERTIES CO,ECKHARDT DOREEN;;TORRE CLAUDIA;;SIKORA REGINA;;UNVERHAU KERSTIN;;WIENEKE JAN;;KUESTER FRANK;;HEIMINK JAN;;FORSTER JAN DANIEL;;RADEK BETTINA;;CHASTEK THOMAS Q;;DEVOLDER ROSS JOHN;;WANG SHUJUN S J;;WAID ROBERT DENNIS;;ZOLLER PANU K;;WILLETT PEGGY SPERL;;GADBOIS GREGORY BERNARD;;DEL UNRUH JEREMY;;BRAY STEVEN DEAN;;WILLIAMS JACK JEFFERSON;;CHEN ZHONG,,https://lens.org/153-899-110-591-777,Patent Application,yes,46,5,4,4,0,C08K7/28;;C09J2433/00;;C09J2433/006;;C09J2453/00;;C09J2400/243;;C09J7/38;;C09J7/22;;C09J2301/124;;C09J2301/41;;C09J2301/412;;C09J2301/414;;C09J2433/00;;C09J2433/006;;C09J2453/00;;C08K7/28;;C09J2400/243;;C09J7/22;;C09J7/38;;C09J2301/41;;C09J2301/124;;C09J2301/412;;C09J2301/414;;B32B2266/14;;C09J7/387;;C09J7/385;;C09J7/26;;B32B5/20;;B32B7/12;;B32B27/065;;B32B27/308;;B32B2266/0242;;C09J11/08,C09J7/26;;B60R13/02;;C03C27/04;;C09J7/22;;C09J7/38;;E04B1/38,,2,0,,,"A.V. POCIUS: ""Adhesion and Adhesives Technology: An Introduction"", 2002, HANSER GARDNER PUBLICATION;;""Mixing in Polymer Processing"", 1991, MARCEL DEKKER INC., article ""Mixing in Single-Screw Extruders"", pages: 129,176 - 177,185-",DISCONTINUED
